S-1. Caregiving Burden Linked to More Menopause Symptoms

Marina Khodareski, Ekta Kapoor, MD, Juliana M. Kling, MD, MPH1, Chrisandra Shufeld, MD, MS1, Rajeev Chaudhry, MBBS, MPH1, Joan Griffin, PhD2, Nancy Saivan, MD, Kristin Mara, MS3, Felicity Enders, PhD4, Stephanie S. Faubion, MD, MBA4. 1Mayo Clinic Center for Women’s Health, Rochester, MN; 2Internal Medicine, Mayo Clinic Minnesota, Rochester, MN; 3Internal Medicine, Mayo Clinic in Florida, Jacksonville, FL; 4Internal Medicine, Mayo Clinic Arizona, Scottsdale, AZ; 5Health Care Delivery Research, Mayo Clinic Minnesota, Rochester, MN; 6Quantitative Health Sciences, Mayo Clinic Minnesota, Rochester, MN; 7Kern Center for the Science of Medicine, University of Pittsburgh, Pittsburgh, PA; 8Division of Community Internal Medicine, Mayo Clinic, Rochester, MN; 9Health and Human Development, University of Pittsburgh, Pittsburgh, PA; 10Psychiatry, University of Pittsburgh, Pittsburgh, PA; 11Psychiatry, University of Michigan, Ann Arbor, MI; 12Medicine, University of Alabama, Birmingham, AL; 13Neurosurgery, Columbia University, New York, NY

Objective: The aim of this study was to evaluate the impact of caregiving on menopause symptoms and trajectories of insomnia symptoms in midlife women. Caregiving has been associated with adverse outcomes including a higher risk of anxiety, depression, and coronary heart disease. Employed midlife women caregivers were more likely to quit or change their jobs compared to non-caregivers. Limited literature has evaluated the impact of caregiving on menopause symptoms. This study aimed to assess the association between caregiving and menopause symptom burden in midlife women.

Design: A cross-sectional analysis from the Hormones and Experiences of Aging (HEA) study was undertaken utilizing questionnaires completed by women aged 45-60 years receiving primary care at one of four Mayo Clinic geographic locations between March and June 2021. Caregiving status was assessed by asking the participants whether they were currently caring for or making healthcare decisions for someone with a medical condition or disability. Participants were also asked about caregiving and their conditions, time spent providing care, and their daily stress levels. Menopause symptoms were assessed using the Menopause Rating Scale (MRS) which consists of 11 items including somatic, psychological, and urogenital domains. Each item is scored on a 0-4 scale. The cut-off scores for moderate or greater menopausal symptoms are 8 for the somatic and psychological domains, and 6 for the urogenital domain. The insomnia-sleep duration trajectories were assessed using the Insomnia-sleep duration trajectories in relation to CVD, multivariable

Results: A total of 4295 women were included in the analysis, 19.7% of whom were caregivers. Women were of mean age 54.6 yrs, White (96.6%), partnered (77.9%), educated (93.5% with at least some college), employed (91.6%), and 37.6% had moderate or greater menopausal symptoms in at least one domain. Women were classified according to the number of hours/week spent caregiving: no caregiving, <5 hrs/week, 5-14 hrs/week and ≥15 hrs/week. Caregivers were evenly distributed among the three caregiving groups. The proportion of women who had moderate or greater menopause symptoms in at least one domain increased sequentially as the number of caregiving hours increased: 34.1% in the <5 hrs/week group, 42.6% in the 5-14 hrs/week, and 50.4% in the ≥15 hrs/week (p<0.001). In the univariate analysis, caregiving for ≥15 hrs/week significantly increased the odds of having moderate or greater menopause symptoms in at least one domain compared to no caregiving (OR 1.77, 95% CI 1.39-2.6, p<0.001); this was noted across all symptom domains. The association remained significant in multivariable analysis after adjusting for potential confounders (OR 1.57, 95% CI 1.22-2.02, p<0.001). Conclusion: This cross-sectional study is the first to identify an association between caregiving hours and menopause symptom burden. With the expected increase in the demand for caregiving on midlife women as the population ages, there is a critical need for efforts to improve menopause care and to provide support for women in this transition. Further, women with moderate or greater menopause symptoms may require more tailored stress management to cope with their caregiving responsibilities.

Sources of Funding: None

S-2. Trajectories of Sleep Over Midlife and Cardiovascular Disease Risk: The Study of Women’s Health Across the Nation

Rebecca C. Thurston, PhD1, Yuefang Chang, PhD2, Christopher Kline, PhD3, Samar R. El Khoudary4, Leslie Swanson5, Carol A. Derby7. 1Psychiatry, University of Pittsburgh, Pittsburgh, PA; 2Epidemiology, University of Pittsburgh, Pittsburgh, PA; 3Neurosurgery, University of Pittsburgh, Pittsburgh, PA; 4Health and Human Development, University of Pittsburgh, Pittsburgh, PA; 5Psychiatry, University of Pittsburgh, Pittsburgh, PA; 6Hair, and UCLA School of Medicine, Los Angeles, CA; 7MedStar Georgetown University Hospital, Washington, DC; 8Radiology Health Inc, Boston, MA

Objective: Insomnia affects about one in three women and one in five men aged 50 years. Despite a vertebral fracture substantially increasing the risk of a subsequent vertebral fracture, the vast majority of US women and men with osteoporosis and a recent vertebral fracture are not treated with an osteoporosis medication. There is increasing evidence suggesting the clinical benefits of sequential treatment with an anabolic (such as abaloparatide [ABL]) followed by an antiresorptive (such as alendronate [ALN]) in women with and a low or moderate high fracture risk. However, no evidence supports the cost-effectiveness of this treatment strategy in patients with a recent vertebral fracture. Given the increasing importance of efficiently allocating scarce resources, this study was designed to assess the cost-effectiveness of sequential ABL/ALN compared to relevant treatment strategies in both US women and men with moderate or greater high fracture risk. Design: An economic model designed from the US healthcare decision-maker perspective was used to estimate the lifetime costs and health outcome (expressed in quality-adjusted life years [QALY’s]) of sequential ABL/ALN compared to a similar sequence starting with another anabolic (unbranded teriparatide [TPTD]), to ALN monotherapy and to no treatment. The population included US women and men aged 50 to 80 years with a recent vertebral fracture and densitometry-confirmed osteoporosis (bone mineral density T-score ≤−2.5). Model data were derived from US literature and approved by US clinical experts. The incremental cost-effectiveness ratios (ICERs) expressed in costs (in 2022 dollars) per QALY gained were estimated for sequential ABL/ALN compared to each alternative strategy. If the ICER fell below the US cost-effectiveness threshold value at $150,000 per QALY gained, sequential ABL/ALN was considered cost-effective. Probabilistic sensitivity analyses were conducted to assess the effects of joint uncertainty across most input parameters. Results: In all simulations, sequential ABL/ALN was associated with more QALYs for lower costs compared to sequential unbranded TPTD/ALN. Furthermore, sequential ABL/ALN was cost-effective compared to no treatment and ALN monotherapy in men aged 50 years and women aged ≥55 years. The probabilistic sensitivity analyses suggested that sequential ABL/ALN was cost-effective in 86% of the simulations in women aged 70 years at the US cost-effectiveness threshold compared to 1%, 13%, and 0% for unbranded TPTD/ALN, ALN monotherapy, and no treatment, respectively. Similar results were found in men aged 50 years. Conclusion: This study suggests that sequential ABL/ALN led to more QALYs for less
costs than sequential unbranded TPTD/ALN, and is cost-effective compared to ALN and a recent vertebral fracture.

Sources of Funding: This study was funded by Radius Health, Inc.

S-4.

Long-term cognitive effects of menopausal hormone therapy: preliminary data (KEEPS-Continuation) with later cognition (KEEPS Continuation)

Table 1

<table>
<thead>
<tr>
<th>Cognitive Test</th>
<th>Estimate (95% Confidence Interval)</th>
<th>P-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Slope of Verbal Attention &amp; Executive Function performance</td>
<td>0.031 (0.008, 0.056)</td>
<td>0.187</td>
</tr>
<tr>
<td>Slope of Speeded Language &amp; Mental Flexibility performance</td>
<td>-0.041 (0.001, 0.080)</td>
<td>0.159</td>
</tr>
<tr>
<td>Slope of Auditory Attention &amp; Working Memory performance</td>
<td>-0.062 (0.017, -0.150)</td>
<td>0.324</td>
</tr>
<tr>
<td>Slope of Verbal Learning &amp; Memory performance</td>
<td>-0.076 (-0.133, -0.020)</td>
<td>0.001</td>
</tr>
<tr>
<td>Slope of Association between baseline cognition and later cognition</td>
<td>-0.063 (0.009, 0.196)</td>
<td>0.035</td>
</tr>
<tr>
<td>Slope of Executive Function performance</td>
<td>0.012 (-0.049, 0.073)</td>
<td>0.579</td>
</tr>
<tr>
<td>Slope of Auditory Attention &amp; Working Memory performance</td>
<td>0.013 (0.001, 0.026)</td>
<td>0.132</td>
</tr>
<tr>
<td>Slope of Verbal Memory &amp; Learning performance</td>
<td>-0.084 (-0.138, -0.032)</td>
<td>0.129</td>
</tr>
</tbody>
</table>

**Objective:** To examine the degree to which hair and salivary cortisol levels correlate with depressive symptom severity and cognitive performance on verbal memory, verbal learning, and attention, and working memory tasks among healthy women in late peri/early postmenopause.

**Sources of Funding:** The cardio-protective roles of endogenous estrogens may be particularly important in women with HIV, who have relatively reduced estrogen exposure and elevated cardiovascular disease risk. The gut microbiome metabolically interacts with sex hormones, but little is known regarding how such interplay may impact cardiovascular risk. Our objectives were to examine the relationship of serum sex hormones with the gut microbiome and subclinical atherosclerosis in post-menopausal women with and without HIV.

**Design:** Among 197 post-menopausal women in the Women’s Interagency HIV Study, we measured 15 sex hormones in serum using gas or liquid chromatography coupled to mass spectrometry, and assessed the gut microbiome in stool using shotgun sequencing. Carotid artery B-mode ultrasound was used to determine carotid artery plaque in a subset (n=133). We examined associations of (1) sex hormones and gut microbiome, (2) sex hormones and plaque, and (3) sex hormone-related gut microbiota and plaque.

**Results:** Participants median age was 58 years (interquartile range 54-61) and the majority were living with HIV (81%). Sex hormones were associated with gut microbiome diversity and the abundance of specific species; specific hormones were associated with gut microbiota and plaque. For example, estragol (which is involved in hormone metabolism, aryl-hydrocarbon receptor agonists, and androsterone-glucuronide, were associated with higher abundance
S-7  
Estetrol (E4), A Promising New Treatment for Menopausal Vasomotor Symptoms: Beneficial Lipid and Carbohydrate Metabolism in a Phase 3 Randomized, Double-blind, Placebo-Controlled Trial

Wulf Utian,1 Melanie Taziaux,1 Amanda Black,1 Ulysses Gasparid2, Rogerio Lobos2, Jean Michel Foird1,2 1Case Western Reserve University School of Medicine, Cleveland, OH; 2Estera SRL, an Affiliate company of Mithra Pharmaceuticals, Liege, Belgium; 3Université de Liege, Liege, Belgium; 4Columbia University, New York, NY; 5University of Ottawa, Ottawa, ON, Canada.

Objective: Estetrol (E4)- a native estrogen in development for menopausal vasomotor symptoms (VMS) in postmenopausal (PM) women. A previous phase 2 trial found that E4 was effective for the treatment of VMS, genitourinary syndrome of menopause (GSM) symptoms and quality of life, with a favorable safety profile. Moreover, E4 had minimal impact on hemostasis and had potentially beneficial effects on lipids, carbohydrate metabolism, and bone turnover. Data from two Phase 3 trials demonstrated a significant reduction in the frequency and severity of moderate to severe VMS. Here, we present the results on lipid and carbohydrate metabolism from a Phase 3 trial (E4Comfort I), which was conducted at 151 enrolling sites in 14 countries in Europe, Latin America, Russia, and North America.

Design: In this randomized, placebo-controlled, double-blind phase 3 trial, 640 postmenopausal women 40–65 years of age were randomized to receive E4 15 mg (n=213), E4 20 mg (n=213), or placebo (n=214) daily for 12 weeks. To ensure endometrial protection all non-hysterectomized women received progesterone 200 mg 15 mg (n=213), E4 20 mg (n=213), or placebo (n=214) daily for 12 weeks. To ensure endometrial protection all non-hysterectomized women received progesterone 200 mg once daily for 14 days after completion of E4 treatment. Because the primary VMS efficacy objective, the impact on lipid and carbohydrate metabolism was assessed, for which blood samples were taken at baseline and at Week 12 (W12). Lipid parameters included total cholesterol (total C), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), total CHD/C ratio, triglycerides (TG) and lipoprotein (a). Parameters for carbohydrate metabolism included fasting plasma glucose, insulin, glycated hemoglobin (HbA1c) and homeostasis model-assessment-estimated insulin resistance (HOMA-IR). Samples were analyzed by a central laboratory. Mean and median change from baseline to W12 were calculated and statistical analyses on changes from baseline to week 12 were performed using ANCOVA. Results: Statistically significant changes (p<0.05) from baseline at W12 were observed for cholesterol/HDL ratio (decrease), HDL-C (increase), and lipoprotein (a) (decrease) for both E4 15 mg and E4 20 mg compared to placebo. Statistically significant decreases in LDL-C and increases in TGs were observed only for E4 15 mg compared to placebo. TGs were numerically increased with E4 20 mg, but this was not statistically different from placebo. Reductions in fasting plasma glucose and HbA1c from baseline to Week 12 were statistically significant with E4 15 mg and E4 20 mg compared to placebo. Decreases in insulin levels and HOMA-IR for the E4 treatment arms compared to the placebo arm did not reach statistical significance. Conclusion: 12-week treatment with E4 15 mg and E4 20 mg resulted in beneficial effects on the lipid profile with an increase in HDE-C and a decrease in total CHD/C ratio, LDL-C and lipoprotein (a). Beneficial effects were also seen on carbohydrate metabolism with a decrease in fasting plasma glucose and in HbA1c associated with an obvious trend to decrease in insulin and HOMA-IR.

Sources of Funding: Estera SRL, an affiliate company of Mithra Pharmaceuticals, Liege, Belgium.

S-8  
Effect of fezolinetant on moderate-to-severe vasomotor symptoms in subgroups based on hormone therapy history: pooled data from two randomized phase 3 studies

Nanette Santoro,1 Genevieve Neal-Perry2, Petra S Crate,1 Martin Blogg,3 Shayna Mancuso,4 DO, Antonia Morga,5 Faith D. Ottery,6 Emil Sdiddrik.7 1University of Colorado School of Medicine, Aurora, CO; 2’UNC School of Medicine, Chapel Hill, NC; 3’Inselspital, Bern, Switzerland; 4’Astellas Pharma Europe Ltd, Addleston, United Kingdom; 5’Astellas Pharma Global Development Inc, Northbrook, IL.

Objective: Two phase 3 studies (SKYLIGHT 1 and 2; NCITX041315 and NCITX043142) demonstrated the efficacy, safety, and tolerability of fezolinetant treatment for vasomotor symptoms (VMS) due to menopause. As a non-hormonal agent, fezolinetant may be a potentially useful alternative for those unable or unwilling to take hormone therapy (HT). Additional analyses using pooled data from SKYLIGHT 1 and 2 assessed fezolinetant efficacy in participant subgroups who were considered potentially unsuitable for HT. Design: SKYLIGHT 1 and 2 had the same design. Both were double-blind, placebo-controlled studies of once-daily placebo, fezolinetant 30 mg or 45 mg for 12 weeks in women ≥40–65 y with moderate-to-sever VMS (minimum average ≥7 hot flashes/day). HT history subgroups were mutually exclusive and categorized using the following hierarchy: contraindicated, caution; stopped for medical concerns; aversive: non-willing. Subgroup assignments were based on participant answers to the HT questionnaire that was completed as part of the electronic case report form at baseline. Results: A total of 1022 participants took ≥1 dose of study medication and comprised the pooled group (placebo, n=342; fezolinetant 30 mg, n=339; fezolinetant 45 mg, n=341). Irrespective of HT history, there was an improvement in the frequency of moderate-to-severe VMS from baseline to weeks 4 and 12 (Table) in both fezolinetant groups compared with placebo. Improvement is indicated by a least squares mean difference mean change. Reduction in insulin for patients with placebo, we found no evidence of a difference in insulin between all HT subgroups in the severity of moderate-to-severe VMS from baseline to Week 4 and 12 in both fezolinetant groups compared with placebo. In the subgroup who were HT unsuitable (including aversive), treatment-emergent adverse events (TEAEs) occurred in 41.3% (121/293) of the placebo group, 40.8% (118/293) of the fezolinetant 30 mg and 39.4% (112/284) of the fezolinetant 45 mg groups. The most frequent TEAE was headache (5.5% placebo; 4.2% fezolinetant 30 mg; 5.6% fezolinetant 45 mg). There was 1 drug-related serious TEAE (transaminasins increased in the fezolinetant 30 mg group. Conclusion: This pooled analysis from SKYLIGHT 1 and SKYLIGHT 2 demonstrates the efficacy of fezolinetant in reducing the frequency and severity of VMS due to non-menopause compared with patients considered unsuitable for or unwilling to take HT. The findings are consistent with the effect observed in the overall participant population, which included women with a wide range of HT history. In addition, fezolinetant was well tolerated in the HT unsuitable (including aversive) subgroup.

Sources of Funding: Astellas Pharma Inc. Medical writing support was provided by Becky Ayles of Envision Pharma Inc. and funded by Astellas Pharma Inc. Table.
following E2 treatment, whereas controls did not (t=3.0, p<.009). In both groups, E2 administration reduced activation in the cerebellum, left inferior and medial frontal gyr, and right occipital pole (Z=2.58, pFWE<.05). Conclusion: The concurrent reduction of anhedonia and right prefrontal activation during reward anticipation in PO-MDD after 3 weeks of E2 administration suggests a potential mechanism for the rapid antidepressant effects of E2. Future research will examine dopamine transmission and frontal-striatal activation at the network level to better understand the role of E2 in perimenopausal women.

Sources of Funding: NIH K23MH105569 (CES); R01MH128238 (GD, CES)

### S-10. The use of menopausal hormone therapy after bilateral oophorectomy in perimenopausal Swedish women: a register-based study

Mikael Sundell, PhD-student1; Jan Brynhildsen2; Mats Fredriksson3; Mikael Hoffmann1; Anna-Clara Spetz Holm1,11; Department of Biomedical and Clinical Sciences, Linköping universitet, Linköping, Sweden; 2Department of Obstetrics and Gynecology, Region Kalmar lan, Kalmar, Sweden; 3Faculty of Medicine and Health, Oerebro universitet, Oerebro, Sweden; 4Linköpings universitet Institutionen for medicin och halsa, Linköping, Sweden; 5Department of Obstetrics and Gynecology, Universitetssjukhuset i Linköping, Linköping, Sweden

Objective: To investigate the use of menopausal hormone therapy (MHT) in perimenopausal women after bilateral oophorectomy. Design: Swedish women aged 35–44 years without malignancy who underwent bilateral oophorectomy 2005–2020 were identified using the Swedish National Quality Register of Gynecological Surgery (GynOp). In 2020, 98% of all clinics in Sweden conducting oophorectomies or hysterectomies reported to GynOp. Data on MHT dispensations were retrieved from the Swedish Prescribed Drug Register. Results: In total, 1,231 of all women (n = 1,706) were dispensed MHT at some point after surgery, whereof 1,177 were dispensed within one year. This proportion increased from 64% in 2005 to 84% in 2019 (p < 0.001). However, in 2020, during the COVID-19 pandemic, there was a small decrease in MHT dispensations, as has previously been reported for other drugs. The mean duration of the first treatment episode for the women who were dispensed MHT within one year after surgery (n = 1,177) was 25 months. The median age at time of surgery was 41 years. Younger women were more likely to have received at least one dispensation compared with women who underwent bilateral oophorectomy closer to the age of expected menopause (OR 0.88, 95% CI 0.85–0.92, p < 0.001). Women with a simultaneous hysterectomy were more likely to receive at least one MHT dispensation (77%) compared with women with exclusively oophorectomy (63%) (OR 1.88, 95% CI 1.51–2.33, p < 0.001). The total follow-up time for all women was 10,484 woman-years. In the total population, 4,537 treatment years transpired, corresponding to 43% of mean time covered. In women dispensed MHT within one year, the proportion of time covered was 63%. Conclusion: Only 69% of all women without malignancy who underwent bilateral oophorectomy were dispensed MHT within one year after surgery, and the treatment duration was limited. It is important to further study the reasons behind the low dispensation rate in this group to increase adherence to treatment guidelines, improve quality of life, and avoid increased morbidity and mortality.

Sources of Funding: The Medical Research Council of Southeast Sweden (FORSS-64640, FORSS-746391 FORSS-981620).

### S-11. Treatment satisfaction among women with moderate to severe vasomotor symptoms (VMS) due to menopause and physicians who treat women with VMS in the United States

Barbara J. DePree, MD1; Aki Shiozawa, DrPH, MBA2; Janet Kim, PhD2; Yao Wang, MPH2; Hongbo Yang, PhD2; Shanya Mancuso, DO2; 1Holland Hospital, Holland, MI; 2Astellas Pharma US Inc, Northbrook, IL; 3Analysis Group Inc, Los Angeles, CA

Objective: Hormone therapy (HT) and nonhormonal therapies are available to treat VMS. This study assessed treatment satisfaction among women with moderate to severe VMS and among physicians who treat women with VMS in the United States. Design: This noninterventional study included 2 phases: qualitative interviews and quantitative surveys. The interviews were administered to 4 patients and 2 physicians to inform design of a quantitative survey for a larger sample of women with VMS. Participants were recruited from nationally representative patient and physician panels. Participating patients were women age 40–65 years with moderate to severe symptoms to undergo HT and to complete a questionnaire about their treatment experience. Treatment satisfaction was measured by the Menopause Symptoms Treatment Satisfaction Questionnaire (MS-TSQ) among patients and by an adapted MS-TSQ among physicians. MS-TSQ total scores (0–100; higher scores indicate greater satisfaction) were summarized by treatment class (HT, non-HT, and OTC medication). Surveys queried participants on treatment needs and expectations for new treatments. Results: Interviews were conducted June 22–29, 2022, with 4 women (2 with moderate and 2 with severe symptoms) and 2 physicians (1 OB-GYN and 1 PCP). All 4 women wanted more effective treatments with minimal side effects and convenient administration. Both physicians were satisfied with current treatments and had no concerns about prescribing HT. Patients had no concerns about prescribing HT and would consider prescribing a new HT if the non-HT offered “better symptom control than current treatment” (71% of patients) and “fewer long-term safety concerns” (82% of physicians). Patients most valued when the new treatment could improve sleep quality (60%) and reduce severity (59%) and frequency (58%) of VMS. Physicians most valued when the new treatment could reduce severity (67%) and frequency (60%) of VMS and have a better safety profile (56%). Conclusion: Patient satisfaction is similar across treatments, while physicians are most satisfied with HT and least satisfied with OTC medications. Patients’ primary concern with their current treatment is lack of effectiveness, while physicians were primarily concerned with long-term safety. Treatment satisfaction, unmet needs, and new treatment expectations differed between patients and physicians, however, the need for safer and more effective treatments for VMS was identified.

Sources of Funding: The study was sponsored by Astellas Pharma, Inc. (Northbrook, IL). Writing support provided by Nicole Boyer, MPH, PhD, and LeeAnn Braun, MPH, MEed, of Peloton Advantage, LLC, an OPEN Health company, was funded by Astellas.

### S-12. Physiologically-measured vasomotor symptoms and systemic inflammation among midlife women

Mary J. Carson, PhD1; Rebecca C. Thurston, PhD2. 1Psychology, University of Pittsburgh, Pittsburgh, PA; 2Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA

Objective: Vasomotor symptoms (VMS) are the classic menopausal symptom experienced by approximately 70% of midlife women. VMS are associated with impairments in quality of life and potentially with physical health risk, such as cardiovascular disease. Emerging data suggest that VMS may be associated with heightened systemic inflammation. We also considered the role of VMS in the context of cardiovascular disease. Design: The analytic sample included 276 women from the MsHeart study of nonsmoking peri- and post-menopausal women aged 40–60 years with and without VMS. Women completed ambulatory monitoring (sternal skin conductance) and self-report measurement of VMS during wake and sleep, as well as fasting phlebotomy (inflammatory markers and estradiol measures) via liquid chromatography tandem mass spectrometry. Relationships between VMS and high sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6) were tested in separate linear regression models controlling for age, education, race/ethnicity, body mass index, and immune medications. Estradiol was included in a separate step.

Result: Among women who reported VMS, 14 VMS/24 hours were physiologically detected.
S-13. Self-Reported Efficacy of Hormone Therapy and Symptom Burden in Menopausal Patients with Obesity

Anita Pershad, MD1,2, Joshua Morris, MD MA NCMP3,4, Hayley Ward, Sarah Kroner2, Diane Pace, PhD APRN NCMP5, Pallavi Khamna2, Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, VA; 6Obstetrics and Gynecology, The University of Tennessee Health Science Center, Memphis, TN; 7Reproductive Endocrinology and Infertility, Eastern Virginia Medical School, Norfolk, VA; 8Shady Grove Fertility, Norfolk, VA; 9College of Nursing, The University of Tennessee Health Science Center, Memphis, TN

Objective: There is paucity of data on impact of comorbidities on the efficacy of hormone therapy in menopause. Our study aimed to investigate the association of obesity and self-reported efficacy of hormone therapy in peri- and postmenopausal women. Design: We conducted a medical record review based study of patients presenting to a menopause clinic at an urban, university-affiliated, academic medical center in the Midsouth between July 2018 and December 2022. Statistical analysis was performed with student t-tests and odds ratios. P-values ≤ 0.05 were considered statistically significant. During the five-year study period, 119 eligible patients were included. Obesity was defined as a body mass index ≥ 30.

Results: There was no statistically significant difference in age, duration of menopause, use of hormone therapy and therapy acceptance between the 2 groups. Women with obesity were more likely to identify as black, report presence of vasomotor symptoms, genitourinary/vulvovaginal symptoms, mood disturbances, and decreased libido. Women with obesity were less likely to experience symptomatic relief after either systemic and/or localized hormone therapy compared to women without obesity. (OR 0.07; 95% CI 0.01, 0.64) (p-value 0.006) Conclusion: Our pilot study suggests that menopausal women with obesity experienced an increase in symptom burden and lower efficacy of hormone therapy. We are not aware of prior studies examining the impact of obesity on symptom burden and efficacy of hormone therapy in menopausal women.

Sources of Funding: None


Talia Sobel, MD1, Alison Huang2, Nadra Lisha, PhD3. 1Women’s Health Internal Medicine, Mayo Clinic Arizona, Scottsdale, AZ; 2Internal Medicine, University of California San Francisco, San Francisco, CA

Objective: Menopausal hormone therapy (HT) is first-line treatment for vasomotor symptoms of menopause and is used to manage premature menopause, treat symptoms associated with genitourinary syndrome of menopause, and prevent osteoporosis. After the Women’s Health Initiative trials were published in 2002-2004, HT prescribing rates decreased due to fears regarding risk of cardiovascular disease, venous thromboembolism, and breast cancer. HT prescription rates fell an estimated 38%-66% in 2002, and by 2008, rates dropped by more than 70%. More recently, research has examined the benefits and risks of HT by timing of initiation, and newer formulations of HT have been developed that are bioidentical as opposed to synthetic. United Kingdom prescribing rates have increased by >13% from 2010 to 2021, but no recent U.S. studies have reported prescribing rates in representative ambulatory care samples. This study aims to provide updated information on HT prescribing trends for U.S. in ambulatory care settings from 2018-2019. Design: Data from the 2018-2019 National Ambulatory Medical Care Survey (NAMCS), which uses multistage probability sampling to obtain a representative sample of U.S. ambulatory care visit data, were analyzed to examine HT prescribing in ambulatory visits involving U.S. women aged 50 and older. Descriptive statistics were used to examine documented prescription or continuation of HT (including estradiol, ethinyl estradiol and conjugated estrogen therapy, with or without progestin therapy) in ambulatory visits across both years, stratified by key patient demographic and clinical characteristics, and incorporating NAMCS sampling weights. Initial differences in the prevalence of HT prescribing by key demographic and clinical patient characteristics were examined using Rao-Scott Chi-Square tests. Multivariable logistic regression was used to examine independent associations between patient characteristics and HT use in ambulatory visits. Results: In 2018-2019, HT was documented in an estimated 2.2% of 10,997 U.S. ambulatory visit records (representing approximately 24.3 million visits) involving female patients aged 50 and older. In multivariable analysis, HT was more likely to be documented in visits involving women diagnosed with depression (OR 2.0, 95%CI 1.1, 3.7) or polypharmacy defined by five or more total medications (OR 5.0, 95%CI 2.8-8.9), but less likely to be documented in visits with women of Hispanic ethnicity (OR 0.2, 95% CI 0.1-0.5), or with heart disease (OR 0.3, 95%CI 0.1-1.0) or diabetes (OR 0.4, 95% CI 0.2-0.9). No significant associations were found between HT prescribing or continuing rates and age, race, presence of obesity, cancer, dementia, stroke, thromboembolic disease, hypertension, hyperlipidemia, or osteoporosis (p>0.05 for all). Conclusion: In this national sample of U.S. healthcare visits from 2018-2019, the prevalence of HT prescription or continuation was low in women aged 50 or older presenting for ambulatory care visits. Prescribing of HT was more likely in visits with women who had depression or polypharmacy, but less likely in visits with women who were Hispanic, had ischemic or congestive heart disease, or diabetes mellitus. These findings suggest that HT prescribing may be appropriately lower in certain patient groups where HT use may be associated with adverse outcomes, such as ischemic or congestive heart disease, while HT may be inappropriately withheld from patient groups who may

Meenakshi Goel, MD, MRCOG1, Kelsey Mills, MD, MSc, HSEJ, FRSCC, NCMP1,2, Joan Ko1, Trish Barbato4, Wendy Wolfman, MD, FRCS(C), FACOG, NCMP1. 1Professor, Obstetrics and Gynecology, University of Toronto, Toronto, ON, Canada; 4Obstetrics and Gynecology, University of Victoria, Victoria, BC, Canada; 4Clinical Associate Professor, Obstetrics and Gynecology, The University of British Columbia, Vancouver, BC, Canada; 4Menopause Foundation of Canada, Rosseau, ON, Canada; 4Obstetrics and Gynecology, University of Toronto, Toronto, ON, Canada

Objective: Women account for almost half of the Canadian workforce of which more than five million are over the age of 40. Approximately one-quarter of the country's 19 million person labour force are either going through the menopause transition or are postmenopausal. Despite this sizable demographic, menopause remains a largely unacknowledged and unsupported issue in many workplaces, with one in ten women leaving their jobs due to menopause-related challenges. The aim of this study is to assess the impact of menopause on women's experiences in the workplace and to establish the level of support they receive with regards to managing menopause related symptoms. By addressing this knowledge gap, we hope to inform strategies for improving workplace culture and policies to better support menopausal & perimenopausal women.

Methods: The study utilised data from an online survey completed by 1,023 Canadian women aged 40-60 were surveyed, ensuring representation across various demographic variables including region, education, income, and ethnicity ensuring a diverse range of perspectives from across the country. Results: Impart on work performance and relationships 4 out of 10 reported that perimenopause or menopause had a negative impact on their work experience. 32% reported that their symptoms affected their work performance and 16% indicated that their symptoms negatively affected work relationships. 24% women reported that they required more support at work and to provide support to women undergoing this natural transition. Conclusion: The underreporting and taboo associated with menopause and its symptoms in the workplace have significant implications for the well-being and productivity of female employees. There is an urgent need to dispel the silence and stigma around menopause at work and to provide support to women undergoing this natural transition. Creating a menopause-inclusive workplace, while prioritizing education and training on this issue, as well as developing policies and support systems can help address the unique needs of women experiencing menopause-related challenges.

S-16. Menopausal Vasomotor Symptoms and Plasma Alzheimer’s Disease Biomarkers

Rebecca C. Thurston, PhD1, Pauline Maki, PhD2, Yuefang Chang, PhD3, Minjie Wu, PhD4, Howard Aizenstein, PhD5, Carol A. Derby1, Thomas K. Karikari4,6. 1Psychiatry, Epidemiology, and Psychology, University of Pittsburgh, Pittsburgh, PA; 2Psychiatry, Psychology, and Obstetrics & Gynecology, University of Illinois Chicago, Chicago, IL; 3Neuroimaging, University of Pennsylvania, Pittsburgh, PA; 4Psychiatry, University of Pittsburgh, Pittsburgh, PA; 5Neurology, Albert Einstein College of Medicine, Bronx, NY; 6Psychiatry and Neurochemistry, Goteborgs universitet Sahlgrenska Akademi, Goteborg, Sweden

Objective: Women comprise two thirds of individuals with Alzheimer’s disease (AD). Midlife and the menopause transition are important times for women’s cognitive health, as the hallmarks of AD begin to emerge at midlife. Prior work links the cardinal menopausal symptom, vasomotor symptoms (VMS), with poor memory and with alterations in brain structure, function, and cognition. These associations are evident when VMS are monitored objectively with ambulatory scalp conductance monitors. However, it is unknown whether VMS are associated with AD biomarkers. Recent advances in assessing AD in vivo include the emergence of AD blood-based biomarkers, which are particularly useful to assessing risk decades before the emergence of AD dementia. The study objective was to determine whether objectively-assessed VMS are associated with adverse AD biomarker profiles.

Design: Between 2017 and 2020 the McBrain study enrolled 274 women aged 45-67 who had a uterus and at least one ovary and were late perimenopausal or postmenopausal. No participants had a neurological disorder or recent use of hormonal or non-hormonal VMS treatments. Women underwent assessment of their VMS via ambulatory scalp monitoring for 24 hours, physical measures, an interview, three days of sleep actigraphy assessment, and a fasting blood draw for apolipoprotein E genotyping, estradiol (via liquid chromatography-tandem mass spectrometry), and the assessment of plasma concentrations of AD biomarkers amyloid β (Aβ) 42/40 ratio, phosphorylated tau (p-tau 181 and 231), glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) (via Single molecule array technology). AD biomarkers were considered both continuously and Aβ42/40 additionally considered as clusters using the K-medoids clustering method. Associations between sleep and wake VMS and AD biomarker levels or clusters were tested in linear or logistic regression models with covariates age, race/ethnicity, education, body mass index, and apolipoprotein E4 status. Results: A total of 248 (mean age=59.06 years, 81% white, 99% postmenopausal) MsBrain participants contributed data. Objectively-assessed VMS, particularly sleep VMS, were associated with significantly lower Aβ42/40 (BSE)=-0.010 (100p), n=0.18, multivariable. Further, a greater number of sleep VMS were associated with an increased likelihood of being in the low/abnormal Aβ42/40 cluster [OR(95%CI)=1.18(1.05, 1.33), p<0.06, multivariable]. Findings remained significant after additional adjustments for estradiol and actigraphy assessed sleep duration and wake after sleep onset. Conclusion: Sleep VMS were associated with adverse Aβ42/40 profiles, indicating that VMS experienced during sleep may be a marker of women at risk of AD dementia. Women with a high burden of sleep VMS may warrant AD dementia risk reduction efforts.

Sources of Funding: Funded by National Institutes of Health, National Institute on Aging grants RF1AG053504 and R01AG053504 (Thurston & Maki).

FRIDAY CONCURRENT SESSION #1

S-17. Associations of Trajectories of Anti-Müllerian Hormone over the Menopause Transition with Trajectories of Cognitive Function after Menopause:

The SWAN Study

Samar R. El Khoudary, PhD1, Meryuzhen Qi, Arun Karlamangla2, Nanette Santoro3,4, Ken Howard5, Mary Sammel5, Emmeline Finkelstein1,6. 1University of Pittsburgh, Pittsburgh, PA; 2University of California Los Angeles, LA, CA; 3University of Colorado, Aurora, CO; 4University of Massachusetts, Worcester, MA; 5Massachusetts General Hospital, Boston, MA

Objective: Women have a greater prevalence of Alzheimer disease than men. They experience a faster cognitive decline starting as early as post menopause. Anti-Müllerian hormone (AMH), which drops progressively over the menopause transition (MT), has recently showed paracrine/autocrine actions in regulating synaptic transmission in the hippocampus in mouse model. Whether AMH trajectory over the MT contributes to cognitive function trajectory post menopause is unknown. Our aim was to assess associations of AMH trajectories over the MT with trajectories of cognitive function in 4 domains after menopause. Design: SWAN participants who transitioned without using hormone therapy or having had a hysterectomy or bilateral oophorectomy, and had AMH measured over the MT and cognitive function domains [working memory, processing speed; and verbal episodic memory immediate and delayed recall] measured repeatedly post menopause were included. Group-based trajectory modeling was used to identify the trajectories of AMH and cognitive function domains relative to FMP. Associations of AMH trajectories with cognitive function trajectories were assessed using multivariable logistic regression adjusted for study site, race/ethnicity and baseline age, menopause status, education, ability to pay for basics, body mass index, glucose, and systolic blood pressure.

Results: We evaluated 2432 women (Baseline age 42.5 years). Two distinct AMH trajectories were identified (Figure A): High-fast decline and Low-slow decline. For cognitive function, women clustered into either a high or a low trajectory group for each cognitive domain (Figure B-E). In final models, compare to women in the High-fast decline AMH trajectory, women in the Low-slow decline group were at a
higher risk of experiencing a low processing speed trajectory after menopause (Figure F). No other associations were found. Conclusion: AMH decline over the MT could be a novel marker of cognitive function, particularly processing speed, later in life for women. Sources of Funding: The Study of Women’s Health Across the Nation (SWAN) has grant support from the National Institutes of Health (NIH), DIHS, through the National Institute on Aging (NIA), the National Institute on Minority Health (ORWH) (Grants R04DD04066; AG012505, AG012535, AG102539, AG102546, AG102553, AG102554, AG102495, and U19AG063720).

S-19. Efficacy of a behavior change intervention for menopausal symptoms delivered through a mobile application

Health A. Muir1, Alex Handy2, Rebecca Love1, Louise Draper1, Holly Pederson1,2,3
1Vira Health, London, United Kingdom; 2Cleveland Clinic, Cleveland, OH; 3Institute for Health Informatics, University College London, London, United Kingdom; 4Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH

Objective: Behavior change interventions, based on randomized controlled trials, have proven to be effective in the management of menopausal symptoms. Today, many people are using mobile applications to access medical information and seek such interventions. This research study explores the efficacy of a behavior change intervention for menopausal symptoms, administered via a mobile application to a real world cohort. This study therefore assesses not only the ability of behavior change interventions to improve symptoms, but also the efficacy of a mobile application as a contemporary mode of delivery. Design: Data is obtained via an in-application baseline assessment and repeated self-reported symptom check-ins. The in-application symptom check-in tracks 14 symptoms aligned with the Greene-Climacteric-Scale which are scored for severity from 0 (None) to 4 (Severe). Users are provided with a personalized 12 week plan, consisting of three 4 week modules under the focus areas: mood, weight, sleep, body (pelvic floor symptoms), sex and hot flushes. Additionally, users have access to in-application educational material and live coach support. The overall study cohort were users that completed a baseline symptom check-in and at least one subsequent symptom check-in. Sub-cohorts were also analyzed for users who completed a full behavior change plan, users who completed at least one module, and users who only engaged with material outside of behavior change plans. Symptom change was assessed within cohorts via paired t-tests comparing baseline to final symptom scores. Comparative symptom change between different sub-cohorts was assessed via unpaired t-tests. Results: The final analytic sample included data from 5,174 women (mean age: 55, SD 6). The descriptive statistics incorporating sample weights were conducted for key characteristics. The final analytic sample included data from 5,174 women (mean age: 55, SD 6). The majority were postmenopausal (68%), natural menopause: 46%, surgical menopause: 22%); White, Non-Hispanic (63%); and working full- or part-time (67%). Over 42% of participants reported lifetime cannabis use in any form, most commonly via smoking or edible products. Over 30% of participants who reported ever smoking cannabis endorsed daily or near-daily smoking for a year or longer. Most reported recreational use (62%); smoke and secondhand smoke were the most common forms of cannabis use, and sleep, mood, and chronic pain are primary targets for medical cannabis use among women in midlife. A sizeable minority endorse smoking and/or using edible products on a daily or near daily basis, which may increase health risks related to cannabis use. This study highlights the importance of recognizing and discussing cannabis use in the health care setting, and the need for additional research to evaluate the potential harms and/or benefits of use in this vulnerable population. Sources of Funding: Tobacco-Related Disease Research Program (T32KT4693, PI: CJG), VA HSR&D CDA (IK2 HX002402, PI: CJG), VA Research Career Scientist Award (R6 CX002366, ALB).

S-18. Medical and Recreational Cannabis Use in the Menopause Transition: Evaluation of Trends from a Large, Nationally Representative Sample of Midlife Women

Carolyn J. Gibson, PhD, MPH1,2, Amy L. Byers, PhD2, Beth E. Cohen, MD, MAS2, Salomeh Keyhani, MD, MPH2,3
1San Francisco VA Health Care System, San Francisco, CA; 2University of California San Francisco School of Medicine, San Francisco, CA

Objective: With rapidly expanding legalization and normalization, recreational and medical cannabis use is increasing. The menopause transition may be a critical and underrecognized period for cannabis use, with limited evidence for benefit and potential for harm. Women and adults aged 50 and older have been identified as among the fastest growing groups of users. Medical cannabis use is also more often reported in both women and older adults, frequently targeting common menopause- and aging-related symptoms including insomnia, anxiety, and chronic pain. Cannabis is also directly marketed to women for menopause symptom management despite a lack scientific studies. Medical cannabis use for these chronic concerns may contribute to more frequent use, increasing risk for the development of tolerance and adverse health outcomes. However, little is known about the prevalence or characteristics of cannabis use among women in and after the menopause transition. To address this gap, we sought to examine frequency, forms, and motives of cannabis use in a large, nationally representative sample of midlife U.S. women. Design: Data were drawn from a cross-sectional survey of women and gender-diverse members of Ipos KnowledgePanel, an established U.S. probability-based online panel. Eligible members were aged 45-84 and self-identified as female sex at birth, with no use of gender-affirming hormone therapy or surgery. A nationally representative sample was derived with purposive sampling by race/ethnicity within the specified age range and the application of sample weights for all analyses. Participants completed structured-item questions to self-report sociodemographic characteristics, menstrual history, frequency, forms (smoking, vaping, topicals, edibles), and motives (recreational, medical or therapeutic) of lifetime and past 30-day cannabis use. Descriptive statistics incorporating sample weights were conducted for key characteristics. Results: The final analytic sample included data from 5,174 women (mean age: 55, SD 6). The majority were postmenopausal (68%); natural menopause: 46%, surgical menopause: 22%); White, Non-Hispanic (63%); and working full- or part-time (67%). Over 42% of participants reported lifetime cannabis use in any form, most commonly via smoking or edible products. Over 30% of participants who reported ever smoking cannabis endorsed daily or near-daily smoking for a year or longer. Most reported recreational use (62%); 25% reported both recreational and medical use, and 13% reported that their only motive was medical use to manage symptoms and chronic health conditions. The most common therapeutic targets for medical use were chronic pain (28%), anxiety (24%), sleep (22%) and stress (22%). Cannabis use to manage menopause symptoms was endorsed by 6% of women with a history of use, primarily to target menopause-related mood and sleep difficulties. Over 10% of participants had used cannabis in the past 30 days, most often smoking (56%), ingesting edible products (52%), or using cannabis in more than one form (39%). Among those with past 30-day use, 31% reported smoking cannabis on a daily or near-daily basis, while 19% reported daily or near-daily use of edible cannabis products. Conclusion: Both current and lifetime medical and recreational cannabis use was relatively common in this nationally representative sample of midlife women. Consistent with past research largely focused on men and younger adults, smoking is the most common form of cannabis use, and sleep, mood, and chronic pain are primary targets for medical cannabis use among women in midlife. A sizeable minority endorse smoking and/or using edible products on a daily or near daily basis, which may increase health risks related to cannabis use. This study highlights the importance of recognizing and discussing cannabis use in the health care setting, and the need for additional research to evaluate the potential harms and/or benefits of use in this vulnerable population. Sources of Funding: Tobacco-Related Disease Research Program (T32KT4693, PI: CJG), VA HSR&D CDA (IK2 HX002402, PI: CJG), VA Research Career Scientist Award (R6 CX002366, ALB).

S-20. Effects of a Pelvic Yoga Program on Genitourinary Quality of Life in Midlife and Older Women with Urinary Incontinence: a Multisite Randomized Trial

Alison Huang, MD, MAS1, Margaret Chesney, PhD1, Michael Schembri1, Harini Raghavanthan1, Sarah Pawlowksy2,1, Leslee Subak1
1University of California San Francisco, San Francisco, CA; 2San Francisco State University, San Francisco, CA; 3Stanford University, Stanford, CA

Objective: Pelvic yoga has been recommended as a complementary behavioral treatment strategy for women with genitourinary symptoms such as urinary incontinence that frequently emerge in midlife, but there is little evidence of its impact on women’s genitourinary quality of life (QOL). We examined changes in genitourinary QOL among midlife and older women in a randomized trial of a group-based pelvic yoga program versus non-specific physical conditioning program for incontinence. Design: The Lessening Incontinence with Low-impact Activity (LILA) study is a multisite trial of a group-based yoga program designed by an expert yoga and clinician panel to improve pelvic function in midlife and older women. Ambulatory women aged 45 or older with incontinence were recruited from the general communities surrounding three study sites in California in 2019-2022. Eligible women were randomly assigned...
to a therapeutic yoga program consisting of twice weekly group instruction by trained yoga instructors and once weekly individual practice of study-specific Hatha yoga techniques for 3 months, versus a general physical conditioning program involving equivalent-time group instruction and individual practice of skeletal muscle stretching and strengthening exercises. Linear mixed models examined change in scores on multiple validated self-report measures of genital urinary symptom bother or quality of life over 3 months, including the Urgency/Obliteration Distress Inventory-6 (UDI-6), Incontinence Impact Questionnaire (IIQ), and Patient Perception of Bladder Condition (PPBC), adjusting for site and intervention cohort. **Results:** Among the 240 participants randomized (121 to yoga, 119 to physical conditioning), mean age was 62.0 (±8.7) years (total range 45 to 90 years), and 40% self-identified as racial or ethnic minorities (14% Latina/Hispanic, 6% African American, 16% Asian American, 4% multiracial). At baseline, mean scores on genitourinary QOL measures were 38.8 (±19.2) for the UDI-6, 101.0 (±7.7) for the IIQ, and 3.4 (±1.0) for the PPBC. Over 3 months, scores on all genitourinary QOL measures improved by more than the minimum important difference thresholds in the pelvic yoga group (Table), and improvements in UDI-6 scores were modestly greater in the pelvic yoga than the physical conditioning group (estimated between-group difference of 5.8 (95% CI 1.6-10.0) points in favor of yoga, P=0.02). However, no significant between-group differences in change in overall IIQ or PPBC scores were detected (Table). **Conclusion:** Among midlife and older women with urinary incontinence, genital urinary QOL assessed by multiple self-reported measures improved over 3 months among women assigned to a group-based pelvic yoga program, but improvements were similar or similar to those observed with a non-specific muscle conditioning program. Findings from this multisite trial provide new evidence to support benefits of engagement in pelvic yoga among midlife and older women with genital urinary symptoms, but also suggest that women may benefit from other general physical-based interventions.

**Table:** Change in Genitourinary Quality of Life Scores from Baseline to 3 Months, by Intervention Assignment

<table>
<thead>
<tr>
<th>Group</th>
<th>Mean Change</th>
<th>SD</th>
<th>P</th>
<th>Mean Change</th>
<th>SD</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pelvic Yoga</td>
<td>P</td>
<td>P</td>
<td></td>
<td>P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical Conditioning</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>genitourinary QOL</td>
<td>5.8 (-1.6-10.0)</td>
<td>2.4</td>
<td>&lt;0.01</td>
<td>4.0 (-1.0-9.0)</td>
<td>2.4</td>
<td>&lt;0.01</td>
</tr>
</tbody>
</table>

*Abbreviations: UDI-6, Urgency/Obliteration Distress Inventory-6; IIQ, Incontinence Impact Questionnaire; PPBC, Patient Perception of Bladder Condition.

**S-16. Menopause Care in the Veterans Healthcare Administration: A Qualitative Investigation of Women Veteran and Provider Perspectives**

Haley Miles-McLean, PhD², Anna Blanken, PhD³, Francesca Nicossa, PhD³, Carolyn J. Gibson, PhD³, Veterans Integrated Services Network 5 Mental Illness Research Education and Clinical Center, Baltimore, MD; Psychiatry, University of Maryland School of Medicine, Baltimore, MD; San Francisco VA Health Care System, San Francisco, CA; Psychiatry & Behavioral Sciences, University of California San Francisco, San Francisco, CA; Institute for Health & Aging, University of California San Francisco School of Medicine, San Francisco, CA

**Objective:** Menopausal women are the fastest growing population served by the Veterans Healthcare Administration (VHA). Over half of women VHA users are ages 45 or older, an important time for menopause-related concerns. Accordingly, VHA has prioritized improvement of women Veterans’ healthcare. Despite this, little is known about Veteran experiences and the practice of menopause care within VHA. We conducted a qualitative study to better understand Veterans and provider experiences related to menopause care within VHA.**Methods:** Veterans also reported variability in ways they access care. Women Veterans and VHA primary care providers, the typical providers for care. Women Veteran participants (mean=56.3 years, SD=5.1) were primarily postmenopausal (72%). Most women Veterans self-reported their race as either white (56%) or Black (22%). Provider participants (n=13) were on average 34.7 (SD=11.0) years post-residency training. Veterans and providers offered diverse perspectives on how Veterans discussed menopause care in VHA. Regarding current practices, providers described varied approaches and treatment recommendations for assessment and management of menopause concerns, including some who do not address menopause at all. Veterans also reported variability in ways they access menopause care, some discussing menopause with all primary care providers and some discussing menopause only with health providers or others who never raise menopause concerns. Within healthcare communication both Veterans and providers described variability regarding comfort with discussing menopause symptoms, particularly genitourinary or sexual concerns; with who initiates discussions of menopause; and where menopause concerns fall in relative importance to other health issues. **Results:** Veterans identified a preference for whole-person care, including non-pharmacological and medication options. Providers highlighted a preference for adequate mental health care options. Finally, regarding needs, Veterans indicated a desire for better menopause education, trusting relationships with empathetic providers, sufficient appointment time to address all concerns, and a collaborative treatment approach. Providers identified needing clear ways to consult with other disciplines, additional training resources, standardized assessments, and decision-making tools for medical interventions. **Conclusion:** In this study, women Veterans and providers described their experiences related to menopause care within VHA. Findings suggest that menopause care in VHA can vary widely from both Veteran and provider perspectives, emphasizing a need for more resources, education, and shared decision-making strategies to assist Veterans and providers navigating this stage of life. **Sources of Funding:** This research was supported by a VA HSR&D CDA (IK2 HX002402) to C.J.G. and drew upon VA Women’s Health Research Network infrastructure, including the VA Women’s Health Practice-Based Research Network (VA HSR&D SDR 10-012). **FRIDAY CONCURRENT SESSION #2**

S-22. Post-Traumatic Stress Disorder Symptoms and Sexual Functioning Among Midlife Women

Karen P. Jakubowski, PhD¹, Pauline Maki, PhD¹, Karestan Koenen³, Carolyn J. Gibson³, Rebecca C. Thurston, PhD²; Psychiatry, University of Pittsburgh, Pittsburgh, PA; Psychiatry, University of Illinois Chicago, Chicago, IL; Harvard University T H Chan School of Public Health, Boston, MA; San Francisco VA Health Care System, San Francisco, CA

**Objective:** Post-traumatic stress disorder (PTSD) symptoms are common, reported by approximately 10% of women, and are related to adverse mental and physical health outcomes and lower wellbeing. However, limited work has examined relations between PTSD symptoms and sexual functioning among midlife women. We tested whether PTSD symptoms were associated with worse sexual functioning among midlife women after accounting for potentially confounding factors. **Design:** Participants were 274 postmenopausal women not taking hormone therapy or selective serotonin reuptake inhibitors or serotonin norepinephrine reuptake inhibitors. Women reported past-month PTSD symptom severity (PTSD Checklist-Civilian Version; total score range=17-85; also yields three symptom clusters: re-experiencing, hyperarousal, and avoidance/m numbing), past-month sexual function (6-item Female Sexual Function Index; queries sexual desire or interest, including vaginal intercourse, self-stimulation, and sexual fantasy; total score range=2-30, lower scores=worse sexual function), depressive symptoms (Center for Epidemiological Studies-Depression), and alcohol use (yes/no), and provided medical history and medication use via interview. Per FSFI scoring, analyses were restricted to women reporting past-month sexual activity, resulting in an analytic sample of N=121. Associations between PTSD scores (log) and sexual function were tested in linear regression models adjusted for age, race/ethnicity, education, vaginal estrogen use, alcohol use, and depressive symptoms. **Results:** Women were 45-66 years old (mean age=58 years) and identified as Asian or Pacific Islander (2%), Black (16%), Multiracial (1%), or White (81%). On average, women reported low to moderate severity of PTSD symptoms (M=23.9, SD=6.8) and normal sexual function (M=20.5, SD=5.1). Moderate and severe PTSD symptoms were related to lower sexual functioning [B(SE)=−4.00 (2.47), p=0.016; multivariable, Figure 1]. When specific aspects of PTSD symptoms were considered, greater avoidance/numbing symptoms were related to poorer sexual function [B(SE)=−3.20 (1.61); multivariable, p=0.049]. **Conclusion:** Greater past-month PTSD symptomatology was related to worse sexual functioning. Results suggest the importance of assessing and addressing PTSD symptoms among midlife women to improve women’s sexual health and functioning as they age. **Sources of Funding:** K23HL159293; RFA1GO53504; K24HL123565

Figure 1. PTSD symptom severity and FSFI sexual function total score
**S-23. Associations of sexual function and sexual orientation in cisgender women**

**Table 1.**

<table>
<thead>
<tr>
<th>Study</th>
<th>Population</th>
<th>Design</th>
<th>Setting</th>
<th>Intervention</th>
<th>Outcome measures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study A</td>
<td>Cisgender women</td>
<td>Prospective cohort</td>
<td>Tertiary care</td>
<td>Group-based mindfulness</td>
<td>Sexual function, sexual orientation</td>
</tr>
<tr>
<td>Study B</td>
<td>Cisgender women</td>
<td>Randomized controlled trial</td>
<td>Primary care</td>
<td>Computer-based intervention</td>
<td>Sexual function, sexual orientation</td>
</tr>
</tbody>
</table>

**Objective:** Cisgender, sexual minority women (SMW) reportedly have worse mental and physical health outcomes compared to cisgender, heterosexual women, including increased rates of substance use, obesity, and stroke. There is a paucity of literature on sexual function in sexual minority women. The current study has some showing significant differences in sexual function between SMW and heterosexual women, while others have reported better sexual function in SMW compared to heterosexual women. Improved understanding of the relationship between sexual function and sexual orientation may lead to better healthcare and prevention strategies for SMW. This study aims to explore sexual function and sexual distress in cisgender SMW compared to cisgender, heterosexual women.

**Design:** A retrospective analysis was completed using questionnaire data in the Data Registry on Experiences of Aging, Menopause and Sexuality (DREAMS) collected from women aged 18 and older who presented to women’s health clinics at Mayo Clinic in Rochester, Minnesota, Scottsdale, Arizona, and Jacksonville, Florida from December 2016 thru February 2023. The Female Sexual Function Index (FSFI) and Female Sexual Distress Scale (FSDS) were used to assess sexual function (FSFI ≥ 26.55 and FSDS ≥ 11).

A multivariable logistic model assessed the association between sexual dysfunction and SMW after adjusting for age, race/ethnicity, body mass index (BMI), menopause status, current hormone therapy use, quality of life, relationship status, depression (PHQ-9 ≥ 5), anxiety (GAD-2 ≥ 5), history of abuse in the last year, adverse childhood experiences, sleep, and relationship satisfaction. Results: A total of 2,241 sexually active women were included in the analysis. Of these, 38% (189/6241) were SMW and 97% (6052/6241) were heterosexual; mean age 51.6 years, 92.6% White, 8.4% married/partnered, 26.5% on hormone therapy, 3.5% with BMI ≥ 30 kg/m², and 62.9% postmenopausal. Hormone therapy use was significantly higher in SMW compared to heterosexual women (p = 0.015), while SMW had significantly lower quality of life scores (7 vs 8, p = 0.012) and relationship satisfaction scores (4.3 vs 4.6, p = 0.022), compared to heterosexual women. SMW were more likely to endorse anxiety and depression symptoms compared to heterosexual women (52.7% vs 35.5%, p < 0.001; 53.8% vs 37.3%, p < 0.001, respectively). On univariate analysis, SMW had lower total FSFI scores (18.2 vs 19.7, p = 0.037) than heterosexual women, though this was not a statistically significant difference. SMW had higher total FSDS scores (17 vs 15, p = 0.037), demonstrating significantly worse sexual distress compared to heterosexual women. No statistically significant differences were seen for sexual dysfunction by combined endpoint on univariate (SMW 6.5% vs heterosexual 5.7%, p = 0.612) or multivariable (OR 1.15, 95% CI 0.64-1.58, p = 0.57) analysis.

**Conclusion:** Risk for sexual dysfunction was similar between SMW and heterosexual women. Quality of life and relationship satisfaction scores were statistically significantly higher in heterosexual women compared to SMW, while hormone therapy use rates were similar. Anxiety and depression symptoms were higher in SMW, consistent with prior research on minority stress. Limitations of this study include the observational design and lack of prospective data.


Sheryl M. Green, PhD, CPsc^2, Melissa Furtado, MSc, PhD (Candidate)^3, Elena C. Ballantyne, PsyD^4, Alison Shea, MD, PhD, David L. Streiner, PhD^4, Benicio N. Frey, MD, PhD^2, Randi E. McCabe, PhD^4, Judy M. Kling^1,3. 1Psychology, Neuroscience, and Behaviour, McMaster University, Hamilton, ON, Canada; 2Women’s Health Concerns Clinic, St. Joseph’s Healthcare Hamilton, Hamilton, ON, Canada; 3Women’s Health Clinics Concern, St. Joseph’s Healthcare Hamilton, Hamilton, ON, Canada; 4Obstetrics and Gynecology, St. Joseph’s Healthcare Hamilton, Hamilton, ON, Canada

**Objective:** Sexual concerns are reported by 68% to 85.6% of peri- and post-menopausal women, which negatively impact physical and emotional well-being. Despite this, little attention has been paid to this area in the literature and no well-established, non-pharmacological treatments exist. The primary objective of this study is to evaluate the efficacy of a four-session individual Cognitive Behavioural Therapy protocol in improving sexual satisfaction and reducing distress during peri- and post-menopause (CBT-SC-Meno). Secondary objectives include sexual functioning, relationship satisfaction, menstrual symptoms, quality of life, and anxiety.

**Study Design:** A unique way to go about it.” Second, women in both intervention and control groups helped them cope with their symptoms more effectively. Qualitative treatment satisfaction analyses were conducted individual interviews with participants in a RCT of a group-based mindfulness intervention versus an educational control group (N=25) as we were initially interested but did not attend any groups (N=9). A semi-structured interview guide was developed by the principal investigator (PI), a co-investigator, and qualitative research specialist. The qualitative research specialist conducted the interviews with trial participants over video conference. The PI conducted interviews with those who were interested but did not attend any sessions via telephone. All interviews were audio recorded and transcribed. We used a phenomenological approach to analysis. The qualitative research specialist and the PI used a subset of interviews to develop and refine a codebook, then the PI assigned codes to all data. Codes were grouped into subthemes and themes and key insights were extracted. Results: Three key themes emerged. First, women were given more in-depth conversations about happiness and well-being while participating in the group. Second, women in both intervention and control groups gained perspective about life and their relationship with menopause.

**Study Design:** A semi-structured interview guide was developed by the principal investigator (PI), a co-investigator, and qualitative research specialist. The qualitative research specialist conducted the interviews with trial participants over video conference. The PI conducted interviews with those who were interested but did not attend any sessions via telephone. All interviews were audio recorded and transcribed. We used a phenomenological approach to analysis. The qualitative research specialist and the PI used a subset of interviews to develop and refine a codebook, then the PI assigned codes to all data. Codes were grouped into subthemes and themes and key insights were extracted. Results: Three key themes emerged. First, women were given more in-depth conversations about happiness and well-being while participating in the group. Second, women in both intervention and control groups gained perspective about life and their relationship with menopause.
menopause. So when we were talking about bone density, I was like, oh, huh. I mean, it was interesting and helpful, but it wasn't what I was expecting. I was in the control group and I thought, and another said, "I wanted her to be more like a class. Like, here's some slides and we're going to talk about this. Having a little bit more visual reinforcement." Participants who were randomized but did not attend any sessions listed time conflicts and lack of private space to participate in groups as their top reasons for dropping out. One of these women said, "I was excited about this one. And I got in my e-mail a list of dates and times for meeting. And I was looking over it and every single one of them I KNEW I would be working. And I'm looking at all of them like, this one too? Come on!"

Conclusion: Women with low sexual desire are curious about mindfulness, group interventions are well received in this population, and participants desire a balance of didactic and interactive elements.

Sources of Funding: National Institute of Health’s National Institute on Aging

Table 1. Outcomes by Randomized Treatment

<table>
<thead>
<tr>
<th>Vaginal Estrogen</th>
<th>Hyaluronic Acid</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline (SD)</td>
<td>Change at 12 weeks (n=22)</td>
</tr>
<tr>
<td>Vaginal symptoms questionnaire, mean (SD) or mean difference (95%)</td>
<td></td>
</tr>
<tr>
<td>Overall</td>
<td>5.2 (3.7)</td>
</tr>
<tr>
<td>Symptoms</td>
<td>1.7 (1.0)</td>
</tr>
<tr>
<td>Emotions</td>
<td>0.8 (1.3)</td>
</tr>
<tr>
<td>Life impact</td>
<td>0.7 (1.1)</td>
</tr>
<tr>
<td>Sexual desire</td>
<td>1.9 (1.0)</td>
</tr>
</tbody>
</table>

Vaginal symptoms index score, mean (SD) or mean difference (95% CI):
- Dyshydrosis: 5.3 (1.6) vs. 3.6 (1.5, -2.2), P=0.049
- Vaginal itching: 2.3 (2.0) vs. 0.8 (1.6, -1.2), P=0.09
- Vaginal dryness: 6.8 (2.3) vs. -4.5 (2.6, -2.3), P=0.908

Female sexual function index score, mean (SD) or mean difference (95% CI):
- Overall: 6.8 (3.7) vs. 3.1 (1.4, -2.3), P=0.360
- Dryness: 2.3 (0.9) vs. 1.2 (0.6, -0.7), P=0.319 (0.10, 0.91) P=0.749
- Soreness: 1.2 (2.0) vs. 0.7 (0.1, -0.6), P=0.170 (0.04, 0.14)
- Irritation: 1.3 (1.0) vs. 0.6 (0.2, -0.4), P=0.12 (0.08, 0.99) P=0.764
- Discharge: 0.2 (0.6) vs. 0.4 (0.8, -0.2), P=0.12 (0.02, 0.90) P=0.12

Visual analog scale score, mean (SD) or mean difference (95% CI):
- Overall: 5.8 (1.3) vs. 2.8 (1.3, -2.3), P=0.360
- Dryness: 1.8 (1.0) vs. 0.9 (0.4, -0.5), P=0.360
- Soreness: 1.3 (1.0) vs. 0.7 (0.2, -0.5), P=0.119 (0.01, 0.02) P=0.810

Visual analog scale score was collected by measuring where the patient placed an X on a 10 cm line between the end points of no symptoms or extreme symptoms.

P-2.

False Positive Pap Smear as the first sign of Genitourinary Syndrome of Menopause

Alberto Dominguez-Bali, MD1, Toriiseju Areneyeka1,2, Ravarasha Murpeziwa1,2, Allison Palacios1,2, Kiran Hashmi3, Augusta Ezen1,2, Miea Bahho1,2, Vikram Pooni1,2, Jael Reyes Chea1,2, Ahmosha Azzam1,2, Sodjinin M. Kassa, RN BSN BS1,2, Milo Obas, MD1,3, Clinical science, American University of Antigua, Coolidge, Antigua and Barbuda; Miami Center for Obstetrics, Gynecology and Human sexuality, Miami, FL; Office of international affairs, Florida International University, Miami, FL

Objective: Around 2010, we noticed an increase in the number of perimenopausal women presenting with abnormal Pap smears (cytological dysplasia) in our clinics. These women had no previous history of cervical abnormalities and were in long-term, stable sexual relationships with one or two partners. After consulting with our pathologist, we

POSTER PRESENTATIONS

P-1.

A randomized, pilot trial comparing vaginal hyaluronic acid to vaginal estrogen for the treatment of genitourinary syndrome of menopause

Surbhi Agrawal, MD1, Zoe LaPier, MD1, Shavy Nagpal1,2, Antoinette Oot1,2, Steven Friedman3, Eren Hade1, Lila Nachtlag1,2, Benjamin Brucker1, Christina Escobar1, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; New York University, New York, NY

Objective: The objective was to compare the preliminary efficacy of a non-hormonal alternative, vaginal hyaluronic acid (HLA), to standard care hormonal therapy, vaginal estrogen, for treatment of genitourinary syndrome of menopause (GSM). Design: This was a randomized, parallel arm trial of two study treatments: HLA vaginal suppository (investigational, 5mg HLA) and vaginal estrogen cream (standard of care, 0.01%). Postmenopausal women with GSM were randomized in a 1:1 ratio and followed for 12 weeks to compare the primary outcome, the vulvovaginal symptom questionnaire (VSQ) score, between groups. Secondary outcomes included: the female sexual function index (FSFI), vaginal symptom index (VSI), visual analog scale (VAS) for dyspareunia, vaginal dryness, and vaginal dryness, patient global impression of improvement (PGI-I), vaginal maturation index (VMI), and vaginal pH. Descriptive statistics characterized participants at study entry. Treatment effects were estimated through linear models adjusted for baseline score. The difference between groups at 12 weeks, adjusted for baseline score, is presented for continuous outcomes, with the associated 95% confidence interval (CI), and the risk difference is estimated for categorical outcomes with the exact 95% CI. The two-sample t-test assuming unequal variance was used to test the hypothesis that HLA improved primary and secondary outcomes. Results: From September 2021 to August 2022, 49 women were randomized: 26 to vaginal estrogen and 23 to HLA. Baseline characteristics were similar in both groups. There was no observed difference in overall VSQ score adjusted for baseline between HLA and vaginal estrogen at 12 weeks (0.38, 95% CI -3.53, 2.78; p=0.8095) and all sub-domains improved in both groups after 12 weeks (Table 1). The VAS score, total VSI score, total FSFI score were all also improved and the level of improvement did not differ between study arms (Table 1). Similarly, vaginal pH did not differ between groups (-0.17, 95% CI -0.27, -0.08; p=0.2376). There was a significantly higher level of improvement for the VMI (33.94, 95% CI 21.25, 46.63; p<0.001) in the vaginal estrogen group as compared to HLA. Most participants (96.8%) were satisfied with the PGI-I in both study arms (Table 1). No treatment-related serious adverse events occurred in either group. Conclusion: Vaginal HLA and vaginal estrogen both improved GSM symptoms after 12 weeks of treatment. Vaginal HLA may be a promising non-hormonal therapy for the treatment of GSM.

Sources of Funding: Bonafide Health, LLC
learned that vaginal atrophy could be the cause of these abnormal results. Our objective is to investigate and determine the prevalence of false positive cervical dysplasia in premenopausal women, caused by genitourinary syndrome of menopause (GSM) and to evaluate the effectiveness of local estrogen therapy as a treatment option through a prospective study. We aimed to provide evidence-based data on the impact of GSM on cervical health and the potential cost savings from using local estrogen therapy to prevent complications.

Design: A prospective study was conducted on perimenopausal and post-menopausal women with cervical dysplasia and low risk for sexually transmitted infections (STIs). The study included women between the ages of 30-70 years with Pap smears (cervical dysplasia) and low risk for STIs. Participants were recruited from multiple centers. Participants were placed on local vaginal with or without systemic estrogen therapy for multiple centers for several months. A Pap smear was conducted for 4 months and then 1 year after the initiation of therapy. Pap smear results for each participant were reviewed and repeated if cervical dysplasia was included in the study over a period of 12 years. Participants were recruited through our centers and through referral from our pathologist. Women between the ages of 30-70 years with abnormal Pap smears (Cervical dysplasia) and low risk for STIs, with no previous history of cervical abnormality and in a long-term stable sexual relationship with a maximum of 1 or 2 sexual partners were included in the study. Women with a history of cervical cancer, cervical dysplasia or any other Gynecological malignancies were excluded from the study. Results: A total of 1500 perimenopausal women with abnormal Pap smears were included in the study over a period of 12 years. Most patients (96.7%) were successfully treated with local estrogens. The study revealed that a high number of patients who initially presented with cervical dysplasia underwent further interventions such as colposcopies, biopsies, LEEP excisions, cryotherapy, and even cone biopsies and hysterectomies due to the persistence of cervical atrophy. However, after treatment with local estrogens, most patients (over 96%) showed normal Pap smear results. This suggests that false positive cervical dysplasia in the perimenopausal period is often secondary to the genitourinary syndrome of menopause as the first sign of this syndrome, before any other symptoms of menopause has been presented and can be easily treated with the use of local estrogens. On the other hand, it was observed that some patients who underwent cone biopsies and hysterectomies and did not receive local estrogens treatment experienced persistence of “vaginal dysplasia”. This is likely due to the persistent vaginal epithelial atrophy, which led to a continued false reading of cervical dysplasia. The use of local estrogens in this population not only prevented the persistence of vaginal epithelial atrophy, which led to a continued false reading of cervical dysplasia. We also demonstrate how the use of local estrogen therapy can prevent a significant number of interventions and procedures, resulting in significant cost savings. This is particularly relevant as the number of Pap smears conducted in this population represents 50-60% of all Pap smears performed on women. Sources of Funding: none

P-4. Relationship between the type of hormone therapy and incidence of myocardial infarction and stroke in Korea

Youngki Cho, Hye In Kim, Eunjung Bae, Clinical fellow, Jaekyung Lee, MD, Seok Kyo Seo, MD. Ph.D. Obstetrics and Gynecology, Severance Hospital, Seoul, Asia, Korea (the Republic of)

Objective: To investigate the relationship between hormone therapy (HT) types and myocardial infarction (MI) and stroke incidence in postmenopausal women in Korea.

Design: This nested case-control study used data from the National Health Insurance Service database. Among the women aged ≥50 years and menopausal between 2004 and 2007, MI and stroke incidence up to 2017 was analyzed in 36,464 women using or having used HT for >1 year and in 36,464 women who did not use any HT for more than 1 year. HT types and duration were classified into three categories. Results: With HT initiation in women ≥50 years, MI risk (MIR) was lower with all types of HT. When using estrogen-progestogen therapy (EPT) and estrogen-only therapy (ET) in ≥50 years, EPT in 60s, and tibolone in 70s, Stroke risk (SR) was decreased. Except for the using EPT for 3-5 years, MIR decreased when using any HT. SR was decreased when using tibolone for ≥5 years or when using EPT and ET for 1-3 or ≥5 years. Conclusion: In Korean women ≥50 years, EPT decreased MIR and SR; for all ages, any HT for >5 years showed lower MIR and SR. After the WHI study, HT use decreased, and different results from previous studies may have occurred because HT was prescribed only for those with a low risk. Sources of Funding: none

P-5. Increasing Access to Healthcare for Older Women Through Faith Based Organizations

Elle E. E. Bartholus, MPH, Loyola C. Fernandez, MBS, Tayra L. Keshivener, BA, Gloria A. Bachmann, MD, MMS, Juana Hutchinson-Colas, MD, MBA. Robert Wood Johnson Women’s Health Institute, Rutgers The State University of New Jersey, New Brunswick, NJ

Objective: Throughout time, faith and medicine have been intertwined, leading to the fortuitous outcome of both health promotion and disease prevention. Faith Based Organizations (FBOs) remain a cornerstone in modern society, as well as serving as centers for spiritual wellness. A FBO is classified as any religious place where people come together with shared beliefs, missions, and purposes. Research suggests that regular congregants of FBOs primarily consist of women, with more than 50% being older women (Derosse et al., 2018). Therefore, FBOs are the ideal location to target under-screened older women. This literature review will explore the outcomes of having accessible healthcare for older women in Faith Based Organizations. Design: A Literature review via Pubmed, the Rutgers University Libraries, and Google Scholar was conducted. Keywords included “accessibility of healthcare for women in faith-based organizations,” and “accessible healthcare for older women in faith-based organizations.” Results: According to the World Health Organization, having accessible healthcare in FBOs helps to bridge the gap in health disparities by reaching traditionally underserved populations (2008). Furthermore, a church-based Health Promotion program was conducted to make the aging population more aware of the aging process and increase understanding of disease prevention. The menopause transition is linked to a variety of physical and psychological symptoms that may persist over 10 years and can have a serious influence on one’s well-being. Symptoms due to menopause can be exacerbated in incarcerated women as they may be restricted availability of therapeutic interventions. Adding to the stress of being in prison, incarcerated women usually do not have the ability to alter their lifestyle to ameliorate menopausal symptoms (such as wearing layers of clothes, drinking cold beverages as needed, and taking frequent showers). Focused attention to this group of women, as being housed within the prison system is an efficient and effective way to address these menopausal women’s health issues. Design: A literature-based review of articles pertaining to menopause management within incarcerated populations was conducted through online databases including PubMed and Google Scholar. Keywords and phrases such as “menopause in prisons” were used to narrow and specify results. Results: The data suggest that there are obvious barriers to optimal management of menopausal symptoms for aging women in prison. For example, many incarcerated women do not have access to optimal management of their symptoms. Further, once reentered into their communities, incarcerated women cannot afford medical care and prescriptions; as well, many cannot afford the co-pays. Supporting this finding, in targeted research conducted by the North Carolina Department of Public Safety it was found that less than 5% of incarcerated women between the ages of 45 and 54 received estrogen-containing medication during their incarceration. This is an entity that recognizes the need for women, including menopausal women and is implementing ways to optimize wellness for them, both while incarcerated and upon their reentry. Conclusion: In general, female inmates experience more specific health issues than male inmates, which results in a higher demand for prison health care services. It is important to consider the incarcerated/ reentry menopausal woman and support for her comprehensive health and wellness care is essential. Sources of Funding: None


Amanda Black1, Jean Michel Foidart2. 1University of Ottawa, Ottawa, ON, Canada; 2Universite de Liege, Liege, Belgium; "Estetral SRL, an affiliate company of Mithra Pharmaceuticals, Liege, Belgium

Objective: The extensive program of pre-clinical and clinical research that has been undertaken in the last 30 years to understand the properties and clinical applications of E4 is a great example of successful translational medicine. We summarize and contextualize the key findings, outcomes, and present an update on new insights. Design: Narrative
Pharmaceuticals, Belgium. Funded by Estetra SRL, an affiliate company of Mithra the hope that E4 would be a distinct and improved estrogen for therapeutic use. Evidence generation and exhibits a neutral hemostatic profile. Thrombin generation. Notably, E4 in combination with DRSP does not impact thrombin damage relevant in breast cancer development, and E1, which has been associated with 20 or 40 mg E4. The primary metabolites of E4 in plasma following oral administration subjects) with locally advanced and/or metastatic ER+/HER2- breast cancer treated with growth of the unwanted effects of estrogen treatment on non-target tissues such as the breast. A similar way to E2, it does not activate membrane associated non-genomic signaling α estrogenic actions (such as epithelial proliferation in the uterus and vagina, the prevention of bone demineralization, glucose homeostasis, and cardioprotective effects). This has important implications for its potential use in the menopause. Daily treatment with E4 for 12 weeks in a phase II trial (NCT02534312) led to improvements in the symptoms of genitourinary syndrome of menopause, vaginal atrophy, and quality of life as assessed using the Menopause Rating Scale, in addition to improved VMS in postmenopausal women. Short-term treatment with E4 in this study also resulted in a reduction in markers of bone turnover associated with osteoporosis. Although E4 activates ERα pathways in a similar way to E2, it does not activate membrane associated non-genomic signaling in all tissues. This unique feature is associated with E4’s potential to mitigate some of the unwanted effects of estrogen treatment on non-target tissues such as the breast. Preclinical data indicate that E4 has a weaker potency to induce human breast cancer cell growth in vitro and in vivo when compared to E2. Clinical data have also shown that E4 has a pro-apoptotic effect on tumor tissue in pre- and post-menopausal women with ER+ early-stage breast cancer as anti-tumor effect (postmenopausal women with breast cancer subjects) with locally advanced and/or metastatic ER+/HER2- breast cancer treated with 20 or 40 mg E4. The primary metabolites of E4 in plasma following oral administration are E4-16-glucuronide, E4-3-glucuronide, and E4-glucuronide-sulfate, thus confirming that E4 is the terminal product of metabolism. This contrasts with other estrogens, including E2 which is converted to hydroxylated metabolites associated with DNA damage relevant in breast cancer development, and E1, which has been associated with thrombin generation. Notably, E4 in combination with DRSP does not impact thrombin generation and exhibits a neutral hemostatic profile. Conclusion: An extensive program of pre-clinical and clinical research was undertaken to understand the properties of E4 in the hope that E4 would be a distinct and improved estrogen for therapeutic use. Evidence to date provides support for this.

Sources of Funding: Funded by Estetra SRL, an affiliate company of Mithra Pharmaceuticals, Belgium.

P-7. Menopause in Healthcare Workers: Entirely Digital Program Provided as Healthcare Benefit to Treat Symptoms, Address Quality of Life, and Improve Work Satisfaction

Objective: Menopause was assessed in an estimated 55 million US women per year with data suggesting a cost of $26.6 billion per year due to lost productivity and health expenses. Menopause is particularly relevant for health systems, with a workforce that is 76% female and 50% of employees over age 50. Given the pressing challenge of employee retention, it is imperative to understand and effectively treat healthcare workers’ menopause experience and build solutions to support this population. Recent data suggest that menopause plays an important role in women’s work sentiment and productivity: 21% have passed on a promotion, 40% report menopause symptoms affect work performance or productivity on a weekly basis, and 17% have quit or are considering resigning because of menopause symptoms. To address this critical unmet health and workforce need, a joint venture between a leading health system and a technology startup created a menopause telehealth company. An initial pilot was offered as a covered benefit to health system employees. Design: This observational cohort analysis evaluated pilot members seeking menopause support from February to May 2023. The entirely digital program provided medical care with NAMS-certified ObGyn physicians in conjunction with health coaching for lifestyle factors and health behavior modifications delivered by board-certified health coaches. In June 2023, baseline and end of pilot data were analyzed with health coaching for lifestyle factors and health behavior modifications delivered by board-certified health coaches. In June 2023, baseline and end of pilot data were analyzed with health coaching for lifestyle factors and health behavior modifications delivered by board-certified health coaches. In June 2023, baseline and end of pilot data were analyzed with health coaching for lifestyle factors and health behavior modifications delivered by board-certified health coaches. In June 2023, baseline and end of pilot data were analyzed with health coaching for lifestyle factors and health behavior modifications delivered by board-certified health coaches. In June 2023, baseline and end of pilot data were analyzed with health coaching for lifestyle factors and health behavior modifications delivered by board-certified health coaches. In June 2023, baseline and end of pilot data were analyzed.

Results: The sample was composed of 874 women, out of which 58.8% were in pre-menopause and 41.2% were in postmenopause. Out of these women, 31.4% of the premenopause and 24.4% of the postmenopausal women had an altered waist circumference. This was associated with MS (RR = 1.72 [95%CI 1.05-1.31]), and in post menopause, it was associated with the consumption of fatty meat/chicken at least 3 times a week (RR = 1.28 [95%CI 1.01-1.80), with MS (RR = 1.15 [95%CI 1.03-1.29], and with the absence of physical activity (RR = 1.90 [95%CI 1.10-3.57]). Conclusion: Menopause women showed high prevalence of lifestyle-related diseases, more than 25% with type 2 diabetes, more than 30% with hypertension and more than 40% with hypercholesterolemia. Targeted lifestyle interventions could improve menopause symptoms, decrease the risk of chronic diseases, and improve overall health. In this study, we observed a significant association between menopause status and waist circumference.

Sources of Funding: None

P-9. Menopause and Multiple Sclerosis: A Need for Clarity for OBGYN Providers
Bolly Boden, Antonia Oldsipo, Krupa Pandey1. School of Medicine, Hackensack Meridian Hackensack University Medical Center, Hackensack, NJ; 2Hackensack Meridian Hackensack University Medical Center, Hackensack, NJ.

Objective: Multiple Sclerosis (MS) is a chronic demyelinating disease that affects over 2 million people in the United States. It is the highest incidence in the northeast of the country. Women of childbearing age are mostly affected at a ratio of 3:1 compared to men. As the treatment armamentarium for MS continues to expand, patients in the menopausal period with MS who will need care will also arise. Symptoms of MS and menopause can often overlap such as mood, sleep, and bladder function, creating challenges for providers in the management of patients. This study intends to understand the clinical care and knowledge gaps of obstetric and gynecological providers for patients.
P-10. Correlations Among COMMA-recommended VMS Outcomes in MsFLASH Trials

Janet S. Carpenter, PhD, Joseph C. Larson, MS, Myra S. Hunter, PhD, Sarah Lensm, PhD, Chen X. Chen, PhD, Katherine A. Guthrie, PhD. IU School of Nursing, Indiana University Purdue University Indianapolis, Indianapolis, IN; "Fred Hutchinson Cancer Center, Seattle, WA; 'King’s College London, London, United Kingdom; 'The University of Melbourne, Melbourne, VIC, Australia

Objective: The historical lack of conceptual or methodological agreement on the measurement of vasomotor symptoms (VMS) creates barriers for exchanging, pooling, and comparing data. The study purpose was to advance understanding of VMS measurement using recommendations of the Comma Core Outcomes in Menopause (COMMA) global initiative and pooled baseline and post-treatment data from midlife women enrolled across three MsFLASH trials. Specific aims were to examine (1) correlations among VMS frequency, severity, bother, interference (including impact on sleep), and standardized sleep scales (insomnia severity, sleep quality/disturbance) at baseline and post-treatment and (2) relationships between satisfaction with VMS treatment and baseline to post-treatment changes in VMS frequency, severity, bother, interference (including impact on sleep), and standardized sleep scales (insomnia severity, sleep quality/disturbance). Design: Across the three randomized controlled trials, participants self-reported VMS frequency, severity, and bother using daily diaries; completed standardized measures of VMS frequency, severity, bother, and interference (including impact on sleep); and standardized sleep scales (insomnia severity, sleep quality/disturbance). The four MsFLASH-designed items measuring satisfaction with VMS treatment. Participant characteristics were analyzed using descriptive statistics. Aim 1 relationships were analyzed using Pearson’s correlations for the pooled sample at baseline and post-treatment (n=176 participants who received placebo only; n=389). The Aim 2 analysis included independent samples t-tests and analysis of variance. Results: Participants were mostly postmenopausal (82.9%) and a mean of 54.5 years old. VMS frequency was fairly correlated with severity, bother and interference for pooled baseline and placebo post-treatment samples (r=.21 to .39) and moderately correlated with severity, bother and interference for pooled post-treatment (r=.01 to 0.44). VMS severity, bother, and interference were moderately correlated with one another (r=.41 to .48), with one exception (r=.37). VMS severity and bother were strongly correlated (r=.90 to .92). VMS interference was moderately correlated with insomnia (r=.45 to .54) and fairly to moderately correlated with sleep quality/disturbance (r=.31 to .44). Other VMS outcomes were weakly to fairly correlated with insomnia (r=.07 to .33) and sleep quality/disturbance (r=.06 to .26). Greater improvement in all outcomes over time was associated with greater satisfaction with VMS treatment (ps < .0001). Conclusion: This pooled analysis advances understanding of VMS outcomes measurement. Findings suggest (1) VMS frequency was not strongly correlated with other VMS outcomes, (2) severity and bother are highly correlated, (3) 3-item and 10-item interference measures performed equally well, (4) the insomnia scale that was used may be more relevant to VMS research than the sleep quality/disturbance measure, (5) findings were similar over time, and (6) each of the four items measuring satisfaction with treatment performed well. These findings have implications for selection of measures and raise questions to be addressed in future research.

Sources of Funding: None

P-11. “Quick Flutter Skip”: Women’s Descriptions of Menopause Palpitations

Euna Choi, Clinical fellow, Heeyoon Kim, MD, PhD., Bo Hyun Yun, MD, PhD, Young Sik Choi, MD, PhD, Seok Kyo Seo, MD, PhD. Department of Obstetrics and Gynecology, Severance Hospital, Seodaemun-gu, Korea (the Republic of)

Objective: To track the change of HRT use and breast cancer incidence in Korea.

Results:


Euna Choi, Clinical fellow, Heeyoon Kim, MD, PhD., Bo Hyun Yun, MD, PhD, Young Sik Choi, MD, PhD, Seok Kyo Seo, MD, PhD. Department of Obstetrics and Gynecology, Severance Hospital, Seodaemun-gu, Korea (the Republic of)

Objective: Following the Women’s Health Initiative (WHI) publication in 2002, HRT (hormone replacement therapy) use for postmenopausal women has decreased worldwide. Since then, it has been reported that breast cancer incidences have decreased. Understanding whether the decrease in HRT use affected breast cancer incidences is still unclear. In the case of breast cancer in Korea, incidences by age group have different characteristics from the West. In addition, there was a question that the breast cancer risk caused by HRT could also have different characteristics. Therefore, this study tries to analyze breast cancer incidence data in Korea from 2002 to 2020, and analyze breast cancer incidence in Korean women to reveal the relationship between the use of HRT and breast cancer risk in Korean women.

Design: This study used tumor registry information from 2002 to 2020 in Korea. We compared age-specific and age-adjusted breast cancer incidence rates from 2002 to 2020. Information on the prescriptions of Estrogen, Estrogen-progesterin drugs, Tibolone used for HRT in Korea from 2002 to 2020 was collected from pharmacy data. Results: In Korea, the rate of change in Estrogen therapy (Estrogen-Progesterin therapy) prescription has decreased from 2002 to 2007, to the lowest level of -50.9%, and then gradually increased to -24.6% in 2010.
but then decreased again, and the ET/EPT prescription in 2020 was to be -21.7% as of 2002. However, in the case of Tibolone, the prescription amount decreased to -25.4% in 2004, and then gradually increased, showing that it was +91.7% in 2020. Changes in the prescription amounts of ET and EPT were analyzed separately from 2007 to 2020, and in the case of EPT, it showed a slight increase from 2007 to 2010, but has continued to decrease since 2020. The number of breast cancer in Korea continued to increase from 2002 to 2020, and incidence rate per 100,000 people also increase from 34.5 in 2002 to 96.4 in 2020. In particular, the number of breast cancer patients in women over the age of 50 who are commonly prescribed HRT is increasing more steeply compared to women under the age of 50. Comparing the changes in hormone receptor expression rate in Korea by year, ER positive was 58.2% and PR positive was 56.7% in 2002, and it gradually increased to 76.7% and 67.3% in both cases, at 2019. 

Conclusion: In the case of Korean women, the incidence of breast cancer steadily increased from 2002 to 2020, and in particular, the incidence of breast cancer increased rapidly in women over the age of 50. The proportion of ER and PR positive breast cancer also increased. However, the prescription amount of Estrogen/Estrogen-progestin drug for HRT in Korea has decreased compared to 2002. In the case of EPT, the prescription amount showed a steady decline for 10 years from 2010. In conclusion, HRT, especially EPT, does not tend to increase breast cancer incidence in Korean women, and further research on breast cancer risk factor suitable for Korean women is needed.

Sources of Funding: None

---

### P-13.

**Survey of perimenopause symptom prevalence and tracking – importance for treatment planning**

Sarah Berga1, Suruchi Thakore1, Lucy Broadbent1, Joanna Pike1, Fiona Clancy, PhD1, 2R&D, Clearblue Innovation Centre, Bedford, United Kingdom; 3Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY; 4Reproductive Endocrinology and Infertility, University of Cincinnati, Cincinnati, OH; 5Marketing, Swiss Precision Diagnostics GmbH, Geneva, Switzerland

**Objective:** Over 55 million US women are approaching or in menopause, with the typical age at menopause of 51 years. Often perimenopause symptoms start years before and may be confused with other health issues. The prevalence of menopause symptoms in women age 35-60, and the use of methods to track them, was investigated. **Design:** 1022 US women aged 35–60y completed an online survey (conducted by Hotspex, February 2022). Incidence of 22 menopause-related symptoms experienced in the previous 6 months were surveyed and ranked. The use of methods to track menopause symptoms, and perceptions and attitudes towards menopause, were also studied. **Results:** Vasomotor symptoms including hot flashes (16-51%) and night sweats (23-44%) increased with age, but declined in the 56-60y cohort (41% and 34%). Vaginal dryness also became more troublesome with age, peaking in 56-60y cohort (33%). Fatigue was consistently listed in the top 5 symptoms for all age groups (incidence of 33-44%). Younger women were more likely to experience mood symptoms including irritability (30-37%) and mood swings (29-39%) but these were less common among those 56-60y (19% and 14% respectively). Use of cycle tracking apps was most common in women ≤45y (7-10%), however, few women of any age used menopause tracking apps (<3%). **Conclusion:** Though menopause symptoms are common across all ages, women seldom track them. Tracking perimenopause symptoms along with menstrual cycles would be beneficial to facilitate conversations between patient and physician and to better tailor personalised treatment/management plans.

Sources of Funding: None

---

### Table 1: Percentage of women using apps to help track or treat menopausal symptoms:

<table>
<thead>
<tr>
<th>App type</th>
<th>35-49y</th>
<th>40-44y</th>
<th>45-50y</th>
<th>50-55y</th>
<th>55-60y</th>
</tr>
</thead>
<tbody>
<tr>
<td>App type</td>
<td>35-49y</td>
<td>40-44y</td>
<td>45-50y</td>
<td>50-55y</td>
<td>55-60y</td>
</tr>
<tr>
<td>A general period cycle tracking app</td>
<td>8.6</td>
<td>9.5</td>
<td>9.0</td>
<td>3.4</td>
<td>0.0</td>
</tr>
<tr>
<td>A menopause tracking app</td>
<td>2.6</td>
<td>0.5</td>
<td>2.0</td>
<td>0.4</td>
<td>0.0</td>
</tr>
</tbody>
</table>

---

### P-14.

**Use of serial FSH measurements to detect menopause transition**

Sarah Berga1, Suruchi Thakore1, Sinead Tohill1, Nuzhat Ashra4, Fiona Clancy, PhD1, 2R&D, Clearblue Innovation Centre, Bedford, United Kingdom; 3Obstetrics and Gynecology, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY; 4Scientific and Medical Affairs, Clearblue Innovation Centre, Bedford, United Kingdom; 5Reproductive Endocrinology and Infertility, University of Cincinnati, Cincinnati, OH

**Objective:** The timing and symptoms of the menopausal transition vary for each individual. The inherent variation complicates clinical recognition and diagnosis. Single measure, home follicle stimulating hormone (FSH) tests claim to determine menopause status but interpretation may be limited by fluctuations in hormones including FSH. To account for fluctuations, serial urinary FSH were measured, in combination with cycle length, to determine the utility for indicating menopausal stage. **Design:** Daily urines were collected for up to 90 days from women whose menopausal status was classified according to STRAW+10 (n=108). Quantitative urinary FSH concentrations were determined using the Tecan autoanalyzer. A FSH concentration ≥25 IU/L was classified as ‘positive’. **Results:** Median urinary FSH levels increased across the menopause transition (pre-menopause 6.4 IU/L (n=1232), early peri-menopause 10.6 IU/L (n=1044), late peri-menopause 32.8 IU/L (n=2725), post-menopause 45.0 IU/L (n=872)). Averaging across cycles, the percentage of positive tests increased as women moved through menopause stages (3.8%, 8.0%, 37.6%, 96.4% from pre- to post-menopause respectively). FSH alone differentiated pre- from post-menopause. The addition of cycle length (< and ≥35 days) to FSH concentration (< and ≥25 IU/L) differentiated peri- from pre- and post-menopause. Percentage of positive FSH tests increased with longer cycle length as defined by STRAW+10 cohorts. **Conclusion:** Serial urinary FSH measurements at home, combined with cycle length information, could provide women with an initial indication of her menopause stage.

Sources of Funding: None

Average FSH concentration for each STRAW+10 status group

<table>
<thead>
<tr>
<th>STRAW+10 Classification</th>
<th>Number of FSH observation</th>
<th>Mean</th>
<th>SD</th>
<th>Median</th>
<th>Min</th>
<th>Max</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-menopausal</td>
<td>1232</td>
<td>9.97</td>
<td>11.12</td>
<td>6.38</td>
<td>0.37</td>
<td>120.55</td>
</tr>
<tr>
<td>Early peri-menopausal</td>
<td>1044</td>
<td>16.71</td>
<td>17.98</td>
<td>10.58</td>
<td>0.55</td>
<td>201.27</td>
</tr>
<tr>
<td>Late peri-menopausal</td>
<td>2735</td>
<td>40.48</td>
<td>33.86</td>
<td>32.78</td>
<td>0.00</td>
<td>247.64</td>
</tr>
<tr>
<td>Post-menopausal</td>
<td>872</td>
<td>57.33</td>
<td>42.71</td>
<td>45.00</td>
<td>0.00</td>
<td>373.23</td>
</tr>
</tbody>
</table>
Objective: Though menopause hormone therapy (MHT) is an effective treatment for menopause symptoms, studies have shown that Black women have more severe vasomotor symptoms (VMS) yet are prescribed MHT less than White women. Women with psychiatric conditions (PsyC) often have worsening moods and severe VMS during the menopause transition. Despite evidence that MHT may improve responses to psychiatric medications during menopause, data is lacking on the rate of MHT prescribing. The aim of this study was to determine if there were racial disparities in MHT prescribing for menopausal Black women compared to White women with and without a psychiatric diagnosis. Design: A retrospective chart review using EPIC slicer-dicer was performed assessing the rate of MHT treatment among menopausal patients with PsyC seen between January 2017 and September 2022 at MetroHealth Medical Center. Inclusion criteria was female sex and age 45-60 years old. Exclusion criteria was race identified as “other or unavailable.” Descriptive [statistics were used to calculate demographic and clinical characteristics. Provider proportions were reported for menopause and PsyC based on ICD-10 codes. A chi-square test of independence, with a significance level of 0.05 was used to analyze the presence of racial differences in women with menopause symptoms and PsyC who were prescribed MHT. MetroHealth’s Institutional Review Board approved this study. Results: Between January 2017 and September 2022, 65,762 female patients between age 45-60 were seen at MetroHealth; 31.6% (20,810) were Black, 54.8% (36,035) were White and 13.9% (9,153) were “other or unavailable”. Of the study population, 10.7% (6,117) had documented menopausal symptoms (MPS) and 19.9% (19,977) had PsyC. 6.4% (4,359) had both menopausal symptoms and PsyC. 17.3% (3,459) of women with PsyC had menopause symptoms and 7.2% (2,658) of women without PsyC had menopause symptoms. 16.9% (449) of women with menopause symptoms but without PsyC received MHT and 20.7% (716) of women with menopausal symptoms and PsyC received MHT. Compared to White women, Black women were more likely to have menopause symptoms, X² (1, N = 6,459) = 49.642, p < .0001 but less likely to receive MHT, X² (1, N = 6117) = 53.3756, p < .0001. Women with PsyC were more likely to receive an MHT prescription than Black women with menopause symptoms but without PsyC, X² (1, N = 56,845) = 49.642, p < .0001. However, data from White women with menopause symptoms and a PsyC were prescribed MHT more than Black women, X² (1, N = 3459) = 31.0078, p < .0001. Conclusion: In a population with a high percentage of Black patients known to have more menopause symptoms, the data demonstrated a surprisingly low rate of documented menopause symptoms (11%) compared to prior reports of up to 80%. This low rate may be related to patient reporting, physician inquiry, or physician documentation of menopause symptoms. Women with PsyC were more likely to have menopause symptoms than those without a PsyC. Similarly, women with menopause symptoms were more likely to have a PsyC than women without menopause symptoms. These results support prior reports that menopause symptoms and PsyC may independently exacerbate each other. The results showed a higher percentage of women with both menopause symptoms and PsyC were prescribed MHT compared to women with menopausal symptoms who did not have a PsyC. This could indirectly reflect a higher severity of menopausal symptoms among psychiatric patients, eliciting higher rates of providers recommending MHT. Lastly, White women with PsyC and menopause symptoms were 40% more likely to receive an MHT prescription than Black women. Overall, if MHT was prescribed at the same rate to menopausal women with and without a PsyC, then PsyC receive MHT significantly less than their White counterparts. Educating clinicians on disparities among menopausal women with PsyC may aid in addressing this healthcare disparity.

Sources of Funding: None

P-17.

Information es poder (information is power): Menopause knowledge, attitudes, and experiences in midlife Latinas

Yamila I. Cortes, PhD, MPH, FNP-BC, Andrea Cazaless, BSN, RN, Mayra Duran, Lorena Tencz, ISSA CPT. Nursing, The University of North Carolina at Chapel Hill, Chapel Hill, NC

Objective: Latinas constitute nearly 20% of midlife women in the United States (U.S.) but remain underrepresented in menopause research. Many midlife Latinas are disadvantaged by limited English proficiency, less formal education, living below the federal poverty level, lack of health insurance, and social isolation and discrimination — factors that negatively affect menopause-related symptoms and health outcomes. To provide Latinas with culturally-relevant menopause education and clinical care, it is necessary to have deeper insight into their knowledge and experience of menopause. The purpose of this study was to understand knowledge, attitudes, and experiences of the menopause transition among midlife Latinas. Design: We conducted a qualitative descriptive study using five focus groups with 29 Spanish-speaking midlife Latinas (aged 40-60 years). Focus groups, lasting approximately 90 minutes, were conducted in Spanish via Zoom using a semi-structured interview guide. Focus groups were led by a bilingual research assistant and community health worker with a notetaker present. Audio

---

**Figure 1:** Percentage of positive FSH tests (>25 mIU/mL) per cycle, by STRAW+10 and cycle length

---

**Figure 2:** Percentage of tests with FSH > 25 mIU/mL per cycle by STRAW+10 and Status
that is experiencing perimenopause-related menstrual cycle changes or symptoms in the ages at which they will occur, are influenced by social and cultural contexts. Whenantes to menopause should include expectations that are realistic and positive, and may not be anticipated or experienced in their entirety until well after menopause. The need to develop culturally-relevant education on menopause in Spanish. The next steps in this research are to determine the best menstrual cycle messages and educational formats for midlife Latinas.

Sources of Funding: This study was funded by the UNC-Chapel Hill’s Center for Health Promotion and Disease Prevention.


Nancy F. Woods, PhD, RN1; Nina Coslov, MBA2; Marcie K. Richardson, MD3; Biobehavioral Nursing, University of Washington, Seattle, WA; Women Living Better, Cambridge, MA; 1OB/GYN, Beth Israel Deaconess Medical Center, Boston, MA

Objective: People’s expectations about the timing of developmental events, specifically the ages at which they will occur, are influenced by social and cultural contexts. When expected timing and lived experience are divergent, events such as menopause may be associated with greater stress or distress. We hypothesized that being “off-time”, that is experiencing perimenopause-related menstrual cycle changes or symptoms in a timeframe before a person expects them, would lead to worse ratings on measures of stress, satisfaction, and health. Design: Participants responded to the online Women Living Better (WLB) survey during March to August of 2020; 1262 met eligibility criteria for inclusion in hypothesis-testing. Being “off-time” referred to experiencing changes related to perimenopause at a younger age than at which participants anticipated experiencing such changes. Using a 1-way analysis of variance (ANOVA) we examined differences in being “off-time” vs “on-time” on 7 participant-rated measures: stress (overall and health-related stress), satisfaction (with life roles and activities, and well-being and health ratings), interference with daily activities, interference with relationships, not feeling like myself, and perceived health. Using 2-way ANOVA we then tested hypothesized differences between being “off-time” and “on-time” and experiencing perimenopause-related menstrual cycle changes, vasomotor disturbance, or volatile mood symptoms on the same 7 measures. Results: Those who were “off-time” vs “on-time” reported significantly poorer health ratings in a one-way ANOVA. Experiencing more noticeable perimenopause-related menstrual cycle changes was significantly related to greater health stress, overall stress, satisfaction with life roles and activities, interference with daily activities, interference with relationships, not feeling like myself (all p<.05). There were no significant differences of being “off-time” and experiencing perimenopause-related menstrual cycle changes or VMS. In contrast, having more bothersome volatile mood symptoms significantly affected health stress, overall stress, satisfaction with life roles and activities, interference with daily activities, interference with relationships, not feeling like myself more of the time, and perceived health. Finally, there was a significant interaction effect of being “off-time” and volatile mood symptoms on health stress, satisfaction with life roles and activities, and perceived health (all p<.05). Conclusion: Being “off-time” alone had little effect on studied measures with the exception of poorer perceived health. Experiencing more noticeable perimenopause-related menstrual cycle changes or having more bothersome vasomotor symptoms influenced several measures but there were no interactive effects with being “off-time”. In contrast, those who were “off-time” and experiencing more bothersome volatile mood symptoms reported greater health stress, lower satisfaction with life roles and activities, and poorer perceived health. These interactive effects of being “off-time” and experiencing volatile mood suggest a need for greater attention to the link between volatile mood and perimenopause. Moreover, anticipatory guidance for those on the path to menopause should include the possibility of volatile mood symptoms.

Sources of Funding: None

P-19. Eliciting the Meaning of “Not Feeling Like Myself” during Perimenopause: Observations from the Women Living Better Study

Nancy F. Woods, PhD, RN; Nina Coslov, MBA; Marcie K. Richardson, MD; Women Living Better, Cambridge, MA; 1OB/GYN, Beth Israel Deaconess Medical Center, Boston, MA

Objective: “Not feeling like myself” (NFLM) is a phrase used regularly by those on the path to menopause. Clinicians hear it in patient encounters, but what does it mean? We asked Women Living Better Survey participants about not feeling like themselves to identify correlates and clarify its significance. We explored the relationship of specific bothersome symptoms women reported during the LRS and MT to their ratings of NFLM. Design: Methods: Participants responded to the online Women Living Better (WLB) survey from March to August of 2020; 1258 met eligibility criteria. In order to measure not feeling like myself, they were asked to respond to the item “Many women feel ... themselves during this phase of life. How often was this true for you over the past 3 months?” Responses were chosen from a 5-point scale ranging from “none of the time” (1) to “all of the time” (5). In addition, participants provided data about their age, education level, difficulty paying for basics, satisfaction with daily activities, overall stress, and reproductive aging stage. They also were asked about 61 symptoms and rated their bother on a scale from not at all bothered (1) to extremely bothered (7). The symptoms were summed to create symptom bother scale bothers for 8 scales based on results of a principal components analysis for which eigenvalues of each scale exceeded 1.00: anxiety/vigilance, fatigue/pain, brain fog, sexual symptoms, volatile mood, GI symptoms, VMS/sleep, skin and hair, breast and acne. Analyses: We calculated the frequencies of and bother ratings for individual symptoms as well as the symptom bother scales. We correlated the symptom bother scales with the NFLM score using a set of dependent t-tests. These symptoms included: irritability (r=.348), sleep (r=.398), overwhelming/less able to cope (r=.463), worry more (r=.302), low anxiety (r=.440), tearfulness/crying (r=.306), can’t calm down on the inside (r=.333), more forgetful (r=.332), difficulty concentrating (r=.378), difficulty making decisions (r=.376), and more fatigue (r=.491). We found correlations with volatile symptoms and disrupted sleep were much lower (e.g., r=.167 for waking up in the middle of the night for an hour or more, night sweats r=.237, hot flashes r=.277). Next, we tested a multiple regression model including the symptom bother scale scores for vigilance/anxiety, fatigue/pain, brain fog, sexual symptoms, and volatile mood symptoms. The importance of involving Latinas, including the definition of perimenopause, potential symptoms, and treatment options. The importance of involving family members in menopause education efforts was also revealed. This study highlights the need to develop culturally-relevant education on menopause in Spanish. The next steps in this research are to determine the best menstrual cycle messages and educational formats for midlife Latinas.

Sources of Funding: None

P-20. GENITOURINARY SYNDROME OF MENOPAUSE: PREVALENCE OF SYMPTOMS, ASSOCIATION WITH SEXUAL DYSFUNCTION, KNOWLEDGE OF THE PARTNER AND IMPACT ON THE COUPLE’S SEXUAL LIFE

Lucia Costa Paiva, MD, PhD1; Maria Maria Perini, graduating student2; Jaina F. Pio, MD1; Ana Lucia R. Valadares, MD, PhD1. 1Department of Obstetrics and Gynecology, Universidade Estadual de Campinas, Campinas, Brazil; 2Universidade Nove de Julho, Sao Paulo, Brazil

Objective: To assess the prevalence of the various symptoms of Genitourinary Menopause Syndrome (GSM) and their association with female sexual dysfunction, the partner’s knowledge of the woman’s symptoms, and the repercussions on the couple’s sexual life. Design: A cross-sectional study was carried out with 266 couples (total of 532 individuals) between 50 and 70 years. The sample size was calculated based on the estimated prevalence of and sexual dysfunction in women at 35%, and in men at 28% and an estimation precision with a difference between the proportion of the population and with a significance level of 5%, the number of calculated was 125 men and 125 women. The men and their partners were selected using the “snowball” technique, formed from the “ego” couples who answered the interview on sociodemographic, general health, and sexual function questions, carried out via internet telephony by interviewers trained for the research. Interviews were conducted separately with the sexual partner. Female sexual function was evaluated using the Short Personal Experiences Questionnaire (SPEQ), male sexual function Sex Quotient - Male Version (QS-M), urinary incontinence using the International Consultation on Incontinence Questionnaire - Short Form (ISIQ-SF), the incontinence questionnaire overactive bladder (ICIQ-OAB),
P-21. Effect of menopause stage on cerebral hemodynamics during typical aging

Niko L. Damastani, PhD1, Jacob van Doorn, BS2, David H. Salat, PhD1, Meher R. Juttikala, PhD3, Matthew R. Baugher, PhD1, 1Department of Radiology, Massachusetts General Hospital, Boston, MA; 2Department of Psychiatry, University of Illinois Chicago, Chicago, IL; 3Neuroimaging Research for Veterans Center, Veterans Affairs Boston Healthcare System, Boston, MA; 1Department of Radiology, Harvard Medical School, Boston, MA.

Objective: Changes in cerebral physiology during aging may precede the appearance of structural biomarkers of neurodegeneration, and characterizing such age-related changes is crucial for improving our understanding of typical versus atypical aging. The menopause transition has a major influence on physiology during aging, driven by changing estrogen levels. Estrogen receptors populate numerous brain regions, including the prefrontal cortex, and cerebral glucose metabolism is affected during the perimenopause stage. However, the relationship between the menopause transition and age-related changes in cerebral physiology remains incompletely understood. Here, we investigated the role of menopause stage on established measures of cerebral hemodynamics during typical aging.

Design: We performed a cross-sectional retrospective study of 131 women and 125 men (age range = 40 – 60 years) with STRAW+10 menopause staging and arterial spin labeling (ASL) magnetic resonance imaging (MRI) data from the Lifespan Humant Connectome Project in Aging. Demographic variables of interest are shown in Table 1. ASL MRI was used to extract two established measures of cerebral hemodynamics: cerebral blood flow (CBF; the perfusion rate of blood to brain tissue) and arterial transit time (ATT; the time taken for blood that is magnetically labeled at the level of neck to travel to brain tissue). General linear model analysis using the whole brain surface, derived via Freesurfer, was performed for CBF and ATT between age-matched subsets of men for each menopause stage (pre, peri and postmenopause). We controlled for the effects of age, years of education, and ethnicity. There were no significant differences for these variables between groups. We performed multiple comparisons correction using a family-wise error approach (pFWE), thresholded for significance at 0.05.

Results: We found widespread significant differences in mean CBF and ATT between men and women for each menopause stage, and distinct spatial distributions of these differences across the brain were observed. For the comparison of men and premenopausal women, significant differences were localized to the middle temporal cortex for ATT and inferior parietal cortex for CBF. For comparisons between men and perimenopausal women, significant differences were identified within the superior parietal and frontal cortices for both ATT and CBF. Significant differences between men and postmenopausal women were found in the prefrontal and inferior parietal cortices. No statistically significant differences were observed between menopause stage. Conclusion: There is a distinct spatial effect of menopause stage in women on cerebral perfusion measures in comparison with men. This could suggest that physiological neuroprotective mechanisms exist during the menopause transition in typically aging individuals. Validation of these findings requires longitudinal analyses, and future work should also investigate the impact of lifestyle, medical history, and cardiometabolic risk on these findings.

P-22. Investigating the Effectiveness of Estrovera: Insights from a Patient Satisfaction Survey on Menopausal Symptom Relief

Nilima Desai, MPH, RD, Melissa Blake, ND, Anu Desai, PhD, Metagenics Inc, Gig Harbor, WA.

Objective: Estrovera, a clinically-proven nonestrogen supplement derived from plants, was the focus of a patient survey aimed at evaluating its efficacy in alleviating menopausal symptoms such as hot flashes, mood swings, sleep disturbances, and other associated discomforts. This specially formulated supplement contains a standardized extract of ERr 731, sourced from Raphanus rhubarb, which exhibits selective estrogen receptor modulator properties, particularly for estrogen receptor beta. This unique attribute may contribute to both its effectiveness and safety profile. The survey findings are reinforced by numerous randomized controlled trials (RCTs) that have demonstrated the safety and efficacy of Estrovera. For instance, in a 12-week RCT involving 112 perimenopausal women, ERr 731 significantly reduced the frequency of hot flashes from a median of 12 to 5. Furthermore, this study recorded a 9% reduction in total symptom severity, which was significantly better than placebo treatment and also significantly better than the prior study. This study also recorded a significant increase in quality of life in the ERr group compared to placebo.

Methods: The survey was funded by Metagenics, LLC. Patients who had purchased the product between July 2022 and January 2023 were offered a 10% discount on their next Estrovera purchase. The survey was conducted during the period of March to April 2023. The results obtained from the survey were subsequently reviewed and validated by the regulatory team at Metagenics in May 2023.

Results: Among the 424 women who took part in the survey, a significant majority (90%) reported experiencing improvements in their hot flashes, while 71% reported a reduction in skin flushes. Additionally, an overwhelming 95% of the participants noticed improvement in their mood after incorporating Estrovera into their routine. Conclusion: The survey findings highlight the significant positive impact of Estrovera on patient satisfaction and its effectiveness in alleviating common menopausal symptoms experienced by women. As a result, the participants reported an improvement in their overall quality of life. These results align with the outcomes observed in previous RCTs conducted with Estrovera, further substantiating the product’s efficacy and consistency in addressing menopausal symptoms.

P-23. Menopause-related Services and Resources in Veterans Health Administration Medical Centers: A Women’s Health Practice-Based Research Network Practice Scan

Suzan Diem, MD, MPH1, 2, Carolyn J. Gibson, PhD2, 3, Haley Miles-McLean, PhD, 2, Diane Carney, MA1, 4, Jeanette Shekelle, MPH1, 3, Susan Fryane, MD, MPH1, Minneapolis VA Medical Center, Minneapolis, MN; 1University of Minnesota Twin Cities, Minneapolis, MN; 3San Francisco VA Health Care System, San Francisco, CA; 4Veterans Integrated Services Network 5 Mental Illness Research Education and Clinical Center, Baltimore, MD; 5VA Palo Alto Health Care System, Palo Alto, CA; 6University of California San Francisco, San Francisco, CA.

Objective: Providing comprehensive health care for women Veterans across the lifespan is a priority for the Department of Veterans Affairs (VA). This area of focus has historically targeted pregnancy-related issues, menopause has been increasingly recognized as an essential addition to the reproductive lifespan health perspective. To address program evaluation needs of the VA Office of Women’s Health, we assessed current menopause-related services, resources and needs nationally via VA Women’s Health Practice-Based Research Network (WH-PBRN) sites.

Design: WH-PBRN is a network of 76 VA facilities across diverse clinical settings and geographic regions, each with a local WH-PBRN Site Lead. The WH-PBRN facilitates research evaluation, and quality improvement focused on women Veterans’ health care. In February 2023, each active WH-PBRN Site Lead (N=73), as the local key informant, received a 10-item electronic survey, followed by a reminder email if not completed within 2 weeks of receipt. The Site Lead could also query health care providers and other colleagues at their site to assist with survey responses, if needed, for help with describing local practice arrangements. The survey was developed in collaboration with the VA Office of Women’s Health, VA Women’s Health Research Network staff, and content area experts, and was field tested at two sites in the network prior to being widely distributed. It was designed to provide information on current menopause-related services and questions about partner knowledge of GSM. Results: The average age of women was 57.45 (5.08) and men were 59.97 (6.28), most were white and 58.67% of women were men.
and resources within site primary care settings, along with facilitators and barriers to providing menopause-related care, with structured items and open-ended prompts. Survey responses were summarized with descriptive statistics. Results: Of the 73 surveys sent, 60 were completed (response rate 82%). Most sites (88%) reported having consultants based at their VA who assist primary care providers with pharmacological management of menopause symptoms. Available consultants were most often identified as gynecologists (78%), clinical pharmacists (58%), and endocrinologists (43%). A majority (77%) reported having pelvic floor physical therapists (PT) available for referral for management of gynecological symptoms related to menopause. Although 2/3 of sites reported having some educational materials on menopause available for patients, less than half of sites had materials on hormone therapy (42%), non-hormonal pharmacological therapies (30%), and non-pharmacological treatment options (38%) for menopause symptoms. Only 8% of sites reported having menopause-focused classes or groups for patients. Most sites agreed or strongly agreed with the need for more resources or support for a variety of menopause-associated issues (See Table 1). Conclusion: Nearly 90% of responding VA facilities in the WH-PBNN report the presence of consultants at their facility to assist primary care in the management of menopause symptoms and nearly 80% report having pelvic floor PT available. However, most identified a need for more resources related to a variety of menopause-associated concerns within the VA, suggesting a direction for service development. Most sites did not have comprehensive, Veteran-focused educational materials available and few had menopause-focused groups or classes. Further work is needed to understand variability in resources and best practices to improve comprehensive menopause-focused care in the VA setting.

**Sources of Funding:** VA Office of Women’s Health; VA Women’s Health Research Network (VA HSR&D SDR10-012)

% of sites reporting need for more menopause-related resources

<table>
<thead>
<tr>
<th>MENOPAUSE-ASSOCIATED ISSUE</th>
<th>% of sites reporting</th>
<th>% sites reporting were offered more resources/suppor to meet need</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sexual function</td>
<td>90</td>
<td></td>
</tr>
<tr>
<td>Urinary concerns</td>
<td>81</td>
<td></td>
</tr>
<tr>
<td>Vascular symptoms</td>
<td>81</td>
<td></td>
</tr>
<tr>
<td>Sleep disturbances</td>
<td>78</td>
<td></td>
</tr>
<tr>
<td>Vaginal/urinary health</td>
<td>73</td>
<td></td>
</tr>
<tr>
<td>Mood disturbances</td>
<td>71</td>
<td></td>
</tr>
</tbody>
</table>

### P-24. Behavioral Health usage over the menopause transition, an analysis of actuarial data

Hana Mikdachi, MD,1,2,3, Anastasia Kasianchuk, RDN,2, Rebecca Dunsmoor-Su, MD, MSCE1,2,3,1 OBGYN, Washington State University, Pullman, WA; 2Gennev, Seattle, WA; 3VA Loma Linda Healthcare System, Loma Linda, CA

**Objective:** Gennev is a telehealth clinic for women in midlife and menopause. As part of our intake we offer a voluntary and free Menopause Assessment (MA) that inquires about women’s menstrual history, menopause symptoms and quality of life related to those symptoms. We reviewed what women are reporting in the MA about their menopausal transition. **Design:** BRANY IRB determined this project was exempt from IRB review. **Hypothesis** questions which menopause symptoms impact quality and quantity of life in this population. The survey opens with an overall quality of life question (graded 0-7 representing worse quality of life). The symptoms survey inquires about the following: mood, sleep, night sweats, sleep disturbance, mood changes, weight changes, musculoskeletal symptoms, fatigue and energy, libido changes, and skin, nails and hair changes. Data are collected and stored in a de-identified database. Analysis of results was undertaken using descriptive statistics and basic comparative statistics. **Results:** 251,280 women who have completed the MA survey. The average age of women using our online services is 51; age is not asked on the MA specifically. The racial/ethnic makeup is 62% Caucasian, 6% Latina/Hispanic, 20% African American, 2% Asian/Pacific Islander, and 2% Native American. 38.5% of patients who complete the assessment are perimenopausal by menstrual history (some menstrual changes over the last year, or <12 months. Since last menstrual period [LMP]) 8% are premenopausal (no change in menses), 31% are post menopause (>12 months since LMP). 22% of women are “unknow” position in the menopause transition, due to surgical or hormonal interventions. 63% of the women surveyed have moderate to severe impact from their symptoms on an overall QOL scale (5 or above on 0-7 scale), 14% selecting the top impact score. The most commonly reported symptoms were: Mood changes: 63% of women reported this and of those 59% rate them moderate to severe impact on quality of life. Sleep symptom was particularly prevalent in the perimenopause group, 62% rated this a 5 or higher on the Likert scale. 19% gave it a 7 out of 7 for quality of life changes. -Hot flashes: impacted 55% of patients with 62% rating this 5 or above on QOL scale. African American Women were more likely to suffer from hot flashes. Women in the first 2 years of menopause had the highest impact from hot flashes when compared to the other groups. **Conclusion:** Our population is skewed towards perimenopause and women early in the menopause transition. This is a highly symptomatic time. Because of this skew, the symptoms that are most impactful are those that we clinically associate with perimenopause, namely mood, weight, night-time (sleep and night sweats) and libido changes. This is important as many interventions and studies are focused on hot flash relief, and this is not what women are most concerned about. Women are very concerned about less well studied changes and symptoms, and they deserve both good evidence-based information about them and effective management options to combat their symptoms.

**Sources of Funding:** None

### P-25. What women tell us about the menopause transition.

Hana Mikdachi, MD,1,2,3, Rebecca Dunsmoor-Su, MD, MSCE1,2,3,1 OBGYN, Washington State University, Pullman, WA; 2Gennev, Seattle, WA; 3VA Loma Linda Healthcare System, Loma Linda, CA

**Objective:** Gennev is a telehealth clinic for women in midlife and menopause. As part of our intake we offer a voluntary and free Menopause Assessment (MA) that inquires about women’s menstrual history, menopause symptoms and quality of life related to those symptoms. We reviewed what women are reporting in the MA about their menopausal transition. **Design:** BRANY IRB determined this project was exempt from IRB review. **Hypothesis** questions which menopause symptoms impact quality and quantity of life in this population. The survey opens with an overall quality of life question (graded 0-7 representing worse quality of life). The symptoms survey inquires about the following: mood, sleep, night sweats, sleep disturbance, mood changes, weight changes, musculoskeletal symptoms, fatigue and energy, libido changes, and skin, nails and hair changes. Data are collected and stored in a de-identified database. Analysis of results was undertaken using descriptive statistics and basic comparative statistics. **Results:** 251,280 women who have completed the MA survey. The average age of women using our online services is 51; age is not asked on the MA specifically. The racial/ethnic makeup is 62% Caucasian, 6% Latina/Hispanic, 20% African American, 2% Asian/Pacific Islander, and 2% Native American. 38.5% of patients who complete the assessment are perimenopausal by menstrual history (some menstrual changes over the last year, or <12 months. Since last menstrual period [LMP]) 8% are premenopausal (no change in menses), 31% are post menopause (>12 months since LMP). 22% of women are “unknow” position in the menopause transition, due to surgical or hormonal interventions. 63% of the women surveyed have moderate to severe impact from their symptoms on an overall QOL scale (5 or above on 0-7 scale), 14% selecting the top impact score. The most commonly reported symptoms were: Mood changes: 63% of women reported this and of those 59% rate them moderate to severe impact on quality of life. Sleep symptom was particularly prevalent in the perimenopause group, 62% rated this a 5 or higher on the Likert scale. 19% gave it a 7 out of 7 for quality of life changes. -Hot flashes: impacted 55% of patients with 62% rating this 5 or above on QOL scale. African American Women were more likely to suffer from hot flashes. Women in the first 2 years of menopause had the highest impact from hot flashes when compared to the other groups. **Conclusion:** Our population is skewed towards perimenopause and women early in the menopause transition. This is a highly symptomatic time. Because of this skew, the symptoms that are most impactful are those that we clinically associate with perimenopause, namely mood, weight, night-time (sleep and night sweats) and libido changes. This is important as many interventions and studies are focused on hot flash relief, and this is not what women are most concerned about. Women are very concerned about less well studied changes and symptoms, and they deserve both good evidence-based information about them and effective management options to combat their symptoms.

**Sources of Funding:** None

### P-26. Working with a registered dietitian / nutritionist in menopause in an integrated care model, preliminary outcomes from the first 100 patients.

Anastasia Kasianchuk, RDN,1 Yashika Dooley, MD,1,2 Rebecca Dunsmoor-Su, MD, MSCE1,2,1 Medical, Gennev, Seattle, WA; 2OBGYN, Washington State University, Pullman, WA

**Objective:** Gennev is an online telemedicine platform available to patients in 50 states in the US. We provide face to face telemedicine with physicians who are expert in menopause care. We also offer an integrative care model where patients can work on one with a registered dietitian/nutritionist (RDN) with every other week visits and text communication between visits, and this was accompanied by physician appointments at intervals determined by patient needs. RDNs are specifically trained in behavior change theory and application. A systematic review of the use of behavior change theory in dietetics practice in primary health care settings specifically showed when interventions are supported by behavior change techniques, such as cognitive behavioral therapy (CBT), health outcomes demonstrate greater improvement (1). As part of evaluating the program and utility of RDN health coaching we provided the first 66 patients with a survey at the end of their participation to give us insight into their experience. Additionally, the RDNs were asked to complete a survey looking at the purpose of the visits and reason for finishing the relationship. **Design:** IRB exemption was obtained through BRANY IRB to abstract and evaluate the data. The design of the study was a retrospective analysis of patient visit variables and a qualitative look at open-ended comments. The survey opened with “Was your reason for discontinuing service as well as goals and whether they were met. Survey information was downloaded and stored anonymously and could not be linked to the patient file. The RDN survey was filled anonymously and was stored without connection to the patient file. Answers in the patient survey were counted, evaluated, and the impression at the impression and data company, Milliman MedInsight to gather deidentified billing and claims data representing worse quality of life. Sleep symptom was particularly prevalent in the perimenopause group, 62% rated this a 5 or higher on the Likert scale. 19% gave it a 7 out of 7 for quality of life changes. -Hot flashes: impacted 55% of patients with 62% rating this 5 or above on QOL scale. African American Women were more likely to suffer from hot flashes. Women in the first 2 years of menopause had the highest impact from hot flashes when compared to the other groups. **Conclusion:** Our population is skewed towards perimenopause and women early in the menopause transition. This is a highly symptomatic time. Because of this skew, the symptoms that are most impactful are those that we clinically associate with perimenopause, namely mood, weight, night-time (sleep and night sweats) and libido changes. This is important as many interventions and studies are focused on hot flash relief, and this is not what women are most concerned about. Women are very concerned about less well studied changes and symptoms, and they deserve both good evidence-based information about them and effective management options to combat their symptoms.

**Sources of Funding:** None

**Design:**
WebMD (data collection) and UW OBGYN (data analysis). In the US, we found that a majority of respondents in the menopausal transition and early risk in 82 (27%) were experiencing menopause and with symptoms (14/66), and 3) behavioral health concerns including specifically anxiety (6/66). Of these most of the patients seeking weight or nutrition therapy or support for their symptoms were satisfied with their care and felt the program had served them well. Of those seeing the team for behavioral health support, 4/6 were referred to therapy or MD care. Additional themes that were less prevalent were around sleep management and life coaching. Some patients were using the service as a way to get access to physician care more frequently at a lower cost and some had multiple unrelated reasons for using the service. Conclusion: Integrated care models with an aspect of behavior change theory can be beneficial in helping patients make lasting changes in behaviors and can provide symptomatic relief even in the absence of medical treatment. Our initial piloting of an integrated model of care for menopausal symptoms including weight gain and body shape changes shows that focused work can alleviate symptoms and the average amount of time needed to accomplish this in our model was 3-5 months.

Sources of Funding: None

P-27. Menopause symptom experience and management in a diverse US population, 2019
Erin R. Dwyer, MPH1, Pauline Maki, PhD2, Ronit Katz3, Christine Louie1, Stas Zakharik1, Susan Reed, MD, MPH1. Obstetrics and Gynecology, University of Washington, Seattle, WA; 1University of Illinois Chicago, Chicago, IL; 2WebMD LLC, New York, NY
Objective: Provide information regarding US female experience of and attitudes toward menopause symptoms and use of treatments. Design: An online, age-weighted survey of self-identified female respondents was performed in 2019. Respondents were ≥ age 18. Inclusion criteria were self-identified menopause transition or post-menopause status and a 45 years of age. Respondents were asked about attitudes toward menopause and treatment, symptoms experienced, and treatments, including MHT, vaginal ET, DHEA, OTC products, vitamins, herbal or natural supplements, lifestyle changes or alternative therapies (yoga, acupuncture, mindfulness). Age-weighted proportions for demographics, menopause symptoms, and treatments used were calculated. Results: 1818 females ≥45 years completed the survey, 835(46%) in the menopause transition and 983(54%) postmenopausal of whom 116(12%) were <55 years. Mean ages were 45.2(17.3) years for demographics, menopause symptoms, and treatments used. The Evia app delivers hypnotherapy for treating hot flashes. However, knowledge on user characteristics and factors that are associated with length of program use are currently unknown. The purpose of this study was to determine users’ levels of familiarity with hypnotherapy, determine how users heard about Evia, and determine factors that are associated with length of program use. Design: This study was correlational and included the retrospective analysis of data collected by Mindset Health. Participants were included individuals who downloaded and subscribed to the Evia app. This included 604 participants. This study aimed to (1) determine subscribers’ levels of familiarity with hypnotherapy for hot flashes, (2) determine what percentage of subscribers were referred to Evia by a healthcare professional, and (3) determine factors that are associated with program use. It was hypothesized that there would be a significant positive relationship between hot flash severity, hot flash frequency, and hot flash interference with length of program use. It was also hypothesized that individuals who were referred to Evia by a healthcare professional would have completed a significantly higher day of the program than those who were not. Lastly, it was hypothesized that individuals who had heard of hypnotherapy for menopause would have completed a significantly higher day of the program than those who had not. Results: Among individuals who had subscribed to Evia, 14.4% reported that they had heard of hypnotherapy for menopause before, 20.2% reported that they had heard of hypnotherapy before. Among individuals who had heard of hypnotherapy before, 6.2% reported that they had not tried hypnotherapy before. Among subscribers, 6% reported that they were referred to Evia by a healthcare professional. There was no significant difference in maximum program day completed between subscribers who were referred to Evia by a healthcare professional and subscribers who were not referred to Evia by a healthcare professional. There was no significant difference in maximum program day completed between subscribers who had heard of hypnotherapy before and subscribers who had not heard of hypnotherapy before. There was no significant relationship between hot flash severity and maximum program day completed. There was a significant positive relationship between hot flash frequency and maximum program day completed, r = .130, p = .005. There was a significant positive relationship between hot flash interference and maximum program day completed, r = .109, p = .009. Conclusion: Most Evia subscribers had not heard of hypnotherapy for menopause before and a majority had not tried hypnotherapy before. Expectancy can play an important role in hypnotherapy, therefore, psychoeducation components of Evia that help to foster positive expectancy are very important. Most (94%) of Evia subscribers were not referred by a healthcare professional. This could be an important target to get more individuals who are suffering from hot flashes referred to the Evia app and access to hypnotherapy. Hearing about hypnotherapy before, being referred from a healthcare professional, and hot flash severity were not significantly related to length of program use. However, hot flash frequency and hot flash interference were significantly associated with length of program use. Individuals who reported more hot flashes and greater interference completed a higher day of the program. Future studies should investigate the feasibility and efficacy of the Evia app in a randomized controlled trial design.

Sources of Funding: None

Table 1. Menopause Treatment Use and Awareness, Menopause Transition and Postmenopause, N = 1813

<table>
<thead>
<tr>
<th>Menopause Transition</th>
<th>Current Use</th>
<th>Past Use</th>
<th>Nevar Use</th>
<th>N</th>
<th>%</th>
<th>N</th>
<th>%</th>
<th>N</th>
<th>%</th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>MHT</td>
<td>100</td>
<td>12</td>
<td>64</td>
<td>8</td>
<td>493</td>
<td>59</td>
<td>178</td>
<td>21</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vaginal ET</td>
<td>61</td>
<td>7</td>
<td>45</td>
<td>5</td>
<td>496</td>
<td>59</td>
<td>232</td>
<td>28</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OTC vaginal products</td>
<td>165</td>
<td>20</td>
<td>116</td>
<td>14</td>
<td>436</td>
<td>52</td>
<td>118</td>
<td>14</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Herbal supplements</td>
<td>340</td>
<td>44</td>
<td>213</td>
<td>14</td>
<td>326</td>
<td>37</td>
<td>175</td>
<td>18</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alternative therapies</td>
<td>132</td>
<td>16</td>
<td>127</td>
<td>15</td>
<td>371</td>
<td>44</td>
<td>205</td>
<td>25</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Postmenopause</th>
<th>Current Use</th>
<th>Past Use</th>
<th>Nevar Use</th>
<th>N</th>
<th>%</th>
<th>N</th>
<th>%</th>
<th>N</th>
<th>%</th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>MHT</td>
<td>107</td>
<td>11</td>
<td>236</td>
<td>24</td>
<td>484</td>
<td>49</td>
<td>156</td>
<td>16</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vaginal ET</td>
<td>105</td>
<td>11</td>
<td>59</td>
<td>6</td>
<td>505</td>
<td>51</td>
<td>190</td>
<td>20</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OTC vaginal products</td>
<td>127</td>
<td>18</td>
<td>224</td>
<td>22</td>
<td>459</td>
<td>47</td>
<td>133</td>
<td>14</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitamin supplements</td>
<td>391</td>
<td>40</td>
<td>120</td>
<td>12</td>
<td>273</td>
<td>28</td>
<td>199</td>
<td>20</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Herbal supplements</td>
<td>68</td>
<td>8</td>
<td>195</td>
<td>20</td>
<td>464</td>
<td>48</td>
<td>223</td>
<td>23</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alternative therapies</td>
<td>166</td>
<td>17</td>
<td>122</td>
<td>12</td>
<td>412</td>
<td>42</td>
<td>283</td>
<td>29</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
P-29. Examining Characteristics of Users of the Evia App: Digital Hypnotherapy for Hot Flashes
Garrett, A.K., D.D., Psychology and Neuroscience, Baylor University, Waco, TX
Objective: Hypnotherapy has been shown to reduce hot flashes in previous clinical trials (Elkins et al., 2008; Elkins et al., 2013), however, it is not routinely used in clinical practice because of accessibility barriers such as few trained therapists and cost. To expand hypnotherapy intervention for hot flashes, a smartphone app has been developed. Evia is an app that delivers hypnotherapy for hot flashes. The Evia app has made hypnotherapy for hot flashes more widely accessible and has the potential to help women suffering from hot flashes. However, knowledge about the characteristics of users of the Evia app is lacking. The present study examined the characteristics of users of the Evia app. Design: This was a cross-sectional, retrospective study with data collected during one time-point from a self-report questionnaire that is given to users when they download the Evia app. These data were collected prior to the user beginning the intervention. This study analyzed data collected from users who downloaded the app between 10/05/2021 and 07/08/2022. Users were asked about their age, stage of menopause, length of menopausal symptoms, number and severity of hot flashes, what their hot flashes feel like, sleep quality, and mental health using self-report questionnaire items. Results: The mean age of users was 49.31. Out of 9103 valid responses, 0.5% of users reported being not menopausal, 31.2% were perimenopausal, 14.2% were menopausal, 13.1% were post-menopausal, 7.6% were uncertain and 33.5% unknown. Out of 3127 valid responses, 20.4% of users reported experiencing menopausal symptoms for 0-6 months, 20.9% for 6-12 months, 20% for 1-2 years, 13.5% for 2-3 years, 11.3% for 3-5 years, 9.3% for 5-10 years, and 5.6% for >10 years. Out of 4665 valid responses, 13.5% of users reported experiencing 0 hot flashes per day, 9.4% reported experiencing 1 hot flash per day and 9% reported experiencing 2 hot flashes per day. 12.8% reported experiencing 3 hot flashes per day, 9.7% reported experiencing 4 hot flashes per day, and 41.6% of users reported experiencing 5+ hot flashes per day. Out of 4183 valid responses, 1.9% of users reported that their hot flashes were very mild, 30.4% reported that their hot flashes were mild, 40.9% reported that their hot flashes were moderate, 20.3% reported that their hot flashes were severe, and 6.4% reported that their hot flashes were very severe. Out of 4180 valid responses, 83% of users reported that their hot flashes felt like a sudden feeling of warmth, 59.2% reported perspiration, 47.5% reported flushed appearance, 34.5% reported rapid heartbeat, 32.7% reported anxiety, and 14.7% reported dizziness, weakness, and 16.4% reported nausea. Out of 2877 valid responses, results demonstrated that 18% of users reported no difficulty falling asleep each night, 30.8% of users reported a little bit of difficulty falling asleep each night, and 51.2% of users reported having difficulty falling asleep each night. Out of 2626 valid responses, results demonstrated that 47.7% of users reported their sleep quality to be terrible, 44% reported their sleep quality to be fair, 7.8% reported their sleep quality to be good, and 0.5% reported their sleep quality to be excellent. Out of 2877 valid responses, 5.9% of users reported that they never feel anxious or depressed, 38.4% of users reported that they often feel anxious or depressed, and 16.2% reported that they constantly feel anxious or depressed. Conclusion: This is the first study to report on the characteristics of users of the Evia app, which delivers hypnotherapy for hot flashes. Results showed that the average age of app users is in line with the average age of natural menopause onset. Results also showed that the largest percentage of users reported experiencing 5 or more hot flashes per day and reported that their hot flashes were moderate intensity. In line with previous research regarding age and sleep, a majority of users reported difficulty falling asleep each night and reported their sleep quality to be terrible or fair. In addition, a majority of users reported that they sometimes or often feel anxious or depressed. Results of this study will help to inform the optimization and tailoring of the hypnotherapy intervention delivered via the Evia app.
Sources of Funding: None

P-30. Long-term effects of short-term menopausal hormone therapy on white matter integrity
Laura Faubion, BS1, Foon Keat Mak, PhD1, Nirobiul Tosakulwong, Timothy Lesnick, Michael Malek-Ahmadi, Marcelle Cedars, Frederic Naftolin, Nanette Santoro, Barbara Barret, Rosanne Puleo, Dustin Hammers, Laura Faubion, BS1, Foo Keat Mak, PhD1, Nirobiul Tosakulwong, Timothy Lesnick, Michael Malek-Ahmadi, Marcelle Cedars, Frederic Naftolin, Nanette Santoro, Barbara Barret, Rosanne Puleo
Objective: To explore long-term effects of HT on measures of white matter integrity through white matter hyperintensity volume (WMH) and diffusion MRI metrics. Design: The Kronos Early Estrogen Prevention Study (KEEPS) was a double blind, placebo-controlled clinical trial in postmenopausal women within 5 to 36 months past menopause. KEEPS had three treatment groups: continuation participants randomized to the tE2 group (n=68) had higher fractional anisotropy (FA; i.e. more organized white matter) in the inferior temporal white matter (p=0.008) than placebo (n=90). However, the differences between the tE2 and placebo groups were no longer significant when false discovery rate correction was applied for multiple comparisons (p<0.05). There were no significant differences in diffusion MRI measures between placebo and oCEE (n=51) groups in or WMH between oCEE or tE2 relative to placebo. Conclusion: We found no evidence of long-term effect of HT on WMH between treatment groups and placebo. This was some evidence of preservation of white matter integrity in the tE2 group compared to placebo in the inferior temporal white matter tracts, however these were not statistically significant after correction for multiple comparisons. Whether this finding has influence on cognitive performance needs further investigation.
Sources of Funding: NIH grant R21 NS066147

P-31. Quantitative Evaluation of an Evidence-Based Menopause Education Group Program
Melissa Mantifel, Virginia Gooderham, Taryl Felhaber. The University of British Columbia, Vancouver, BC, Canada
Objective: Quantify outcomes of an 8-week, evidence-based, menopause group educational program offered by a primary care clinic via telemedicine to cohorts of 15 women in British Columbia, Canada. The outcomes studied included depression, anxiety, menopause symptoms, confidence in knowledge about menopause, outlook on menopause, and views on hormone therapy. This quality improvement project evaluated the program offered at womenMD Integrative Lifestyle Medicine in Victoria, BC, Canada. Design: Questionnaires were designed using validated tools to evaluate the impact of the program on mood, menopause symptoms, and patient attitudes. The Patient Health Questionnaire-2 (PHQ-2), Generalized Anxiety Disorder-2 (GAD2), and Menopause Rating Scale (MRS) have been found to be reliable and validated tools for evaluating psychological and somatic symptoms pre and post intervention. Questionnaires and study consent were emailed to participants 24 hours prior to their first class and again during the last class. Participants who missed ≥1 class or completed the questionnaire out of the designated time frame were excluded. The program was 8 weeks in duration, with one 1.5 hour group education session per week. The questionnaires were anonymized via Qualtrics software. The responses were compared pre- and post-intervention then analyzed using Student’s paired T-tests. Results: A total of 118 women participated in 9 groups between September 2021 – December 2022. Women between ages 44-58, with a mean age of 53.4 in BC, Canada (n=27) had matched responses to the pre and post intervention questionnaires, a survey response rate of 22.9%. They were found to have a nonsignificant decrease of 28.9% in PHQ-2 scores (p=0.1433) and a significant 25.7% decrease in GAD-2 scores (p=0.0369). MRS scores decreased by 29.6%, which represents somatic, psychosocial, and urogenital domains of menopause (p=0.0007). Participants’ confidence in menopause knowledge increased by 46.3% (p=2.1757e-11). There was a non-significant increase in positive outlook towards menopause of 10.4% (p=0.1183) and a 23.5% increase in positive views regarding...
hormone therapy (p<0.0001). Conclusion: Menopause is a complex midlife transition, with symptoms that vary between women, impacting an individual’s quality of life. Educational changes (CBT and mindfulness) and busy women’s health clinic, group education provides women with the skills and knowledge to be agents in the promotion of their own health while improving access to care.

Sources of Funding: None

P-32. Hysterectomy at the time of RRSO in BRCA patients – a single institution experience
Alexander Stankl, DO1, Holly Thacker, MD1, Mariam AlHilli, MD2, Molly Gumucio, CNP3, Anna Chichura4, Holly Pederson1. 1Specialized Women’s Health, Cleveland Clinic, Cleveland, OH; 2Subspecialty Women’s Health, Cleveland Clinic, Cleveland, OH; 3Lifestyle Medicine, via secure telemedicine due to pandemic restrictions, has been found to significantly impact the participants’ overall menopause experience. The womenMD program also offers different symptom management techniques based on cognitive-behavioral therapy (CBT) and mindfulness. The benefit of the 8-week education program included reduced menopause symptoms, increased confidence in menopause knowledge and an increased positive view towards menopause and hormone therapy. Limitations: This study included the quality improvement period not involving a control group for comparison, analysis of additional therapies patients may have been using during the 8-week program, and response bias. In a limited primary care context and busy women’s health clinic, group education provides women with the skills and knowledge to be agents in the promotion of their own health while improving access to care.

Sources of Funding: None

P-33. Exploring the Relationships Between the Gut Microbiome & Chronic Conditions in Postmenopausal Women
E. F. Finchley, Undergraduate, Veda B. Nambi. Biology, Rutgers The State University of New Jersey, New Brunswick, NJ
Objective: The objective of this project was to review articles related to the gut microbiome and its associations with menopause. Population diversity and gut microbiome differences influence the body create a complex system that is critical in health and regulation. Gut microbiome changes are known to occur with menopause, and associations between the gut microbiome and hypertension have been elucidated through multiple mechanisms. Understanding these mechanisms gives insight into the role of menopause in the development of hypertension which can open another avenue for treatment. Design: Search terms for this project “‘microbiome, ’ ‘hypertension,’ AND ‘postmenopausal’” on Pubmed. Articles focused on only hypertension rather than all chronic conditions. Results: Hypertension is one of the most common medical conditions, particularly affecting post-menopausal women and aging populations, and is a significant risk factor for cardiovascular events. The role of the gut microbiome in hypertension has been identified through multiple studies; for example, the HELIUS cohort study has found associations between the gut microbiota, fecal short-chain fatty acids (SCFA), and hypertension1. Though fecal bacterial composition alone was not found to be associated with blood pressure across racial groups when analyzed with SCFA composition, blood pressure associations were present1. The gut microbiome is an interface to the immune system which has downstream effects that directly impact blood pressure regulation. T-cell activation has been shown to influence blood pressure with proinflammatory T helper 17 cells (Th17) playing a role in the pathogenesis of hypertension2. Lactobacillus spp. survivability was found to modulate Th17 cells, directly influencing blood pressure regulation via intestinal bacterial signaling3. A preclinical model has demonstrated a 20% decrease in systolic blood pressure after a 4-week intervention aimed at optimizing the gut microbiome4. Further research is needed to better understand the role of the gut microbiome in hypertension.


P-34. Proprietary Delivery System Increases Serum Estradiol Levels and Reduces Vasomotor Symptoms in Menopausal Women
Todd Dormian, MD1, Amber Krogsgard, ND2, Alison Gracim, PC-A1, Russell Glenn, BA3. 1Rebalance Health Inc, Boulder, CO; 2Cedalion Health, Boulder, CO; 3Pep tide Rx, Palm Beach Gardens, FL; 4Complete Care Medical Group, Irvine, CA
Objective: Objective: The objective of the study is to demonstrate the benefit of a novel intranasal formula with a proprietary delivery system in decreasing hot flashes in a menopausal population. Initially, two pilot studies were performed in menopausal women utilizing a new supplement regimen delivered by a lozenge using DirectLine® technology. The first study focused on the efficacy of the DirectLine technology compared to leading competitors. The study showed a greater than 300% peak serum level and a 60% longer peak blood level compared to the market leader’s gummy delivery system. The second pilot study demonstrated a significant reduction in the negative symptoms of menopause including hot flashes, insomnia, and irritability. Additionally, serum estradiol levels increased by over 360% in 2 months. Patients also experienced an improvement in day-to-day physical and mental function. Consequently, a much larger IRB-approved and third-party governed study was launched to establish if the supplement system could reduce the incidence of vasomotor symptoms in menopausal women. Design: An IRB-approved, open-label study was conducted to evaluate the effectiveness of the supplement system in reducing hot flashes. We included females who had not used hormone therapy in the past 12 months and were currently experiencing hot flashes. The participants were given a 90-day supply of the supplement system, consisting of five lozenges per day. They maintained a diary of their symptoms and provided blood work during the study
a on a daily questionnaire. Participants who consented also had four separate blood draws taken (before starting the supplement and every 30 days until the study ended) measuring a variety of hormones and other menstrual parameters. Results: Results: The study involves 101 women with a mean age of 53 years old, from various ethnic and socioeconomic backgrounds. To date, 90% of participants reported a reduction in menopausal symptoms, 80% of participants reported a significant reduction in hot flashes and other menopausal symptoms, and 85% of participants reported a significant increase over time as women continue to take the supplement. The initial data demonstrate a statistically significant benefit based on our preliminary data. Additionally, a preliminary assessment of serum estradiol levels shows a significant increase over time as women continue to take the supplement system. The internal data demonstrate a statistically significant benefit based on subjective questionnaire responses and blood serum levels of estradiol proving the efficacy of both the Directline® delivery system and the ingredient profile of the supplements.

P-35. Menopause: Knowledge, preparedness, and experiences of Canadian women

Meenakshi Goel, MD, MRCOG1, Kelsey Mills, MD, MSc, HSEd, FRSCC, NCMP2, Janet Ko3, Trish Barbat4, Wendy Wolfman, MD, FRCS(C), FACOG, NCMP5, Obstetrics and Gynecology, University of Toronto, Toronto, ON, Canada; 2Clinical Associate Professor, Obstetrics and Gynecology, University of Victoria, Victoria, BC, Canada; 3Clinical Associate Professor, Obstetrics and Gynecology, The University of British Columbia, Vancouver, BC, Canada; 4Menopause Foundation Of Canada, Rosseau, ON, Canada; 5Professor, Obstetrics and Gynecology, University of Toronto, Toronto, ON, Canada

Objective: As a natural transition, menopause is experienced by many women without knowledge of the symptoms that can have significant impacts on their health and quality of life. Stigma and taboo around menopause and female aging can discourage open discussions on this topic, leading to a lack of awareness which can leave women unprepared to deal with the challenges in the mid-life. The aim of this study is to assess the awareness, preparedness, and experiences of Canadian women with menopause. This study is focused on menopause-related symptoms and the impact of menopause on relationships. The results of this study provide valuable insights into development of educational and support resources to improve women’s health and wellbeing during this critical period of their life.

Design: The survey was conducted by Leger online in partnership with Menopause Foundation of Canada, between August 2-11, 2022. 1,023 Canadian women aged 40-60 were surveyed, ensuring representation across various demographic variables including region, education, income, and ethnicity ensuring a diverse range of perspectives from across the country. Participants were included from all provinces except Prince Edward Island. Results: Knowledge about menopause: Only one-quarter (23%) are very knowledgeable about signs and symptoms of menopause, while three-quarters have some or no knowledge. 85% are aware that menopausal symptoms can occur before menopause begins. 55% wished they had learned about perimenopause/menopause earlier in life and 46% do/did not feel prepared for it, indicating the need and desire for access to information. 68% are currently going through, or have already been through, perimenopause or menopause. Hot flashes, night sweats, period changes, trouble sleeping, fatigue, and mood changes are the main symptoms women are familiar with and experiencing. Only one-third are aware that incontinence/leakage, pain during intercourse and skin issues are symptoms of perimenopause/menopause, while even fewer are aware that heart palpitations (25%) and urinary tract infections (18%) are symptoms. Of those in a relationship and going through perimenopause/menopause said their symptoms impacted their confidence and self-image in front of their partner or spouse. Support during menopause: Four-in-ten women who are going through (or have gone through) menopause (38%) feel alone during their experience and feel/felt like their symptoms are going/went untreated. More than half (54%) feel that discussing perimenopause/menopause symptoms is still taboo, and at least one-in-five are embarrassed to talk about them with family (28%) or friends (20%). Conclusion: Majority women undergoing menopausal transition feel as though they are alone, unsupported, and undertreated. To address the inequities faced by women in the prime of their lives, we must prioritize education and training on this issue, and develop policies and support systems to deal with menopause-related challenges.

Sources of Funding: none

Survey responses

Survey questions | didn’t know | Strongly disagree | Somewhat disagree | Somewhat agree | Strongly agree | No answer | Agree |
--- | --- | --- | --- | --- | --- | --- | --- |
I was not as prepared for perimenopause/menopause | 8% | 18% | 28% | 31% | 13% | 46% |
I wish I had learned about perimenopause/menopause and its symptoms earlier in my life | 9% | 13% | 25% | 36% | 19% | 55% |
Questionnaire would be embarrassed to ask for help/support about perimenopause/menopause from my family / friends | 5% | 39% | 30% | 29% | 6% | 29% |
I felt/feel alone during my perimenopause/menopause experience | 4% | 29% | 29% | 27% | 11% | 38% |
My perimenopause/menopause symptoms negatively impacted my sex life | 8% | 13% | 17% | 38% | 24% | 62% |
My perimenopause/menopause symptoms negatively impacted my confidence/self-image in front of my spouse/partner | 4% | 26% | 25% | 33% | 12% | 45% |
My perimenopause/menopause symptoms negatively impacted my relationship with my spouse/partner | 7% | 50% | 23% | 33% | 7% | 40% |
I feel discussing perimenopause/menopause symptoms is still taboo for most people | 7% | 17% | 22% | 46% | 14% | 54% |
I was/am embarrassed to talk to my friends about my perimenopause/menopause symptoms | 3% | 41% | 36% | 16% | 4% | 29% |

P-36. Vaginal and vulvar symptoms in patients with ESR1-mutated, ER+/HER2- metastatic breast cancer by baseline characteristics

Shari B. Goldfarb1,2, Sarah Sammons, MD,1 Jane L. Meisel, MD,3 Timothy J. Pharr, MD4, Simon N. Jenkins, PhD, Barry Komm, PhD,5 Dominic Carroll6, David J. Portman, MD1, Memorial Sloan Kettering Cancer Center, New York, NY; 2Weill Cornell Medical Center, New York, NY; 3Dana-Farber Cancer Institute, Boston, MA; 4Emory Winship Cancer Institute, Atlanta, GA; 5Saint Luke’s Cancer Institute, Kansas City, MO; 6Sermonix Pharmaceuticals, Columbus, OH

Objective: Endocrine therapy (ET), particularly aromatase inhibitors (AIs) that lower estrogens to subphysiologic levels, can induce germinotrophic syndrome of menopause (GSM). A previous exploratory analysis from ELAINE 1, a phase 2 study in patients with ESR1-mutated, ER+/HER2- metastatic breast cancer (mBC) that progressed on an AI-CDK4/6 inhibitor combination, showed numeric improvements in vaginal/vulvar symptoms with lasofoxifene versus fulvestrant (Goldfarb et al., 2023, ISSWSH). The objective of this analysis was to evaluate the effects of patient characteristics on baseline vaginal and vulvar symptoms in ELAINE 1. Design: The multinational ELAINE 1 study evaluated vaginal and vulvar symptoms as an exploratory endpoint using the vaginal (VAS) and vulvar (VuAS) assessment scales, validated instruments that assess vaginal dryness, soreness, irritation, and pain using a 4-point scale (0=none, 1=mild, 2=moderate, 3=severe). The mean scores for baseline VAS, VuAS, and composite VAS/VuAS (average of all reported scores for a patient) were stratified by patient characteristics (age, visceral disease, prior adjuvant tamoxifen, duration of prior AI in the adjuvant or adjuvant/metastatic setting) for those who completed the VAS/VuAS assessments. Results: Of 103 enrolled patients, 72 (70%) completed the VAS/VuAS, with a mean age (range) of 61.5 (37-84) years. Vaginal dryness (40%), vaginal dryness (25%), and vaginal pain (22%) were the most frequently reported symptoms at baseline; 74% were unreported, irrespective of treatment assignment. Data were descriptively summarized. Results: Of 103 enrolled patients, 72 (70%) completed the VAS/VuAS, with a mean age (range) of 61.5 (37-84) years. Vaginal dryness (40%), vaginal dryness (25%), and vaginal pain (22%) were the most frequently reported symptoms at baseline; 74% were unreported, irrespective of treatment assignment. Data were descriptively summarized. Results from this exploratory analysis in a limited number of ELAINE 1 patients with ER+/HER2- mBC showed that younger age, non-visceral disease, prior tamoxifen (a marker of pre-menopausal status at diagnosis), and a longer total duration of AI use in the adjuvant or metastatic settings may be associated with more severe baseline vaginal and/or vulvar symptomatology. ELAINE 1, the phase 3, registrational trial evaluating second-line CDK4/6 inhibitor therapy (abemaciclib) plus either lasofoxifene or fulvestrant in patients with ESR1-mutated ER+/HER2- mBC, will help further evaluate the impact of patient and disease characteristics on symptoms, as well as treatment effects on vaginal and sexual health as assessed by patient-reported outcomes.

Sources of Funding: Sermonix Pharmaceuticals
P-37. Using Technology to Advance Menopause Management: A Novel Interactive Website (www.MQ6.ca)  
Susan Goldstein, MD, CCFP, FCP, NCMP, N. Yueksel, BScPharm, PharmD, NCMP, TD, Timothy Rowe, MMSc, FRCSc, CRCOG, Jeanne Bouteaud, MDCM, MSc, FACOG, FACOG, Wendy Wolsitan, MD, FRCSc, FACOG, FACOG, Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada; Obstetrics and Gynecology, University of Toronto Temerty Faculty of Medicine, Toronto, ON, Canada; Obstetrics and Gynecology, The University of British Columbia Faculty of Medicine, Vancouver, BC, Canada;‘Family and Community Medicine, University of Toronto Temerty Faculty of Medicine, Toronto, ON, Canada; Obstetrics and Gynecology, Université de Montréal Faculté de médecine, Montréal, QC, Canada.

Objective: The provision of menopausal care continues to be challenging in the post-WHI world where clinicians exhibit significant knowledge gaps and where in many locations menopausal education for healthcare providers is limited. The MQ6 menopause assessment tool and accompanying treatment algorithm were published in 2017(1) to address these knowledge gaps and to support healthcare providers in providing menopausal care. In addition to clinical utility, the MQ6 assessment tool can be self-administered by patients and used as a valuable counselling tool during the clinical encounter. The accompanying MQ6 treatment algorithm guides clinicians in creating individualized menopausal treatment plans. These tools have been utilized by both primary care and other specialists in the contexts of both clinical care and medical student/resident teaching. As medical education and professional development have expanded to multiple modalities including online platforms and “app’s”, knowledge translation tools that involve technology are desirable and widely accepted. There is a current paucity of professional online interactive tools related to menopause management. (1) Goldstein S. An efficient tool for the primary care management of menopause. Can Fam Physician. 2017 Apr;63(4):295-298. Design: The website https://mq6.ca was developed to provide easy and interactive access to the MQ6-associated tools and to provide other tools and medical information to support both clinicians and patients. The 2017 algorithm was updated to reflect the most recent guidelines and menopausal products available in Canada. Content of the website was informed by the most recently published literature and expert consensus. Content on the site was peer-reviewed by a panel of menopause experts across Canada including physicians and a pharmacist (N=4). The website was then reviewed for relevance and usability by a range of end users. This included academic and community-based family physicians, resident physicians, other physicians and regulated healthcare professionals with menopausal expertise, and members of the public. Their feedback and commentary were positive on these measures. The MQ6 website went “live” on March 31, 2023. Results: The website content, while focussed on interventions have the potential to positively impact sexual desire in menopausal women.


Anna V. Gueldini de Moraes, PhD, Adriana O. Pedro, PhD, Lucia Costa Paiva, MD, PhD. Gynecology and Obstetrics, Universidade Estadual de Campinas, Campinas, Brazil.

Objective: The aim of the study was to evaluate the effect of non-invasive radiofrequency procedure and compare it to vaginal estrogen therapy and vaginal moisturizer in the treatment of genitourinary syndrome of menopause (GSM) symptoms in postmenopausal women. Design: A total of 30 postmenopausal women meeting inclusion criteria were randomly assigned into three intervention arms to receive the following treatments: 3 sessions of intravaginal and vulval non-invasive radiofrequency therapy (RF arm); 1mg of intravaginal estriol cream applied daily for 2 weeks, followed by 1mg applied 2 times weekly or 1 mg of estradiol vaginal fast-dissolving film applied daily for 2 weeks followed by 1mg applied 2 times weekly (E arm). Mean age was 58.6±6.4 years, 10 patients were on hormone therapy. Randomization was made using Vaginal Health Index (VHI), Vaginal Maturation Index, Menopause Rating Scale (MRS), Female Sexual Function Index (FSFI), International Consultation on Incontinence Questionnaire Short Form (ICQ-UI SF) and International Consultation on Incontinence Questionnaire Checklist - Overactive Bladder (ICIQ-OAB). Statistical analysis was made using the Fisher’s exact test and the Chi-square test (categorical variables) and the Kruskal-Wallis test and the Wilcoxon test (numerical variables). The Tukey test was used to assess the interaction’s effect of the different arms vs assessments over time. The profile test by contrast was used to assess the significant differences over thertime of assessment. In addition, the ANOVA test was used for repeated measures to compare parameters intraday inter study arms, with the variables transformed into ranks due to the absence of a normal distribution. The mean age of the participants was 58.6±6.4 years. Ten of the 15 studies excluded participants over 60 years of age. Five of the studies (2), the United States (2), Brazil, Korea, Spain, Thailand, and Turkey (1 each). The studies included both premenopausal and menopausal women. There was notable variability in the types of interventions. The following intervention categories emerged: education (9), mind focused therapies (7), physical body focused therapies (6), aromatherapies (3), and touch therapies (3). Researchers employed a similar number of interventions, consisting of interventions from two or more categories. Of the 15 studies, researchers of 11 studies demonstrated statistical significance suggesting that their intervention positively affected sexual desire in menopausal women. Conclusion: Nonpharmacologic interventions have the potential to positively impact sexual desire in menopausal women.
The small number of studies and relatively small samples sizes limit generalizability. Larger scale and longer duration studies are needed. Future researchers should include diverse racial and ethnic groups. Inclusion: Participants were women who underwent two 24-hour periods of simultaneous monitoring of objective hot flashes and sleep disruptions. For the AS group, sleep duration increased while WASO increased connectivity to this region (t(17) = 2.79, p = 0.013). Additionally, participants with PO-MDD exhibited increased connectivity following treatment between the right amygdala and the medial prefrontal cortex (t(17) = -2.12, p = 0.05), while control participants showed increased connectivity to this region (t(17) = -2.79, p = 0.013). This study provides evidence that PO-MDD is associated with hyperconnectivity between the right amygdala and frontal brain regions. Further, estradiol treatment significantly decreased right amygdala hyperconnectivity to the medial prefrontal cortex and increased connectivity from the right caudate to the left insula. These connectivity patterns may be instrumental in the development of PO-MDD and, in turn, may play a vital role in the therapeutic effects of estradiol.

Sources of Funding: NIMH K23 MH105569 NIMH R01 MH128238

P-42. Evaluating menopausal symptoms in a border population in West Texas Sarah J. Johnson, Doctor of Medicine, Kealey Steffen, Doctor of Medicine, Sheralyn Sanchez, PhD, MPH, Anjana Nair, Doctor of Medicine. Obstetrics and Gynecology, Texas Tech University Health Sciences Center El Paso Paul L. Foster School of Medicine, El Paso, TX

Objective: Menopause is a naturally occurring process for all women, caused by the cessation of ovarian function. Menopause marks a new phase in the life of women, and menopause is experienced differently by each patient. Symptoms vary widely from hot flashes, night sweats, sleep disturbances, vaginal discomfort, and sexual dysfunction. Symptoms vary in severity, duration, and impact on quality of life. Many factors influence how a woman perceives menopause symptoms, including race and ethnicity, socioeconomic factors, level of education, and cultural norms. Most studies exploring menopause and its impact were conducted in women of European descent; this limits the understanding of menopausal symptoms in patient populations of other ethnicities. It is critical to understand how women of non-European descent understand and experience menopause to deliver culturally competent care and improve the quality of life for women with severe menopause symptoms. This study seeks to better understand the menopausal symptoms and concerns experienced by a primarily Hispanic population of women living in a border town of West Texas. Design: In a prospective observational study, 204 women diagnosed with menopause (12 consecutive months of amenorrhea or had bilateral ovaries removed) were invited to participate in an anonymous, self-administered survey in English or Spanish regarding their knowledge of and experience with menopause. The survey included demographic factors, namely race, ethnicity, level of education, annual household income, and smoking status. Participants were asked about their experience with menopause, including: if a healthcare provider had addressed their symptoms, the presence and severity of symptoms, and experience with menopause treatments. Results: There were 204 women enrolled in the study, recruited from January 2021 to March 2023. Participants identified as Hispanic (76.4%), with an average age of 56.8 years (standard deviation 12.6). Survey results were compared based on age and ethnicity. Menopausal participants under 50 years age more frequently reported experiencing menopause symptoms (p < 0.001), with 100% of patients (n = 28) under the age of 50 reporting menopause symptoms, while 64.3% of participants (n = 157) over the age of 50 reported menopause symptoms. The most bothersome symptoms reported by Hispanic women were sleep disturbances (60.6%) and concerns with weight gain (75%), however, there were no significant differences described in the experience of other menopausal symptoms including hot flashes, mood changes, changes in mental abilities, weight gain, or difficulties with sexual intercourse across different ethnicities. Women self-identifying as non-Hispanic White were more likely to report having received prescription hormone therapy for menopause symptoms than Hispanic women (p = 0.012). Non-Hispanic White participants were also more likely to report having received prescription hormone therapy for menopause symptoms when compared to Hispanic women (p < 0.001). Conclusion: A higher percentage of Hispanic women reported not receiving treatment for their menopause symptoms including prescription hormone therapy when compared to their Non-Hispanic White counterparts. Additionally, women younger than 50 years were more likely to report menopause symptoms. Obstetrician-gynecologists and other physicians should be cognizant of this when addressing menopausal symptoms with patients, particularly given that no significant differences in menopausal symptoms are reported across ethnicities. This study also highlights the most bothersome menopausal symptoms reported by Hispanic women and the disparities in treatments especially with regards to use of prescription hormone therapy. It further points to the importance of cultural competence in order to provide high-quality care for all women regardless of ethnicity.

Sources of Funding: None
1University of California, San Francisco and Sutter East Bay Medical Foundation, Berkeley, CA; 2Universitat de Valencia, Valencia, Spain; 3Fondazione Policlinico IRCCS S. Matteo, University of Pavia, Pavia, Italy; 4Astellas Pharma Global Development Inc, Northbrook, IL

Objective: To present pooled safety data from three 52-week phase 3 fezolinetant studies (SKYLIGHT 1, 2 and 4; NCT04003155, NCT04001442, NCT04003389) in women with vasomotor symptoms (VMS; hot flashes and night sweats) associated with menopause.

Design: SKYLIGHT 1 and 2 were double-blind, placebo-controlled studies with the same design. Women aged 40–65 y with moderate-to-severe VMS (minimum average a7 hot flashes/day) were initially randomized to once-daily placebo, fezolinetant 30mg or 45mg (1:1:1). After 12 weeks, those on placebo were re-randomized to fezolinetant 30mg or 45mg, and those on fezolinetant continued on their assigned dose for 40 weeks. SKYLIGHT 4 was a placebo-controlled, double-blind, 52-week long-term safety study. Safety was assessed by frequency of treatment-emergent adverse events (TEAEs) and laboratory assessments including liver safety assessments. Results: A total of 952 participants in the placebo group; 1103 in the fezolinetant 30mg group and 1100 in the fezolinetant 45mg group took ≥1 dose of study medication. Caffeine use was not restricted; 18% of each group were current smokers. Here we present safety data for fezolinetant 45mg (proposed dose for approval); results were consistent for 30mg. By group, TEAEs occurred in 55.3% of participants in the placebo and 62.9% in the fezolinetant 45mg group; exposure-adjusted results were consistent with these results (TABLE). The most frequent TEAEs (>5% in either group) were upper respiratory tract infections (8.2% placebo, 7.7% fezolinetant 45mg); headache (7.7% placebo, 8.2% fezolinetant 45mg); and COVID (4.1% placebo, 6.1% fezolinetant 45mg). There were 6 drug-related serious TEAEs (1 placebo, 5 fezolinetant 45mg). The incidence of elevations of hepatic transaminases was low, events were generally asymptomatic and resolved on treatment or on discontinuation. No Hy’s Law cases were reported. A low incidence of bone fractures was reported, with similar incidences across groups. Endometrial hyperplasia or malignancy determined by the final biopsy diagnosis in fezolinetant-treated participants, assessed by centrally read endometrial biopsies, were within FDA pre-specified limits of ≤1% with an upper limit of 1-sided 95% CI 4%. There was no substantial difference in endometrial thickness measured by transvaginal ultrasonogram during the assessment period between fezolinetant- and placebo-treated participants. Conclusion: Pooled data affirmed the safety and tolerability of fezolinetant over 52 weeks.

Sources of Funding: None


Objective: To present pooled safety data from three 52-week phase 3 fezolinetant studies (SKYLIGHT 1, 2 and 4; NCT04003155, NCT04001442, NCT04003389) in women with vasomotor symptoms (VMS; hot flashes and night sweats) associated with menopause.

Design: SKYLIGHT 1 and 2 were double-blind, placebo-controlled studies with the same design. Women aged 40–65 y with moderate-to-severe VMS (minimum average a7 hot flashes/day) were initially randomized to once-daily placebo, fezolinetant 30mg or 45mg (1:1:1). After 12 weeks, those on placebo were re-randomized to fezolinetant 30mg or 45mg, and those on fezolinetant continued on their assigned dose for 40 weeks. SKYLIGHT 4 was a placebo-controlled, double-blind, 52-week long-term safety study. Safety was assessed by frequency of treatment-emergent adverse events (TEAEs) and laboratory assessments including liver safety assessments. Results: A total of 952 participants in the placebo group; 1103 in the fezolinetant 30mg group and 1100 in the fezolinetant 45mg group took ≥1 dose of study medication. Caffeine use was not restricted; 18% of each group were current smokers. Here we present safety data for fezolinetant 45mg (proposed dose for approval); results were consistent for 30mg. By group, TEAEs occurred in 55.3% of participants in the placebo and 62.9% in the fezolinetant 45mg group; exposure-adjusted results were consistent with these results (TABLE). The most frequent TEAEs (>5% in either group) were upper respiratory tract infections (8.2% placebo, 7.7% fezolinetant 45mg); headache (7.7% placebo, 8.2% fezolinetant 45mg); and COVID (4.1% placebo, 6.1% fezolinetant 45mg). There were 6 drug-related serious TEAEs (1 placebo, 5 fezolinetant 45mg). The incidence of elevations of hepatic transaminases was low, events were generally asymptomatic and resolved on treatment or on discontinuation. No Hy’s Law cases were reported. A low incidence of bone fractures was reported, with similar incidences across groups. Endometrial hyperplasia or malignancy determined by the final biopsy diagnosis in fezolinetant-treated participants, assessed by centrally read endometrial biopsies, were within FDA pre-specified limits of ≤1% with an upper limit of 1-sided 95% CI 4%. There was no substantial difference in endometrial thickness measured by transvaginal ultrasonogram during the assessment period between fezolinetant- and placebo-treated participants. Conclusion: Pooled data affirmed the safety and tolerability of fezolinetant over 52 weeks.

Sources of Funding: None

Patient characteristics are shown in the Table.

<table>
<thead>
<tr>
<th>Table</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Placebo (n=952)</strong></td>
</tr>
<tr>
<td><strong>TEAE (%) or rate per 100 subject-years</strong></td>
</tr>
<tr>
<td>Overall</td>
</tr>
<tr>
<td>Drug-related</td>
</tr>
<tr>
<td>Serious</td>
</tr>
<tr>
<td>Drug-related serious</td>
</tr>
<tr>
<td>Leading to withdrawal of treatment</td>
</tr>
<tr>
<td>Drug-related, leading to withdrawal of treatment</td>
</tr>
<tr>
<td>Death (unrelated to treatment)</td>
</tr>
<tr>
<td><strong>Preferred Terms (%)</strong></td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
</tr>
<tr>
<td>Headache</td>
</tr>
<tr>
<td>COVID</td>
</tr>
<tr>
<td><strong>TEAEs of special interest (%)</strong></td>
</tr>
<tr>
<td>Liver test elevations</td>
</tr>
<tr>
<td>Bone fractures</td>
</tr>
<tr>
<td>Depression</td>
</tr>
<tr>
<td>Weight loss</td>
</tr>
<tr>
<td>Memory</td>
</tr>
<tr>
<td><strong>Centrally-read endometrial biopsy (%)</strong></td>
</tr>
<tr>
<td>Hyperplasia</td>
</tr>
<tr>
<td>Menopause</td>
</tr>
</tbody>
</table>

*Exposure-adjusted incidence rate per 100 subject-years; *Fezolinetant 45 mg group includes placebo subjects who were re-randomized to fezolinetant 45 mg after 12 weeks on placebo from SKYLIGHT 1 and 2 studies; **Determined by final endometrial biopsy diagnosis; **n=304 (upper limit of one-sided 95% CI 1.6%); **n=304 (upper limit of one-sided 95% CI 1.0%).
Objective: Although only approved in the US to treat premenopausal women with hypoxic sexual desire disorder (HSDD), flibanserin has been studied in and prescribed to thousands of postmenopausal women. During the COVID-19 pandemic, telehealth emerged as a critical component of patient care and is now widely accepted. This study utilizes data from an online telehealth screening questionnaire (screener) to explore the key characteristics of postmenopausal women with low libido who self-refer for treatment with flibanserin for low libido. Design: A 25-question screener was used to confirm a diagnosis of HSDD and determine eligibility for treatment with flibanserin. Questions from the Decreased Sexual Desire Screening (DSDS) were included on the screener to facilitate the diagnosis of HSDD. Eligibility for flibanserin was assessed using patient responses to questions related to demographics, coexisting medical conditions, and concomitant medications. The screener provided a brief definition of menopause, and women were asked to respond “Yes,” “No,” or “I don’t know” to the question “Have you gone through menopause?” Women who self-reported as menopausal and completed the screener, between January 1, 2022, to December 31, 2022 (study period) were automatically enrolled (study population). All patient data were captured and stored in a secure and HIPAA-compliant platform. Results: A total of 1246 menopausal women completed the screener during the study period and were automatically enrolled. Ninety-nine percent of the study population indicated a bothersome decrease in libido, 84% indicated that in the past, their libido was good and satisfying, and 93% indicated their HSDD-related symptoms had lasted for >6 months. Time since last wellness exam was ≤12 months for 1033 (83%) of the study population. Our data highlight an unmet need in the management of VMS in women experiencing VMS while on AET. Conclusion: What do women with breast cancer take for menopause symptoms? A real-world analysis of treatment utilization from the US and Europe. Sheryl Kingsberg, PhD; Cecile Janssenswillen; Cecilia Caetano; Lauren Lee; Megan Scott; Nils Schoof; Carsten Moeller; Siir Su Saydam; Lisa Halvorson, Victoria Banks; Departments of Reproductive Biology, Psychiatry and Urology, University Hospitals, Cleveland, OH; 3Bayer Consumer Care AG, Basel, Switzerland; 4Respiratory Franchise & Women’s Health, Adelphi Group Ltd, Bollington, United Kingdom; 5Medical Affairs & Pharmacovigilance, Pharmaceuticals, Bayer plc, Reading, United Kingdom; 6Bayer Corporation, Whippany, NJ; 7Bayer Pharma AG, Berlin, Germany. Objective: Women receiving adjuvant endocrine therapy (AET) for hormone-positive breast cancer report high rates of menopausal symptoms including vasomotor symptoms (VMS). Treatment options for VMS in this patient group are limited due to contraindications to hormone therapy (HT). The REAL-world evidence on vasomotor symptoms (VMS) in women experiencing VMS while on AET. Design: The Adelphi 2020 VMS Disease Specific Program (DSP™) was a quantitative, cross-sectional, ethics board-exempt survey conducted in France, Germany, Italy, Spain, the United Kingdom, and the United States. Oncologists provided demographic, clinical, and treatment data on adult women in remission from breast cancer taking AET (tamoxifen/ aromatase inhibitors) and experiencing VMS. We stratified patients by physician-reported VMS severity; analyses were descriptive. Results: Data were provided by 77 oncologists on 635 women (mean age 53.9 years, standard deviation [SD] 9.5; mean age at onset of induced menopause 48.7 years, SD 7.3; 80.3% White/Caucasian). Physicians reported that 60.5% of women were currently prescribed treatment for VMS related to AET (mean [SD] treatment duration 40.7 [66.7] weeks); 7.1% had previously been prescribed, and 32.4% had never received treatment. Of women receiving VMS treatment, 21.9% were prescribed one or more HT products (alone or in combination with other drugs), including bioidentical hormones; 65.9% were prescribed serotonin-norepinephrine reuptake inhibitors (SSRI/SNRI), alone or in combination; and 12.2%-other treatment only (gabapentin/pregabalin/ clonidine/others). Estradiol products were the most common HT (8.3%) and venlafaxine the most frequently prescribed SSRI/SNRI (25.0%) (Table). Route of administration for all HT products (n=84) included: Oral pill/tablet/capsule (63.1%), patch (13.4%), and cream/gel (17.9%). Of women with severe VMS, 81.4% were prescribed VMS treatment (19.3% received HT), while 48.3% with mild VMS received VMS treatment (22.7% HT). Conclusion: We found that around one-fifth of the women receiving treatment for VMS were prescribed HT (61.1% by oral route), which is in principle contra-indicated in this population. Our data highlight an unmet need in the management of VMS in women taking AET for the prevention of breast cancer recurrence.
**P-48. Clearing the fog: Learning about menopause through the experiences of 4,578 women ages 40-65**

Benjamin Klein, Anne Matthews, Ben Serbiak. Self Care, Johnson & Johnson Services Inc, New Brunswick, NJ

**Objective:** Studies suggest that there is a disconnect between symptoms associated with menopause and a woman’s self-identification with menopause. By gaining comprehensive insights into the experiences and attitudes of women navigating the challenging symptoms associated with menopause, this study aimed to better understand how women are currently identifying and managing their symptoms, to all the care and experience for each woman's perimenopausal journey.

**Design:** An Attitudes and Usage study was conducted among women* age 40-65 in the US, with 4,578 participants. This study consisted of an online survey completed over a 3-week period. The main sample included 4,046 women between the ages of 40-65, with additional representation from specific (historically under-represented) cohorts, including an additional 135 Black women and 122 Hispanic women. The study is one of the largest (likely the largest) quantitative study of women of perimenopausal/menopausal age conducted to date in the US. From a recruitment perspective, the study included women from all US regions, and had a representative split across income levels. The study included 4 modules, designed to learn about the unique experiences of each woman through both qualitative and quantitative feedback. Module 1 explored lifestyles and attitudes, with a variety of question formats. Example questions: - Numeric scale ranking (E.g., “How do you describe your energy level?”) - Choice rank (E.g., “Choose which best describes you: “I like to make my own health decisions” or “I strictly follow medical advice”). - Open-ended (E.g., “What was the significant moment where you first began to think you were entering a different life phase?”) Module 2 explored each woman’s symptoms, as well as her perceived correlation between symptoms and menopause- related medical conditions, while exploring example questions: - “If you develop these symptoms, would you seek treatment?” (E.g., “Is your [SYMPTOM] connected with menopause?”) Module 3 explored sources of trust. Example questions: - “Where do you seek advice for [SYMPTOM], and what triggered you to seek that advice the first time?” - Module 4 probed on each woman’s understanding of HRT, and their openness to learning more. For those taking HRT today, satisfaction levels and feelings during the process were explored. *We recognize that ‘women’ is a gendered term and not all people with ovaries may identify with that gendered term used here.**

**Results:** Our data suggests a disconnect between a woman’s experience with menopause-related symptoms and her ability to identify them as such. Prior to age 50, the proportion of women experiencing symptoms that could be connected to perimenopause is significantly greater than the proportion who are over age 50. Similarly, 45% of women report experiencing symptoms (other than symptoms tied to menstruation, 8.4 symptoms experienced), regardless of if they believe to be in any stage of menopause, indicating that the perception of perimenopause onset is blurred. Notably, 1 in 5 respondents experiencing hot flashes and night sweats at age 45 or 46 years old believe they are not yet in perimenopause. Further, most women reported reluctance to seek help, despite the impact on their quality of life. Using night sweats as an example, 39% of women either sought advice but didn’t take action or meant to seek advice but didn’t. Another 43% did not seek advice at all. Only 17% sought advice and addressed the symptom. The top 10 symptoms of concern are hot flashes, fatigue, night sweats, weight gain, brain fog, loss of libido, slower metabolism, memory issues, bloating, and joint pain.

**Conclusion:** Through this data we can see patterns driven by mis-informed perceptions and a lack of information around symptoms that are connected to menopause onset.

**Sources of Funding:** None

**P-49. Botulinum Toxin (Bottox®) for the Treatment of Vaginismus**

Sunbal Javaid, MD, Natalie Suszozi, BS, Michelle Nezolosky, MPH, Michael Krychman, MD, HerMD, Cincinnati, OH

**Objective:** Vaginismus is a subset of the genito-pelvic pain/penetration disorder (GPPD). It is defined as the involuntary contraction of the muscles surrounding the vaginal opening.1 With vaginismus, the vaginal musculature automatically tightens when something is inserted (e.g., tampons, digits, penis, dilator, or during a pelvic examination). Patients will also present with profound psychological impacts from a vaginismus diagnosis, with women often reporting shame, embarrassment, guilt, and self-deprecating views.2 Various medical conditions are often considered (e.g., vaginismus as a manifestation of panic attacks associated with panic disorder and generalized anxiety or depressive disorder). Pacik et al. report an average duration of vaginismus of 7.8 years from time of discovery, with 70% of women noting severe vaginismus, and a correlation between those symptoms and women’s reported negative outcomes: - Decreased sexuality - Increased anxiety or depressive disorder. Pacik et al. report an average duration of vaginismus of 7.8 years from time of discovery, with 70% of women noting severe vaginismus, and a correlation between those symptoms and women’s reported negative outcomes: - Decreased sexuality - Increased anxiety or depressive disorder.

**Methods:** This is a retrospective chart review examining the safety and efficacy of vaginal botox injections for the treatment of vaginismus during the study period of December 15, 2018 through January 1, 2023. **Results:** During the study period, twenty-five (25) patients were seen at two clinical centers, with 95% of patients seen at one clinical facility and 5% of patients seen at the other. Five patients were lost to follow up. In a subanalysis of the group diagnosed with vaginismus, 70% of the individuals in the final analysis was 31.3 years (range 20-40). 90% of participants were single/other and 10% were married. Seventy analyzable patients received a total of 506 units of botox® with a mean 48 units delivered per individual (range 36-50). Seventy percent (70%) of the individuals received 50 units of botox®. All participants tolerated the procedure well without incidence or complaints. There were no adverse events reported. At the patients’ subsequent follow-up interaction, 95% of those treated reported a positive outcome and improvement in their vaginismus symptomatology, and 88% (15/17) reported successful intercourse.

**Conclusion:** Our unique clinical centers ascribe to the multimodal biopsychosocial treatment of female sexual complaints. While sexual health counseling, dilator use, and pelvic floor physical therapy remain the mainstay for vaginismus treatment, these treatment modalities are often time-consuming and have variable rates of success. Given our centers’ proprietary algorithms of care and specialized medical training and clinical support, personalized treatment paradigms can effectively incorporate innovative therapeutic interventions that result in exceptional improvements and improved symptom resolution across additional symptoms. As exemplified in this encouraging data, the adjunctive addition of vaginal botox to the treatment paradigm for vaginismus can be safe and effective, with encouraging results highlighting the need for additional data collection and analyses demonstrating the benefits of vaginal botox in this setting.

**Sources of Funding:** None

**P-50. Utilizing Advanced, Innovative Technologies To Improve Symptoms Associated with Sexual Health and Menopause Conditions**

Sunbal Javaid, MD, Natalie Suszozi, BS, Michelle Nezolosky, Michael Krychman, MD, HerMD, Cincinnati, OH

**Objective:** Clinical research has shown that systemic hormone therapy may alleviate symptoms of vaginal dryness or atrophy in approximately 75% of cases, while local therapy does so in approximately 80%-90% of cases. While hormone therapy remains one of the most effective treatment options for various gynecological and vaginal symptoms, the use of advanced technological interventions for the treatment of the genitourinary syndrome of menopause (GSM) and sexual health concerns has gained in popularity over the last decade, offering viable treatment alternatives to hormonal medications. One of the latest technological innovations in the women’s health ecosystem is the EmpowerRF treatment platform, which utilizes various technological handpieces to treat a wide range of symptomatology. In the setting of vaginal and urinary symptoms, the FormaV and VTone handpieces are commonly used therapeutic interventions. The FormaV handpiece is designed to improve vaginal elasticity, pliability, and sensitivity. The VTone handpiece provides electrical muscle stimulation (EMS) to strengthen weak pelvic floor muscles, helping to alleviate symptoms of incontinence. Anecdotal reports of treatment with these interventions demonstrate improvements in GSM and urinary incontinence, such as vaginal dryness, incontinence, pain during sexual activity, and pelvic blood flow. **Design:** A retrospective chart review examining the safety and efficacy of the FormaV and VTone handpieces in the treatment of GSM and urinary symptoms was conducted at two clinical centers focused on the specialties of sexual health and menopause between January 1, 2021 through March 1, 2023. **Results:** Across two clinical centers, forty-seven (47) women received treatment with the FormaV or VTone handpieces. A total of 148 treatments were delivered, with a mean of 3.1 treatments administered per individual. A range of 1-7 treatments were delivered, with 74.5% of treatments administered at one clinical facility and 25.5% of treatments administered at the other. The mean age of participants was 53.1 years (range 25-73) and 45% of those individuals were married. 51% of participants received 3 treatments, 25% received 4 or more treatments, and 19% received only 2 treatments. The most common diagnoses were GSM, stress urinary incontinence (SUI), and dyspareunia. **GSM-Diagnosed Group:** In a subanalysis of the group diagnosed with GSM, participants received a total of 70 treatment procedures (mean 3.7 procedures; range 1-7) across two clinical facilities. The mean age of participants was 57 years (range 49-73). 58% of participants were married. The FormaV handpiece was utilized most frequently (79%), followed by the VTone handpiece (56%), and the Morpheus8 and Morpheus 8V handpieces (32%). 95% of patients reported subjective improvement in their overall GSM symptomatology. No serious adverse events were reported at the time of procedure nor at follow-up. **Conclusions:** Summarizing the data, in a subanalysis of the group diagnosed with stress urinary incontinence (SUI), 20 participants received a total of 59 procedures with a mean of 2.96 procedures (range 1-7) for the treatment paradigm across two clinical centers. The mean age of participants was 52.7 years (range 40-63). 45% of participants were married. The FormaV handpiece was utilized most frequently (95%), followed by the VTone handpiece (65%), and the Morpheus8 and Morpheus 8V handpieces (50%). 90% of patients reported improvement in their symptoms. **Conclusion:** The EmpowerRF’s FormaV and VTone handpieces are state-of-the-art technologies, which provide advanced efficacy and safety in treating various gynecological conditions. Given specific proprietary algorithms
of care, specialized medical education, training, and clinical support, the specialized healthcare professionals at these unique centers are able to develop unique, personalized treatment paradigms that incorporate advanced and innovative technological interventions resulting in positive outcomes and improved symptom resolution. While these data are encouraging and demonstrate the safety and efficacy of these innovative interventions, there is a need for larger, randomized, sham-controlled clinical trials to further elucidate the benefits of other novel approaches and handpads in these settings.

Sources of Funding: None

P-51
Drospirenone 4mg use in 44 premenopausal women ages 40 – 51 and its influence on bleeding patterns: Results from a phase III clinical trial
Michael Kychenman, MD1, Megan L. Gilbert, MSN, Saida Arshad, MPH, Medica Affairs, Exelixis USA, Florham Park, NJ; 1The Southern California Center for Sexual Health and Survivorship Medicine, Newport Beach, CA; 0Obstetrics and Gynecology, University of California Irvine, Irvine, CA

Objective: Contraception is an essential aspect of caring for peri-menopausal women not desiring pregnancy. We performed a sub-analysis of 44 participants ≥40 years enrolled in a phase III clinical trial to evaluate the efficacy, safety, and bleeding patterns while using drospirenone 4mg as an oral contraceptive. Design: To be eligible for enrollment, individuals were required to have regular menstrual cycles in the last six months (unless pregnant, breastfeeding, or using hormonal contraception). Participant demographics (including age, substance use, and risk factors for thromboembolism) were collected during study enrollment. A daily e-diary recorded bleeding, medication use, and sexual activity. Adverse event monitoring was conducted via self-report at all study visits. Data were analyzed using SAS and Excel. Results: Of the 44 premenopausal women ages ≥40, 13 participants (30%) had a BMI ≥30 kg/m². No participants reported a family history of VTE or a medical disorder pre-disposing them to VTE. All participants were considered to be non-smokers. A majority of participants (13/44) were current cigarette smokers (14.8%) and nicotine users, 8 participants (18.1%) were former nicotine users, and 30 (68.2%) denied previous nicotine use. Moderate alcohol use was reported by 25 participants (56.8%), while the remaining 19 participants (43.2%) abstained from alcohol use. Five participants discontinued the clinical trial prematurely due to adverse events: one for a macular, papular rash; two participants discontinued the trial due to breakthrough bleeding; one participant discontinued due to mood swings and breakthrough bleeding; and one participant discontinued due to abdominal pain. There was a general trend towards less bleeding and spotting days with continued use. Reported bleeding days, spotting days, and total bleeding and spotting days are presented in Table 1. Contraceptive efficacy was not evaluated in this population. However, no pregnancies occurred in this sub-population. The FDA assigned Pearl Index in participants ≥35 years old is 4.0. In this trial, no cases of hyperkaemila occurred in participants ≥40 years old; two participants under 40 years old discontinued drospirenone 4mg due to persistent hyperkalemia. There were no thromboembolic events or cardiovascular events throughout the clinical development program. Conclusion: Most participants ages 40 – 51 had a bleeding change while enrolled in this clinical trial. Further research is needed to determine the long-term safety profile, tolerability profile, and bleeding changes during 4mg drospirenone use in this sub-population.

Sources of Funding: Exelixis USA, Inc Laboratories León Farina S. A.

Table I. Bleeding and spotting days with Drospirenone 4mg use in premenopausal women aged ≥40 years (N=44)

<table>
<thead>
<tr>
<th>Cycle</th>
<th>Bleeding Days</th>
<th>Spotting Days</th>
<th>Bleeding or Spotting Days</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean</td>
<td>3.9</td>
<td>2.6</td>
<td>6.5</td>
</tr>
<tr>
<td>Median</td>
<td>3</td>
<td>3</td>
<td>6</td>
</tr>
<tr>
<td>SD</td>
<td>4.3</td>
<td>3</td>
<td>5.8</td>
</tr>
<tr>
<td>Cycle 6 (n=33)</td>
<td>Mean</td>
<td>1.6</td>
<td>1.7</td>
</tr>
<tr>
<td>Median</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>SD</td>
<td>3.1</td>
<td>2.8</td>
<td>8.2</td>
</tr>
<tr>
<td>Cycle 13 (n=28)</td>
<td>Mean</td>
<td>0.6</td>
<td>0.3</td>
</tr>
<tr>
<td>Median</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>SD</td>
<td>1.3</td>
<td>0.8</td>
<td>2.1</td>
</tr>
</tbody>
</table>

P-52
Design and verification of mobile application ‘Re-bone’ for the treatment of sarcopenia in perimenopausal women.
Jaekyung Lee, MD1, Justin Y. Jeon2, Jinwoo Kim3, Seok Kyo Seo, MD, PhD.1 1Department of Obstetrics and Gynecology, Yonsei University Health System, Seodaemun-gu, Korea (the Republic of); 2Department of Sport Industry, Yonsei University, Seodaemun-gu, Korea (the Republic of); 3Healthcare School of Business, Yonsei University, Seodaemun-gu, Korea (the Republic of)

Objective: To design and implement ‘Re-bone’, a mobile application for middle-aged women, to confirm its effectiveness and feasibility of digital intervention targeting perimenopausal women for the treatment of sarcopenia. Design: 51 women who are more than 45 years old who shared similar basic characteristics (BMI, waist circumference, skeletal muscle mass etc.) were included in this study. Basic physical parameters such as height, weight, waist circumference, skeletal muscle mass, fat content were collected. Also, parameters that represent muscle strength (hand grip strength) and physical performance (5-time sit-to-stand) were collected. 25 women were allocated to 16-weeks course of complex exercise program consisting of aerobic exercise and resistance exercise performed for three times a week through the mobile application, and the other 26 women were instructed to exercise for three times a week without use of the mobile application. Same measurements were done after the intervention. A paired t-test was performed after the normality test for the difference between the pre- and post-scores for each group and independent t-test was done for comparison of the parameters between two groups. Results: There was no significant difference in all parameters before intervention. Analysis for the application-user group shown statistically significant difference in sarcopenia-related variables before and 16-weeks after application use (grip strength p=0.027, SARC-F score p=0.002, sit-to-stand time p=0.029). On analysis with non-‘Re-bone’ users, significant difference (objective SARC-F score p=0.083, whereas objective parameters did not have significant difference (grip strength p=0.150, sit-to-stand p=0.071). Conclusion: For all collected sarcopenia-related parameters, a statistically significant difference was found in application-implemented groups and grip strength p=0.002, sit-to-stand time p=0.029. This mobile-based intervention is an effective modality for life-style modification and treatment for sarcopenia for perimenopausal women.

Sources of Funding: None

P-53
Effect of black cohosh with St. John’s wort (Feramin-Q®) on breast density in Korean postmenopausal women
Jiwoo Lee1, Ji Yeon Han1, Sung Woo Kim2, Hoon Kim2, Seung-Yup Ku2, Chang Suk Suh3. 1Department of Obstetrics and Gynecology, Seoul National University Hospital, Jongno-gu, Korea (the Republic of); 2Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea (the Republic of)

Objective: Black cohosh with St. John’s wort (Feramin-Q®) is one of the most widely used alternative treatment regimens for postmenopausal women who wish to avoid conventional E or E-P hormone therapy. It is widely known that dense breast is one of risk factors of breast cancer, while the effect of combined preparation of Black cohosh and St. John’s wort, Feramin-Q®, on breast is unknown. The aim of this study is to evaluate the effect of black cohosh and St. John’s wort combination treatment on breast density in Korean postmenopausal women and analyze the changes in breast density in women who were treated with Feramin-Q® for menopausal symptoms at Seoul National University Hospital was retrospectively reviewed from January, 2012 to December, 2022. An automated volumetric breast density measurement techniques were used to calculate the breast density. Patients who underwent mammography (MGM) twice, before and after Feramin-Q® treatment, were included. Patients who had a history of breast cancer or received other hormone medications concurrently were excluded. Pearson correlation analysis was performed to analyze the correlation between duration of Feramin-Q® use, gestational history, breast and St. John’s wort combination treatment and the change of breast density. Results: A total of 70 patients were included. The mean duration of Feramin-Q® was 184.25 ± 163.58 days, and the mean age at initiation of Feramin-Q® was 56.3 ± 6.00 years. Breast density of 3 patients (4.29%) increased, and that of 17 patients (24.29%) decreased, while that of 59 patients (71.42%) remained unchanged. Two women (0.26%) experienced progression of breast lesion to BI-RADS category 3 or 4. Baseline right breast density (%) was 12.43 ± 5.73, and follow up density (%) was 10.87 ± 5.83. Baseline left breast density (%) was 12.43 ± 6.35, and follow up density (%) was 10.91 ± 5.97. The change of breast density was not significantly correlated with duration of Feramin-Q® treatment (right breast; r = -0.008, p = 0.526, left breast; r = -0.020, p = 0.567). Conclusion: Feramin-Q® seems to have no significant effect on breast density, but larger prospective study is necessary for further analysis.

Sources of Funding: None

P-54
Association Between Menopausal Status, Menopausal Hormone Therapy, and Severe Outcomes in COVID-19
Carol Kahle, DO, MPH, Samantha Mannon, MD, Ivana Croghan, PhD, Karen Fischer, MPH, Jennifer St. Sauver, PhD, Ekta Kapoor, MBBS, Vrinda Munjal, MB, BCH, BAO, Dietlind Walner-Roedler, MD. Mayo Clinic Minnesota, Rochester, MN

Objective: Males and females are equally susceptible to infection with COVID-19, but it has been observed that males experience higher rates of severe disease, hospitalization, and death. Several hypotheses have been suggested to explain this observation, including the immunomodulatory effects of estrogen on inflammatory cytokines which may limit the cytokine storm often responsible for respiratory failure in COVID-19. There are some data to suggest a protective effect of oral contraceptive pills in premenopausal women but reported effects of menopausal hormone therapy (MHT) in middle-aged women have been mixed. The purpose of this study is to examine the association between MHT and severe outcomes due to COVID-19 in a large epidemiological database. Design: A retrospective cohort study was conducted using the Rochester Epidemiological Project (REP), a comprehensive medical record linkage system for patients in 27 counties located in southern Minnesota and western Wisconsin. Data were abstracted for women aged 40-65 with documented COVID-19 infection by positive polymerase chain reaction (PCR) between March 12, 2020 – September 29, 2020. Outcomes were stratified by (1) menopausal status, (2) hormone use, and (3) a combination of menopausal status and hormone use (pre-menopausal, peri- or postmenopausal with no hormone use, and peri- and postmenopausal with systemic hormone use). Separate logistic regression models were fit with an outcome of adverse events (defined as emergency room [ER] visit, hospitalization, and/or death) for menopausal status, hormone use, and combined menopausal status/hormone use as defined above. Additional models adjusted for age, Charlson Comorbidity Index (CCI; composite score including age and 16 possible comorbidities), race (binary variable; white or non-white), and body mass index (BMI) (16). Results: Of 1,284,464 women, 1,000,174 women (77.5%) were identified with documented COVID-19 infection. These patients were 71% white, 52% obese, and the large majority (90.4%) had symptomatic COVID-19 infection.
P-55. Healthcare Usage Patterns Across the Menopausal Transition Spectrum

Hana Mkhdachi, MD1, Rebecca Dunsmoor-Su, MD MSC2, 1OBGYN, Washington State University, Pullman, WA; 2Gennev, Seattle, WA; 3OBGYN, VA Loma Linda Healthcare System, Loma Linda, CA

Objective: Gennev.com is an online platform that provides telemedicine services for women in menopause. As part of our work in menopausal medicine we enlisted a large actuarial and data company, Milliman MedInsight, to gather de-identified billing and claims data for major commercial insurers in the United States. We reviewed usage of preventative care, cardiovascular care, overall per-member-per-month (PMPM) cost, as well as pharmacy cost over the menopausal transition in women in general and in several subsets of treatment. Design: BRANY IRB determined this not to be human subjects research and therefore not needing a review. Validated data was received from Milliman MedInsight in pivot tables representing annual usage of services per 1000 clients and PMPM utilization numbers for the years 2020 and 2021. This represents data from private insurers over millions of women, separated into categories based on age, medical utilization patterns, diagnoses, and by treatments used. Across all age ranges, patients in treatment groups were actively using treatment at the point in time; data is not available on length of use. Results: Women in menopause but not using any menopause related treatments had a high overall usage of general preventative services (figure 1), high rate of mammograms [figure 2], and the lowest utilization of cardiovascular (CV) outpatient and professional services [figure 3,4]. They used the least amount of money PMPM and their pharmacy costs were the lowest [figure 5,6]. Women in menopause using hormone replacement therapy (HRT) utilized the highest amount of preventative care, cardiovascular care, overall per-member-per-month (PMPM) cost, as well as pharmacy cost over the menopausal transition in women in general and in several subsets of treatment. Design: BRANY IRB determined this not to be human subjects research and therefore not needing a review. Validated data was received from Milliman MedInsight in pivot tables representing annual usage of services per 1000 clients and PMPM utilization numbers for the years 2020 and 2021. This represents data from private insurers over millions of women, separated into categories based on age, medical utilization patterns, diagnoses, and by treatments used. Across all age ranges, patients in treatment groups were actively using treatment at the point in time; data is not available on length of use. Results: Women in menopause but not using any menopause related treatments had a high overall usage of general preventative services (figure 1), high rate of mammograms [figure 2], and the lowest utilization of cardiovascular (CV) outpatient and professional services [figure 3,4]. They used the least amount of money PMPM and their pharmacy costs were the lowest [figure 5,6]. Women in menopause and using hormone replacement therapy (HRT) utilized the highest amount of preventative general services and mammography across all age groups [figure 1]. They initially had higher CV outpatient and professional usage, but this declined with age and by age 60-69 only were low users of these services [figure 3,4]. They initially had higher PMPM and pharmacy costs, but the curve changed over time with lower benefits in these areas being paid for women receiving HRT [figures 5,6]. Women in menopause using other therapies (venlafaxine, gabapentin, and/or clonidine) were high utilizers of care, and had the highest pharmacy cost [figures 3,6] (Figures available to upload data for this IOM-scrutinized study. Discrepancies were arbitrated by a third reviewer. Androgen preparations used included DHEA, danazol and testosterone patch. Trials studied the impact of androgen supplementation on menstrual pattern, ovarian reserve markers, fertility outcomes, mood, and self-esteem as well as bone mineral density. Conclusion: Based on the limited evidence on premenopausal use, there was no significant effect of androgen supplementation on mood, self-esteem, or bone mineral density. Although one study demonstrated an increase in ovarian volume and antral follicular count, there was no significant change in ovarian reserve, ovarian function, fertility outcome or menstrual pattern. Further long term trials are recommended.

Sources of Funding: None

Summary of the Studies included in the systematic review

<table>
<thead>
<tr>
<th>Article</th>
<th>Year</th>
<th>Country</th>
<th>Age (median)</th>
<th>Number of patients</th>
<th>Type of the study</th>
<th>Androgen</th>
<th>duration of use</th>
<th>Vasomotor symptoms</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wang QHY1</td>
<td>2018</td>
<td>Hong Kong, China</td>
<td>36</td>
<td>31</td>
<td>Prospective observational</td>
<td>DHEA (mg twice daily)</td>
<td>12 months</td>
<td>Women ≥ 40 years, who have POF and commencement of estrogen replacement therapy together with selective SERMs (SERMs) at 1 month.</td>
<td>No significant improvement in ovarian reserve via DHEA supplementation in women with POF.</td>
</tr>
</tbody>
</table>

- **AFC**: Antral follicular count; **DHEA**: Dehydroepiandrosterone; **POI**: premature ovarian insufficiency; **POF**: Premature ovarian failure; **E/P**: Estrogen/ Progesterone; **FSH**: Follicle stimulating hormone.
P-57. Leading causes of death among women and girls aged 10–89 years in the United States: Focus on women aged 45 and older.

Aleya Molony, MSc, Margaret Snyder, MAD, Brandon Finn, Pharm D, Dorothy Fink, MD, Macarena Garcia, PhD, Michael Lademarco, MD, Elizabeth Pathak, PhD, Katrina Trivers, PhD, HHS, OWI, Office on Women’s Health, Washington, DC, US; against/health, Washington DC; NC National Heart Lung and Institute Division of Lung Diseases, Bethesda, MD; NCDCDPHP, Centers for Disease Control and Prevention, Atlanta, GA

Objective: The objective of this study was to examine differences in the leading causes of death among women by age group and between women and men with the National Vital Statistics System (NVSS) data (2020-2022).

Design: The Office on Women’s Health and the Office of Science and Medicine in the Office of the Assistant Secretary for Health in the Department of Health and Human Services have reviewed the leading causes of death certification data for 2001 through provisional 2021 from NVSS. The queries are grouped by the ten leading causes of death, separately for women and men and by age category, based on the underlying cause of death. Underlying causes of death were coded and grouped by leading causes by CDC’s National Center for Health Statistics. Mortality rates were obtained from the publicly available CDC Wonder website.

Results: The leading causes of death differed for adult women and men between the ages of 10–89 in the United States from 2020–2022. The leading cause of death for women aged 45–79 was cancer. Men aged 45 years and older died predominantly from heart disease. Heart disease was the leading cause of death for women aged 80 and older. From 2020–2022, women 45–59 years of age were more than twice as likely to die from cancer than from heart disease. The leading causes of cancer death with the lowest mortality rates had abdominal obesity: 368 (52.5%)

P-59. Maturation 2.0: Menopause Group Education

Alayna Molony, LDNP, Katie Ward, LDNP, Lisa Taylor-Swanson, PhD. The University of Utah College of Nursing, Salt Lake City, UT

Objective: The purpose of this quality improvement project is to educate individuals about the physiology of menopause and evidence-based treatment options for burdensome symptoms. More specifically, our goals are to improve knowledge, symptom perceptions, and attitudes toward menopause. If these aims are successful, then the pilot Maturation 2.0 program would transition into a regularly scheduled virtual class and an inclusive referral system to menopause care providers.

Design: A virtual group education program titled Maturation 2.0 was developed to educate individuals in the menopausal transition. Twenty-two participants ages 38 to 57 were recruited via email, social media, and clinic appointments. Women’s health nurse practitioner and one licensed acupuncturist and nursing scientist conducted a virtual menopause group education session. The curriculum included menopause physiology, symptoms, treatment options, and controversies. Pre-surveys, post-surveys, and eight-week follow-up surveys were distributed to participants to assess changes in knowledge, symptoms, and attitudes toward menopause as well as participant satisfaction with the program.

Results: Post-intervention, we found that participants were highly satisfied with the intervention and rated the course a mean score of 9.2 on a scale of 1 to 10 for their likelihood to recommend the course to a family member or friend. Participant knowledge was assessed via a five-question quiz, and scores increased after the course, demonstrating an improvement in knowledge, which persisted eight weeks later. Menopause-Specific Quality of Life scores decreased, but this did not reach statistical significance (p-value=0.914). Attitudes, which were assessed via Attitude Toward Menopause sub-scales, also improved following the intervention.

Conclusion: Our menopause group education QI project demonstrated that group education can improve knowledge, symptoms, and attitudes toward menopause among mid-life women. The course will change current practice and continue to be offered on a regular basis via live virtual format. By providing group education, our health system will more efficiently educate women in a group setting rather than provide baseline knowledge during individual patient visits, which may not yield adequate time in many settings.

Sources of Funding: University of Utah Educational Resource Development Council (ERDC)

P-60. Specific epidemiological characteristics of the menopause in Tunisian women

Fathi Mrahi2,3, Jihene Basly2,3, Mohamed Mahdi Gharbi2, Amani Mezni2,3, Dalenda Chelli2,3, 1D Department, Maternal center of Tunis, Tunis, Tunisia; 2Tunis Manar university, Tunis, Tunisia

Objective: The aim of this study is to clarify the epidemiological features of the menopause in Tunisian women and to identify the clinical and biological aspects in relation to Menopause.

Design: This is a prospective study conducted in department D of the Tunis maternity and neonatology centre over a 6-month period from January 2023 to June 2023. We included women with clinically confirmed menopause who agreed to take part in the study. We carried out a meticulous interview by the same participant, and we completed by a biological assessment (lipid assessment, fasting glycemia, hormonal assessment) and a bone densitometry.

Results: our study involved...
P-61. Similarities and Differences between US and International Responses to Menopause Needs Assessment

Ashley P. Glazier, MD MPH, Taj Gunti, MD, Peter Schnatz, DO, Jennifer Allen, MD, "OB/GYN, Reading Hospital, West Reading, PA; 2Augusta University, Augusta, GA

Objective: The purpose of this study is to assess menopause education, including existing and desired resources, with a comparison of survey responses from national and global educators and program directors. Survey results were collated from 1059 US and Global respondents to the Menopause Needs Assessment (MNA) conducted through regional listservs of the Council of Affiliated Menopause Societies (CAMS). US program directors completed the survey and 12 international responses were collected: 3 from Australia, 2 each from Afghanistan and the UK, and 1 each from Albania, Andorra, Canada, Jordan, and Hungary. Recognizing significant variations in patient populations, a subgroup of the US responses was also analyzed, looking specifically at the 39 responses that indicated that half or more of patients served were peri- or post-menopause. Descriptive statistics were performed along with Fisher’s Exact Test for statistical significance of observed differences. Results: 39% of US based respondents indicated that half or more of their patients served were peri- or post-menopause, compared to 100% of Global respondents. Global respondents were significantly more likely to endorse having a dedicated menopause curriculum, with 75% (9 of 12) doing so compared to 31% (31 of 99) of US respondents, p = 0.0163. 85% of US respondents, including the subgroup, and 90% of Global respondents identified a need for more menopause education, and over 90% of all groups would use standardized training materials for a menopause curriculum, with 89-90% of all groups indicating that they would be likely or very likely to use self-paced menopause modules in particular. A significant discrepancy was noted in the percent of respondents who would use mock oral exam questions on menopause. Only 44% (4 of 9) in the Global group indicated they would be likely or very likely to use this resource, significantly less than the 87% of US based respondents (p = 0.045) and 92% (35 of 38) of US subgroup respondents (p = 0.004) who indicated the same. When evaluating satisfaction with their current menopause training and perceived effectiveness at preparing trainees to care for menopausal patients after training, US based respondents averaged 38% on a 1-100 satisfaction scale, compared to the 52% satisfaction of Global respondents (p < 0.001). Significant room for improvement among all study groups. Conclusion: Large majorities of both US and Global respondents to the Menopause Needs Assessment identified a need for more menopause education and a desire for standardized materials, especially self-paced menopause modules. US based respondents were more likely to desire mock oral exam question resources compared to Global respondents, reflecting the importance of customizing resources to individual countries. Finally, despite an identified need for improved menopause education among all groups, Global respondents were more likely to endorse an existing menopause curriculum, reflecting the value of organizations such as the North American Menopause Society (NAMS) in promoting menopause education in the US.

Sources of Funding: None

P-62. Characterizing the Spectrum of Distress Symptoms in Midlife Women: A Preliminary Study

Margo Nathan, MD, Juliana Prim, PhD, Lauren Schiff, MD, David Rubinson, MD, Crystal E. Schiller, PhD, "Psychiatry, The University of North Carolina at Chapel Hill, Chapel Hill, NC; 2Obstetrics and Gynecology, The University of North Carolina at Chapel Hill, Chapel Hill, NC

Objective: Perimenopause is a time of increased risk for depression, which is a common source of functional impairment. Despite the prevalence of this condition, efforts to describe the clinical symptomatology in this population have focused primarily on depressed mood and insomnia. Identifying the range of symptoms may improve screening and inform novel and efficacious treatment approaches. We therefore aimed to preliminarily characterize the spectrum of affective symptoms associated with perimenopausal-onset major depressive disorder (PO-MDD), as well as to identify clinical correlates (e.g., age, duration of perimenopause) that may predict distress symptoms in this population.

Design: Participants were women in the late-perimenopause (by STRAW -1 criteria) ages 44-55 (N=90) enrolled in studies examining the effects of estrogen on brain activation. Presented here are baseline data collected prior to estrogen treatment for the purpose of clinical symptom characterization of the women with PO-MDD (n=5) versus a group of perimenopausal women without MDD (“controls”; n=39). The Structured Clinical Interview for DSM-IV (SCID) was used to confirm presence or absence of PO-MDD. Clinical symptomatology was characterized using the Inventory of Depression and Anxiety Symptoms Scale-Self-Report (IDAS), a 64-item scale containing a depression composite, 11 symptom scales, including dysphoria, lassitude, insomnia, suicidality, appetite gain/loss, ill temper, anhedonia, social anxiety, panic, and traumatic intrusions. The Schedule for Non-Adaptive and Adaptive Personality (SNAP) was used to assess personality, with extreme scores (high or low) representing maladaptive traits of either negative temperament (NT, e.g., mistrust, aggression, manipulativeness) or positive temperament (PT, e.g., exhibitionism, entitlement, impulsivity). Student’s T tests were used to describe between group differences and controlled for multiple comparisons. Pearson correlations were used to describe the association between IDAS depression composite scores and anxiety symptoms scales. Results: PO-MDD had higher scores than euthymic controls not only on the depression-related IDAS scales (dysphoria, insomnia, lassitude, anhedonia, and appetite gain), but also across NT or PT temperament, well (ill-temper, panic, and social anxiety), all p’s< 0.001. Correlations between the depression composite score and the anxiety scales ranged from r=0.20 (traumatic intrusions) to .77 (ill-temper). Although neither group endorsed temperament scores that fell outside of the SNAP clinical cutoffs, PO-MDD showed significantly higher negative temperament and lower positive temperament compared with controls. Elevated negative temperament in PO-MDD was driven by elevations in mistrust and eccentric perceptions compared with controls (p’s<0.001).

Conclusion: Findings in this descriptive secondary data analysis show a broad range of PO-MDD symptomatology beyond depressed mood, including NT and PT temperaments (i.e., social anxiety and panic) and psychosocial-related maladaptive traits (i.e., mistrust and eccentric perceptions) not traditionally thought to be associated with the menopause transition. Moreover, low to moderate correlations between depression composite scores and anxiety scale scores suggest that these symptoms can be intertwined and highlights the importance of screening for anxiety related distress, in addition to depression, among this population.

Sources of Funding: K23 MH105569 (CS) Foundation of Hope (CS)

P-63. Effect of fezolinetant on moderate-to-severe vasomotor symptoms according to time of day: pooled data from two randomized phase 3 studies

Genevieve Neal-Perry,1 Marla Shapiro2, Rebecca C. Thurston, PhD,3 Wendy Wolfman,3 Martin Blogg4, Deanna King5, Antonia Morga6, Faith D. Ottery,6 Emad Siddiqui7,1 UNC School of Medicine, Chapel Hill, NC; 2University of Toronto, Toronto, ON, Canada; 3University of Pittsburgh School of Medicine, Pittsburgh, PA; 4Astellas Pharma Europe Ltd, Addlestone, United Kingdom; 5Astellas Pharma Global Development Inc, Northbrook, IL

Objective: Fezolinetant is a non hormonal agent in development for the treatment of vasomotor symptoms (VMS; hot flashes and night sweats) due to menopause. The efficacy of fezolinetant vs placebo in reducing the frequency and severity of VMS and improving sleep was demonstrated in two phase 3 studies (SKYLIGHT 1 and 2; http://clinicaltrials.gov; NCT04003142 and NCT04003155) and the 52-week SKYLIGHT 4 safety study (NCT04003389) confirmed the safety profile of fezolinetant. Night-time moderate-to-severe VMS can impact quality of life through a significant impact on sleep. To further explore the effect of fezolinetant on night-time VMS episodes post hoc analyses using pooled data from SKYLIGHT 1 and 2 were undertaken. Design: SKYLIGHT 1 and 2 were double-blind, placebo-controlled studies with the same design. Women aged 40-65 years with moderate-to-severe VMS (minimum average a7 hot flashes/day) were randomized to once-daily placebo, fezolinetant 30 mg or fezolinetant 45 mg (1:1:1) for 12 weeks. Post hoc analyses assessed the frequency and severity (range 1–3 with 3 being the worst) of VMS between 06:00 and 23:59 (daytime; 8h), and between 00:00 and 05:59 (night-time period; 6h). Results: The pooled dataset comprised 1022 participants who took a1 dose of study medication: placebo, n=342; fezolinetant 30 mg, n=339; fezolinetant 45 mg, n=341. Reductions in the frequency and severity of daytime and night-time VMS were observed with fezolinetant compared with placebo. These improvements were seen each week from weeks 1 to 12 apart from one (night-time frequency at week 1 for fezolinetant 45 mg). At week 12, the least squares means difference vs placebo were numerically greater with fezolinetant 45 mg than with fezolinetant 30 mg (Table). Data at baseline and week 12 are shown in the Table. Improvement for fezolinetant vs placebo is indicated by a least squares mean difference of <0. Further post hoc analyses assessing the relationship between reduction in night-time VMS frequency and severity compared to placebo in outcomes such as sleep are in progress. This pooled analysis demonstrates that fezolinetant 30 mg and 45 mg reduced both the frequency and severity of moderate-to-severe daytime and night-time VMS compared with placebo. SKYLIGHT 1 and SKYLIGHT 2 found that fezolinetant reduced the frequency and severity of VMS compared with placebo in the overall population. This post hoc analysis shows consistency of effect at night as well as during the day.

Sources of Funding: Astellas Pharma Inc. Medical writing support was provided by Becky Ayles of Envision Pharma Group and funded by Astellas Pharma Inc.
Needs assessment surveys pertaining to menopause education have been conducted in obstetrics and gynecology residents, particularly obstetrics and gynecology residents, need comprehensive education on this topic. The majority of faculty members who responded felt “comfortable” or “very comfortable” with the number one topic area in which they had the most experience. Of the 32 attending/residency. Since all responses were categorical, variables were summarized by reporting counts and percentages. Secondary outcomes included resident preferred learning modalities and strategies. Sources of Funding: None

The purpose of this study is to assess self-identified knowledge of menopause medicine and perceptions on the current curriculum pertaining to menopause amongst residents, fellows, and faculty members at two obstetrics and gynecology residency programs in Southern Louisiana. Design: A needs assessment survey was designed and administered through a web-based data collection service to assess resident (n=39), fellow (n=2), and attending physician (n=30) self-reported knowledge on menopause management through a web-based data collection service to assess resident (n=39), fellow (n=2), and attending physician (n=30) self-reported knowledge on menopause management at Louisiana State University Health Sciences Center Obstetrics and Gynecology departments in New Orleans and Baton Rouge, Louisiana. The primary outcomes for both surveys were self-assessed knowledge and comfort with menopause, related health concerns, and management options. Secondary outcomes included resident preferred learning modalities and attending physician exposure to menopause education during residency. Since all responses were categorical, variables were summarized by reporting counts and percentages. Results: Of 39 residents who were surveyed, 17 residents (43.6%) responded. Four PBY-1, six PBY-2, four PBY-3, and three PBY-4 residents participated in the survey. Amongst residents from all postgraduate years, 1 (2.5%) felt very well prepared, 5 (29.3%) felt adequately prepared, 9 (52.9%) felt somewhat prepared, and 2 (11.8%) felt not at all prepared to manage patients experiencing menopause at this time. Of note, 64.7% of resident respondents ranked menopause as being the number one or number two topic in which they had the most experience. Of the 32 attending/ fellows physicians who were surveyed, 11 (34.3%) responded. The results showed that the majority of faculty members who responded felt “comfortable” or “very comfortable” managing menopause and its symptoms. Faculty also overall felt “comfortable” (45.5%) or “very comfortable” (25.7%) guiding the residents through the management of these patients. Conclusion: As a core learning objective for obstetrics and gynecology residency programs, education on menopause remains a priority for residents. Most faculty respondents feel comfortable managing patients with menopause and teaching about this management to residents. However, it is difficult to say if this is a result of residency training or experience working in the field. Meanwhile, many residents feel “adequately prepared” or “somewhat prepared” to work with this population. As researchers continue to explore ways to improve menopause education for residents, it would be beneficial to assess resident knowledge on menopause at the beginning of residency. A subsequent survey to assess knowledge at the end of four years of training would help to determine effective learning modalities and strategies. References: 1. US Census Bureau. Louisiana Population Pyramid. Population by Age and Sex in Louisiana. 2020. https://data.census. gov/visualgw.gdx?g=040XX00US22&infoSection=Age&sex=Accessed 28 April 2023. 2. Christianson MS, Druce JA, Altman K, Khaflay AM, Shen W. Menopause education: needs assessment of American obstetrics and gynecology residents. Menopause. 2013 Nov; 20(11):1210-1215. doi: 10.1097/GME.0b013e3182ced7f. PMID: 23632655. Sources of Funding: None

P-66. Dyspareunia as a Symptom of Urinary Tract Infection
Alberto Dominguez-Bali, MD1,2, Milo Obas, BS1,2,3, Sodjinin M. Kassa, RN BSN BS1,2
1Clinical Science, American University of Antigua, Coolidge, Antigua and Barbuda; 2OBGYN, Miami center for Obstetrics, Gynecology, and Human sexuality, Miami, FL; 3Office of International Affairs, Florida International University, Miami, FL; 4OBGYN, Florida International University, Miami, FL

Objective: UFI’s has been undiagnosed across the spectrum, as clinician are increasingly relying on uroanalysis rather than the symptomology. The presence of dyspareunia is rarely included during evaluation of the patient and may not be found in the history of urination symptoms of UFI. Our First Objective aimed at informing clinicians that dyspareunia is a common symptom of urinary tract infections in almost 80 % of the cases especially in pre-menopausal women, being found more frequently than pollakiuria, urodynia, dysuria and urgency. By increasing awareness of the association between dyspareunia and dyspareunia, clinician will include it in the assessment of patient, rather than relying solely on a urinalysis. Our second objective aimed at educating the patient population about dyspareunia as an abnormal symptom, but a medical condition that needs to be investigated and resolved. Design: In 2010, in the annual meeting of the Society for the Scientific Study of Sexuality (SSSS), in Las Vegas, Nevada, we presented a study about 3000 women trying to describe the attitude and sexual behaviors of the female Spanish population in South Florida. We realized that dyspareunia was present in association with UTI’s in around 80 % of the cases. Since then, in a prospective way, we have confirmed the relationship in more than 2500 additional cases. Participants: Study population: 5500 patients presenting to the Miami Center for Obstetrics Gynecology and Human Sexuality. Age range of study participants: 17 to 72 years old. Since 2007 up to this date, we have continued to follow thousands of women seen in our centers regarding the presence of dyspareunia as a symptom of UTI. Results: In 83% of the UTI cases studied over the years, dyspareunia was endorsed as a symptom. Of these, approximately 94% of cases responded positively to treatment with antibiotics. In the post-menopausal years, dyspareunia is more associated with genitorinary syndrome of menopause rather than UTI associated symptoms. Conclusion: Our data confirmed that Dyspareunia has been described as one of the symptoms of interstitial cystitis but has never been implicated as a significant symptom of regular uncomplicated or complicated UTI. We have found that this symptom is extremely important as part of the symptomatology of the UTI, frequently found along with the classical symptoms of UTI. Why has something so clear, so frequently present, never been described? The answer is simple, physicians and patients do not talk about sex, despite dyspareunia being more a clinical symptom than a sexual one. Medical schools and residency programs in all areas, especially in obstetrics and gynecology, urology, and psychiatry have been neglecting the education of physicians-in-training in this important aspect of human health. In conclusion, this is a field of study which has been and continues to be influenced by religion, culture, and social norms far away from science.

Sources of Funding: NONE

P-67. Sexual Emergencies in Pre/Post-Menopausal Women
Alberto Dominguez-Bali, MD1,2, Catalina Dominguez-Bali, PhD MSN BSN RN1,2, Milo Obas, BS1,2, Sodjinin M. Kassa, RN BSN BS1,2, Rochell Santana, BS1,2, Rey M. Carlos, MD,1 1Clinical Science, American University of Antigua, Coolidge, Antigua and Barbuda; 2Office of International Affairs, Florida International University, Miami, FL; 3Miami Center for Obstetrics, Gynecology, And Human Sexuality, Miami, FL; 4OBGYN, Florida International University, Miami, FL; 5Radiology, Florida International University, Miami, FL

Objective: Our objective is to provide a comprehensive understanding of the scope of sexual emergencies in women on a national and international level. We aim to highlight how these emergencies can differ depending on location, culture, and societal norms. Additionally, we seek to explore the various methods of diagnosing and treating the wide array of conditions that can arise. Our hope is that this knowledge will lead to better management strategies and ultimately improve survival rates for patients experiencing these emergencies. Design: The study aimed to review and present the magnitude, variety, and diversity of sexual emergencies specifically in women pre or post-menopausal ages. To achieve this, a comprehensive literature review was conducted and relevant cases seen in medical facility that had these emergent patients were analyzed. The review was focused on the following aspects: Common coital emergencies in female patients, including cases in neurology, cardiology, gynecology and immunology. Common autoerotic emergencies in female patients, including cases in gastroenterology and related cases. Identification of body packings. Sexual assault in female patient. Sexual dysfunction in female patients, including hyperarousal disorders and related suicide attempts. Sociosexual issues in female patients, such as killings, infidelity, and castration. The data collected was analyzed and presented in a structured manner to highlight the epidemiology, diagnosis, and treatment of these sexual emergencies specifically in women. The study also aimed to identify the variations in these pathologies across different countries, cultures, and populations of female patients. Results: The Review includes: The common coital emergencies in neurology (benign coital headache, subdural hematoma), cardiology (intercurrent illness, subdural hemorrhage, cerebral vascular accidents), in urology: ureterovesical foreign
bodies, obstructive uropathies; cardiology (sudden cardiac death, myocardial infarction),
gynecology (vaginal laceration and/or eversion with/without previous gynecological
surgery), obstetrical (postpartum dyspareunia secondary or not to episiotomy or vaginal
lacerations; postcoital preterm labor), immunological and infectious diseases (local
or systemic, anaphylactic allergic reactions to latex of condoms, to sperm, and tampons).
Common autoimmune emergencies in gastroenterology (foreign objects in rectum, vagina,
proctitis or inflammatory bowel diseases, as well as “body packers” cases (swallowed late-
balloons for smuggling in the GI tract, rectum, or vagina) Sexual assault, Sexual
dysfunction: Hyperactive arousal disorders (compulsive hunt for orgasms with/without
attempt or real suicide, hyperversatility related to SSRI use). Sociosexual issues: Killings
for jealousy during sex, infidelity, castration like Bobbi case. 

Conclusion: The review and presentation of cases in this study reveal that sexual emergencies are
more prevalent than commonly thought and encompass a wide range of pathologies that are
critically significant. This highlights the importance of physicians being prepared to
address sexual emergences in clinical practice. The main advantages of using a centric care
plan can augment these advantages and mitigate the risks with a lfiestyle

Sources of Funding: None

Alberto Dominguez-Bali, MD,1 Catherine Dominguez-Bali, PhD MSM BSN RN,2
Milo Obas, MD,1 Rochell Santana, BS,1 Sodijinn M. Kassa, RN BSN BS1, Rosie Prado,
BS1; 1American University of Antigua, Coolidge, Antigua and Barbuda; 2Miami Center
for Obstetrics, Gynecology, and Human Sexuality, Miami, FL

Objective: From December 2018 to July 2022, our centers diagnosed, assessed, and
managed six cases of vulvovaginal fusion (obliteration). Our analysis of medical literature
reveals that less than 30 cases have been reported so far. All the cases had
common characteristics, including a period of more than 20 years without sexual activity or
menopause. Furthermore, we replaced their medical and behavioral history with our clinical
findings. In our study, all patients had a history of sexual abuse, whether child or adult, and had
infections. Provide information on six cases of a rare genitourinary disorder, including
questions about the diagnosis and medical and surgical management, follow-up, and resolution. Identify
the female longevity factor refers to the biological advantage that women have at birth including genomics, epigenomics,
hormonal, metabolic, telomere and mitochondrial profiles. An individualized female
centric care plan can augment these advantages and mitigate the risks with a lifestyle
based approach. The audience will leave inspired to use this functional medical model to facilitate regenerative, wholistic care.

Sources of Funding: none

P-69. The Female Longevity Factor
Jennifer B. Pearlman, MD CCFP NCMP FAARM ABAARM. Family Medicine, Mount
 Sinai, Toronto, ON, Canada

Objective: Discuss the genomic, epigenetic, metabolic, hormonal and mitochondrial
biological advantages and susceptibilities that are unique to women and confer an
advantage to the female longevity factor. This advantage is evident in length to mitochondrial vitality, women are born
with a longevity advantage but one that is more vulnerable to lifestyle, behaviours and
environmental exposures. We are the first generation of women who can expect to live
twice as long as their reproductive lifespan. The health status and lifestyle of women in
Europe and North America are critically significant. This highlights the importance of physicians being prepared
to address sexual emergences in clinical practice. The main advantages of using a centric care
plan can augment these advantages and mitigate the risks with a lifestyle

Conclusion: The female longevity factor refers to the biological advantage that women have at birth including genomics, epigenomics,
hormonal, metabolic, telomere and mitochondrial profiles. An individualized female
centric care plan can augment these advantages and mitigate the risks with a lifestyle
based approach. The audience will leave inspired to use this functional medical model to facilitate regenerative, wholistic care.

Sources of Funding: none

Correlation between equal production and intestinal microbiota after treatment with isoflavone alone or associated with probiotic and hormonal therapy in postmenopausal women: a randomized clinical trial.
Ana E. Ribeiro, Adriana O. Pedro, PhD, Naice S. Monteiro, PhD, Lucia Costa Paiva, Md, PhD. Gynecology and Obstetrics, Universidade Estadual de Campinas, Campinas, Brazil

Objective: To correlate urinary excretion of equal with intestinal microbiota in response to the use of isoflavone alone or associated with probiotics and compare to hormone therapy in postmenopausal women. Design: A randomized clinical trial was conducted in sixty postmenopausal women aged 40-60 years, randomly assigned to receive oral

Conclusion: The mean age of the women was 52.4 years, while the mean
treatment duration was 42.7 weeks. The mean concentration of vaginal microbiota in the isoflavone group, an increase of Proteobacteria and Fusobacteria phylum were related to an increase of equal, with no increase of genus related with the production of equal and

Sources of Funding: None

P-68. Body Composition and Bone Mineral Density in Postmenopausal Women with Advanced Knee Osteoarthritis Undergoing surgical treatment
Jung Yoon Park, MD,PhD, Mee-Ran Kim. Division of Reproductive Endocrinology, Department of Obstetrics & Gynecology, Seoul St. Mary’s Hospital, Seoul, Korea (the Republic of

Objective: This study sought to demonstrate bone mineral density (BMD) conditions and
body composition in postmenopausal women with knee osteoarthritis (OA) undergoing surgery
for treatment as well as its relationship with isoflavone treatment. Methods: A randomized
cross-over study was conducted in 254 women with OA aged 50 who underwent surgical treatment were enrolled in the study. Body composition (fat mass (FM), lean mass and bone mineral component
(BMC)) and BMD of the lumbar spine, both femoral neck and total hip were measured using dual-energy X-ray absorptiometry (DXA). Appendicular muscle mass (AMM) and
appendicular mass index (AMI) were calculated. The criteria of the knee OA were defined as the American College of Rheumatology (ACR) criteria 2010. Results: The mean age of the patients was 52.4 years, while the mean
treatment duration was 42.7 weeks. The mean concentration of vaginal microbiota in the isoflavone group, an increase of Proteobacteria and Fusobacteria phylum were related to an increase of equal, with no increase of genus related with the production of equal and

Conclusion: The mean age of the women was 52.4 years, while the mean
treatment duration was 42.7 weeks. The mean concentration of vaginal microbiota in the isoflavone group, an increase of Proteobacteria and Fusobacteria phylum were related to an increase of equal, with no increase of genus related with the production of equal and

Sources of Funding: None

Alberto Dominguez-Bali, MD,1 Catherine Dominguez-Bali, PhD MSM BSN RN,2
Milo Obas, MD,1 Rochell Santana, BS,1 Sodijinn M. Kassa, RN BSN BS1, Rosie Prado,
BS1; 1American University of Antigua, Coolidge, Antigua and Barbuda; 2Miami Center
for Obstetrics, Gynecology, and Human Sexuality, Miami, FL

Objective: From December 2018 to July 2022, our centers diagnosed, assessed, and
managed six cases of vulvovaginal fusion (obliteration). Our analysis of medical literature
reveals that less than 30 cases have been reported so far. All the cases had
common characteristics, including a period of more than 20 years without sexual activity or
menopause. Furthermore, we replaced their medical and behavioral history with our clinical
findings. In our study, all patients had a history of sexual abuse, whether child or adult, and had
infections. Provide information on six cases of a rare genitourinary disorder, including
questions about the diagnosis and medical and surgical management, follow-up, and resolution. Identify

Conclusion: The female longevity factor refers to the biological advantage that women have at birth including genomics, epigenomics,
hormonal, metabolic, telomere and mitochondrial profiles. An individualized female
centric care plan can augment these advantages and mitigate the risks with a lifestyle
based approach. The audience will leave inspired to use this functional medical model to facilitate regenerative, wholistic care.

Sources of Funding: none

Correlation between equal production and intestinal microbiota after treatment with isoflavone alone or associated with probiotic and hormonal therapy in postmenopausal women: a randomized clinical trial.
Ana E. Ribeiro, Adriana O. Pedro, PhD, Naice S. Monteiro, PhD, Lucia Costa Paiva, Md, PhD. Gynecology and Obstetrics, Universidade Estadual de Campinas, Campinas, Brazil

Objective: To correlate urinary excretion of equal with intestinal microbiota in response to the use of isoflavone alone or associated with probiotics and compare to hormone therapy in postmenopausal women. Design: A randomized clinical trial was conducted in sixty postmenopausal women aged 40-60 years, randomly assigned to receive oral

Conclusion: The mean age of the women was 52.4 years, while the mean
treatment duration was 42.7 weeks. The mean concentration of vaginal microbiota in the isoflavone group, an increase of Proteobacteria and Fusobacteria phylum were related to an increase of equal, with no increase of genus related with the production of equal and

Sources of Funding: None

P-68. Body Composition and Bone Mineral Density in Postmenopausal Women with Advanced Knee Osteoarthritis Undergoing surgical treatment
Jung Yoon Park, MD,PhD, Mee-Ran Kim. Division of Reproductive Endocrinology, Department of Obstetrics & Gynecology, Seoul St. Mary’s Hospital, Seoul, Korea (the Republic of

Conclusion: The mean age of the women was 52.4 years, while the mean
treatment duration was 42.7 weeks. The mean concentration of vaginal microbiota in the isoflavone group, an increase of Proteobacteria and Fusobacteria phylum were related to an increase of equal, with no increase of genus related with the production of equal and

Sources of Funding: None

Correlation between equal production and intestinal microbiota after treatment with isoflavone alone or associated with probiotic and hormonal therapy in postmenopausal women: a randomized clinical trial.
Ana E. Ribeiro, Adriana O. Pedro, PhD, Naice S. Monteiro, PhD, Lucia Costa Paiva, Md, PhD. Gynecology and Obstetrics, Universidade Estadual de Campinas, Campinas, Brazil

Conclusion: The mean age of the women was 52.4 years, while the mean
treatment duration was 42.7 weeks. The mean concentration of vaginal microbiota in the isoflavone group, an increase of Proteobacteria and Fusobacteria phylum were related to an increase of equal, with no increase of genus related with the production of equal and

Sources of Funding: None

P-68. Body Composition and Bone Mineral Density in Postmenopausal Women with Advanced Knee Osteoarthritis Undergoing surgical treatment
Jung Yoon Park, MD,PhD, Mee-Ran Kim. Division of Reproductive Endocrinology, Department of Obstetrics & Gynecology, Seoul St. Mary’s Hospital, Seoul, Korea (the Republic of

Conclusion: The mean age of the women was 52.4 years, while the mean
treatment duration was 42.7 weeks. The mean concentration of vaginal microbiota in the isoflavone group, an increase of Proteobacteria and Fusobacteria phylum were related to an increase of equal, with no increase of genus related with the production of equal and

Sources of Funding: None
it’s intermediate. In the isoflavone plus probiotic group, an increase of Verrucomicrobia phylum and Lachnospiraceae genus were related to an increase of equal intermediary. The increase of Cyanobacterium phylum, Candidatus, Clostridium, Ostrinium, Barceloniella, Oscillospira genus were related to increase of equal and equal intermediary, while an increase of Bacteroidetes phylum, Bacteroidales and Prevotella genus were related to an increase of equal intermediary in HT group. Conclusion: We found that equal and equal intermediary urinary concentration were directly related with modification in the composition and activity of the intestinal microbial community, and we were able to correlate the phylum and genus bacterial responsible for the increase in these isoflavone metabolites. Isoflavone associated with probiotic was able to increase the number of bacteria responsible for isoflavone metabolism; however it was more evident in the group using HT, evidencing the importance of estrogens in the microbial population of postmenopausal women.

Sources of Funding: This research was funded by The São Paulo Foundation for the Support of Research (Fundo de Amparo à Pesquisa do Estado de São Paulo - FAPESP), grant # 2016/08809-9.

P-71. Is age associated to prevalence and severity of premenstrual syndrome? Results from a Brazilian population-based survey.
Adriana O. Pedro, PhD1, Juliana P. Brandão, PhD2, Samantha B. Silva1, Maria G. Lapa, PhD3, Vivienne C. Castilho, PhD4. Gynecology and Obstetrics, Universidade Estadual de Campinas, Campinas, Brazil; 2Scientific Medical Division, Libbs Farmacuetica Ltda, São Paulo, Brazil
Objective: To evaluate the relationship between premenstrual syndrome and age, analyzing the prevalence and severity of psychoemotional and physical symptoms in a representative sample of Brazilian women. Design: An observational and retrospective study was carried out analyzing data from 5,121 Brazilian women aged 20 to 49 years old from five regions of the country who claimed to have premenstrual symptoms. The participation consisted of answering a questionnaire adapted from the Brazilian validated version of the Premenstrual Symptoms Screening Tool (PSST), with their respective scores. The prevalence and severity of the symptoms were evaluated. The PSST is a self-applied recall tool that reflects the International Society for Premenstrual Syndrome/Disorders criteria, translating its criteria into a scale with degrees of severity, in addition to assessing the functional impact. Data were analyzed through surveys using Pearson’s Chi-Square test and Bonferroni multiplicity correction. The protocol for the data analysis was approved by the Research Ethics Committee under registration number 33794520.1.0000.8098 Results: A total of 23,104 women claimed to have premenstrual symptoms, of which 38.91% (n=8,990) reported that these symptoms caused functional impairment. Finally, 5,121 participants agreed to answer the symptoms questionnaire, distributed in the following age groups: 20-29 years old (46.7%), 30-39 years old (38.3%) and 40-49 years old (15%). The most prevalent and severe physical symptoms of participants aged 20 to 29 years old were acne/oily skin. Headache was the most prevalent and severe physical symptom reported by women aged 30 to 49 years old. Participants aged 40 to 49 years old had headaches (90.5%) and, ultimately, breast tenderness (87.4%). Of the symptoms observed, the most severe was headache (48.2%). Based on the data presented, a trend towards an increase in the prevalence of most physical symptoms can be observed with increasing age and approaching menopause transition, except for acne/oily skin. In the evaluation of psychoemotional symptoms, the most prevalent in the 20-29 years old group and 40-49 years old group was anxiety/tension while for the 30-39 group the most prevalent symptom was irritability/anger. In all groups, irritability/anger was the most severe symptoms. In younger age groups of participating women should be willing to take tetracyclines and oral contraceptives for symptoms relief, mainly in younger groups. Conclusion: Age is one of the factors having the most influence on women’s reports of premenstrual symptoms. The physical symptoms related to premenstrual syndrome vary according to age, but throughout this study, we could note that the psychoemotional symptoms are more intense, with irritability/anger and anxiety being the most severe in Brazilian women of reproductive age. There is a higher willingness to take contraceptives as a treatment for PM in younger women but overall, most participants (74%) would like to take oral contraceptives as a treatment for premenstrual symptoms. So, it is important this data when counselling contraception for women with PM. The physician’s proactive attitude in the investigation of PM and the appropriate therapeutic approach can bring great benefits to the patient, in addition to improving her family, social and work environment.
Sources of Funding: This study has received financial support from Libbs Farmacuetica, São Paulo, Brazil.

P-72. Prevalence of Premenstrual Dyshoric Disorder in Brazilian women: a national cross-section survey
Adriana O. Pedro, PhD1, Roberto C. Verdade, MD2, Juliana P. Brandão, PhD, Maura G. Lapa, PhD3, Vivienne C. Castilho, PhD4. Gynecology and Obstetrics, Universidade Estadual de Campinas, Campinas, Brazil; 2Scientific Medical Division, Libbs Farmacuetica Ltda, São Paulo, Brazil
Objective: Estimate the prevalence of women with Premenstrual Dyshoric Disorder (PMDD) through self-report of somatic and psycho-emotional symptoms. The secondary objectives were to estimate the prevalence of the symptoms according to age group and perform a correlation analysis between psycho-emotional and somatic symptoms. Design: An observational, cross-sectional, population-based study was performed in 303 private health services were analyzed. The women answered the adapted Brazilian version of the Premenstrual Symptoms Screening Tool (PSST) on the prevalence and intensity of somatic and psychoemotional premenstrual symptoms. The sample size calculated to obtain an intended level of statistical significance was 1022 women. A total of 11,943 with premenstrual syndrome agreed to voluntarily answer the questionnaire. Of these, 1,614 had diagnostic criteria for PMDD, according to the International Society of Premenstrual Syndrome. Statistical analysis was performed using Pearson’s chi-square test and Bonferroni multiplicity correction and Poisson regression. The protocol for the study was approved by the Research Ethics Committee under registration number 33794520.1.0000.8098. Results: The prevalence of PMDD was 13.5% (95% CI; 12.9%; 14.1%). Psychoemotional symptoms were more prevalent than somatic symptoms, with anxiety (99.9%) and irritability (98.8%) being more prevalent and of greater intensity in the older age group (40-49 years). Regarding somatic symptoms, weight gain (92.5%) and edema (92.1%) were the most prevalent, with no correlation with age. The correlation of psychoemotional symptoms such as anxiety occurred independently of somatic symptoms and headache occurred independently of psychoemotional symptoms. Binge eating was related to weight gain, acne, and immunological exacerbations, increasing the likelihood of these symptoms occurring by 19.5%, 17.1%, and 12.5%, respectively. Conclusion: The prevalence of PMDD in this sample of Brazilian women was high, with psychoemotional symptoms being more prevalent than somatic symptoms. This demonstrates the impact of premenstrual symptoms on women’s mental health. Knowing the epidemiology of PMDD, as well as the symptomatological profile in different age groups, can help in the design of more effective and specific diagnostic and treatment protocols for each population.
Sources of Funding: This study has received financial support from Libbs Farmacuetica, São Paulo, Brazil.

P-73. Prolactinoma in post-menopausal women: a systematic review
Marcela S. Carneiro, MD, Ticiana A. Mira, Daniela A. Yela, Associate Professor, Cristina L. Benetti-Pinto, Full Professor, Adriana O. Pedro, PhD. Gynecology and Obstetrics, Universidade Estadual de Campinas, Campinas, Brazil
Objective: Evaluate the evolution of prolactinomas after menopause: to identify data on growth, prolactin serum levels, clinical treatment, symptoms, and recurrence of prolactinomas in post-menopause women. The following database: PubMed, BVs, EMBASE, Scopus, Web of Science, COCHRANE, PROQUEST, and grey literature were included, without language and date restrictions. Search strategy with mesh terms was: “Prolactin (PRL)-secreting tumors”, “prolactin adenoma”, “Adenoma” and “Prolactin”, “Hyperprolactinemia”, “Prolactinoma”, “Climacteric”, “Menopause”, “Postmenopause”, until May 2022. Two researchers independently screened records for inclusion. A third author judged disagreements between the reviewers. The papers were selected and judged using the Intelligent Systematic Review (RYYAN). Data were extracted from the articles after reading them in full. The risk of bias will be assessed using the NIH quality assessment tool (NIH) for the observational study. Data were synthesized narratively on the association between changes in prolactinoma and women in the post-menopause period. A meta-analysis was not realized considering the study design included. Registration number: CRD42023364979. Results: From searches in the databases, 260 articles were retrieved that, after analyzing the title and abstract, in addition to applying filters, left 6 for a full reading. The data are summarized according to the flowchart below (Figure 1). After analysis of the risk of bias in the studies, it was identified that 5 studies presented fair quality and 2 studies as good. A total of 158 patients were included. Part of these women was analyzed during menacne, menopause, and post-menopause, with, and without treatment. We could observe the description of 109 included women with microprolactinomas and 47 with macroprolactinomas. Considering the diagnosis in the post-menopause period, there is a greater prevalence of macroprolactinomas (n= 40) against microprolactinomas (n=25), which show a reduction in tumor size with the use of a dopamine agonist, the most commonly used as Cabergoline, as well as a reduction in prolactin levels and symptoms associated with the adenoma. In the follow-up period, the behavior of the tumor and, prolactin levels, maintain stable. Conclusion: Microadenomas diagnosed before menopause can be followed without treatment. When the tumor is diagnosed after menopause, macroadenomas are the most frequent. Cabergoline is still the medical choice, if symptoms of mass effect we recommend. We recommend at least one follow-up for year in despite that the ideal postmenopausal follow-up time has not been defined.
Sources of Funding: None.
Cardiovascular Disease in Menopausal Incarcerated Women
Evan Perkiss, Bachelors of Science in Public Health1,2, Eliana Schach1,2, James McGreevey1, Gloria A. Bachmann, MD., MMS.1,2
1Women’s Health Institute, Rutgers Robert Wood Johnson Medical School New Brunswick, New Brunswick, NJ; 2New Jersey Commission on Women’s Reentry, New Brunswick, NJ
Objective: Midlife and older women have an increased risk of cardiovascular disease (CVD). Since women who are 55 or older are the fastest-growing age group in prison, CVD is a major health concern for them. Data suggest that of newly admitted women prisoners to maximum-security prisons, 34% have CVD. Several adverse determinants of health that menopausal women face in the correctional system may increase this risk of developing CVD. Design: On PubMed, “(women) AND (prison)” AND “cardiovascular disease” were searched. Six articles written in English met the inclusion criteria of addressing CVD among incarcerated women in the criminal justice system. Results: Of the six articles found, three discussed risk factors for CVD, and three discussed potential interventions. In addition to postmenopausal incarcerated women being more vulnerable to CVD due to an increased prevalence of comorbidity conditions, including hypertension, diabetes mellitus (DM), high cholesterol, and obesity, socioeconomic disparities prior to incarceration increase their risk of comorbidities and CVD as well. Aspects of the prison environment also contribute to the increased prevalence of CVD. Those who are incarcerated may have decreased access to adequate optimal health care. Furthermore, prison itself can be defined as a high-stress environment. Incarcerated postmenopausal women may experience sexual harassment, solitary confinement, maternal guilt, and loss of ability to move freely. HIV also is prevalent in those incarcerated and can increase CVD risk. Those incarcerated may have limited exposure to sunlight, leading to vitamin D deficiency, which is associated with CVD, as well as osteoporosis. Regarding prevention of CVD in the criminal justice system, is crucial, but scant data exists. A study hypothesized that lifestyle factors would improve cardiovascular health in prison. A 2016 study proposed an intervention involving indoor biking and education on diet, activity, weight, stress, and smoking, but no data regarding its effectiveness has been published. Other research suggests that a CDC program on heart intervention should be implemented in prisons to decrease the number of follow-up visits, symptom burden, and types of therapy accepted. Design: Eligible patients with menopausal symptoms (both vasomotor and genitourinary) who presented to an incarcerated menopause specialty clinic between July 2018 and December 2022 were included. Data were extracted from retrospective medical record reviews. Travel time was calculated using Google Maps as the average of two times over clinic operating hours from patients listed home addresses on initial registration to clinic. Average travel time was calculated One-way ANOVA and post-hoc analyses were used to examine the association between travel time and therapy type and number of follow-up visits. Student’s t-test was used to examine the association between symptom burden and average travel time. Results: A total of 119 individual patients were included in this study. Median travel time was 22.2 minutes, and median travel distance was 15.8 miles. Women who accepted both local and systemic hormone therapy traveled significantly less time (17.3 ± 7.2 minutes, p < 0.001), compared to women who accepted lifestyle modifications only (28.4 ± 8.3, p < 0.001). Women who visited the clinic once (30.6 ± 10.4 minutes, p = 0.009) had significantly more travel time to clinic compared to those who visited the clinic twice (23.7 ± 11.3 minutes, p = 0.002) and three or more times (16.6 ± 8.6, p < 0.001). Women who reported vasomotor symptoms, genitourinary symptoms, and decreased libido had significantly longer average travel times compared to women without these symptoms [24.5 vs 18.7 minutes (p = 0.005), 24.7 vs 21.6 minutes (p = 0.041), and 25.2 vs 20.7 minutes (p = 0.046)] respectively. Conclusion: Longer travel times to our menopause clinic are a barrier to accessing care, which was found to be associated with less follow-up care, increased symptom burden, and decreased acceptance of hormone therapy for menopausal symptoms. We highlight an access to care barrier that providers should consider. Ultimately patient time is valuable and any increase in travel time might be impactful on their health.
Sources of Funding: None

Vaginal Orgasms: Do They Really Exist in Menopause?
Alberto Dominguez-Bali, MD1, Catherine Dominguez-Bali, PhD BSN RN1, Monica Pevida1, Stephanie Ethier, BS1, ‘American University of Antigua, Coolidge, Antigua and Barbuda; 1Miami Center for Obstetrics, Gynecology and Human Sexuality, Miami, FL
Objective: In 1948, Alfred Kinsey’s investigation of female and male sexuality found that 80% of women reached orgasm mainly through non-coital sexual experiences, such as oral and physical manipulation of the genitals or through sex toys. Many peer-reviewed studies - as well as what we observed in our practice - confirmed these findings. However, the question remains: what happened with the other 20% that reached orgasm through vaginal penetration? Hence, the goal of this study was to examine the relationship between sexual partner history, timing of sexual initiation, and orgasmic responsiveness in post-menopausal women who primarily reach orgasm through vaginal penetration. The study aimed to provide a deeper understanding of the sexual experiences and response patterns in this population, with the ultimate goal of improving female sexual health and well-being. Design: The study was conducted in a medical center and involved the collection of sexual histories from over 3,000 post-menopausal women. Both retrospective and prospective questionnaires were used to gather data on the participants’ sexual experiences, partner history, and timing of sexual initiation.
The questionnaires were administered by trained healthcare professionals to ensure accurate and reliable data collection. In addition, medical records were reviewed to confirm the reported information and to obtain additional relevant data. The data was analyzed using descriptive statistics to examine the prevalence of sexual partner history and timing of sexual initiation among the participants, and to identify correlations between those variables and orgasmic responsiveness. To ensure the privacy and confidentiality of the participants, all data was securely stored and de-identified before analysis. Results: The epidemiological sexual characteristics of this specific group of women who reach orgasm through vaginal penetration are: 75% have had only one sexual partner in their lives; 20% of them have had two sexual partners in their life; 5% of them have had more than two. It has been very scantily found that women with a history of multiple sexual partners enjoy sexual penetration. The orgasmic response resulting from coital sex was more persistent and presently found while the number of sexual partners was lower. Increased orgasmic responsiveness was also present when the initiation of sexual activity with the partner occurred earlier in life. This highlights the importance of a stable sexual relationship in a woman’s sexual response. The results also indicate that the women with a history of multiple sexual partners had a lower likelihood of enjoying sexual penetration, further emphasizing the significance of a stable sexual environment for a woman’s sexual satisfaction. The study found that the orgasmic response resulting from coital sex was more persistent and present in women with fewer sexual partners. Furthermore, increased orgasmic responsiveness was observed in women who initiated sexual activity earlier in life, suggesting that a woman’s sexual development plays a crucial role in her ability to respond to sexual stimulation and reach orgasm through vaginal penetration. The results also show that the orgasmic response was more attainable and persistent when penetrative stimulation was the main form of stimulation, reinforcing previous findings that a woman’s sexual response is directly related to the type and quality of sexual stimulation she receives. Conclusion: The findings of this study provide valuable insights into the sexual characteristics of post-menopausal women who reach orgasm through vaginal penetration. The results support the idea that a stable and supportive sexual environment is crucial for a woman’s sexual satisfaction and overall health. As healthcare providers, we must consider these findings in our approach to sexual health and well-being. When the sexual development of a woman is allowed to mature in the presence of a lifelong partner, her response to penetrative vaginal stimuli is better and is associated with pleasure and orgasm. This response, which persists throughout her life and is more attainable over any other form of vaginal stimulation.

Sources of Funding: None

P-77. Ameliorating Menopausal Symptoms: The Role of Dance
Alexa Pisciotti, Gloria A. Bachmann, MD, MMS. Women’s Health Institute, Rutgers Robert Wood Johnson Medical School, Piscataway, NJ
Objective: Menopause may affect middle-aged cisgender women by causing hot flashes, pain during sex, mood changes, irritability, and depression. Often accompanying these changes that occur with menopause is an increased level of psychological distress, which can manifest in different ways. For example, in a cross-sectional study of 300 women, 85% of post-menopausal women and 47% of peri-menopausal women reported symptoms of physical and mental exhaustion, compared to 20% of pre-menopausal women. This can have a significant impact on the well-being of these women—some may even decide to discontinue activities, including work and hobbies, earlier than they had planned. Research remains divided on whether the increased psychological distress seen in menopausal women stems from biology, societal schemas, or a combination of both. What is known is that hormonal changes occur in menopause, it is unknown whether this contributes to mental health dysregulation in some. On a societal level, Western countries often convey menopause as a major sign of aging and loss of sexuality in women, creating societal pressure that may lead some women to develop unrealistic expectations and therefore experience increased stress. Regardless of the reason for the increase in psychological stress, stress management modalities may be one way to improve the menopausal woman’s quality of life. Dance Movement Therapy (DMT) is an emerging strategy for reducing psychological stress. Since early human history, many cultures have used dance as a healing ritual for ills and maladies. Today, dance has been used as a complementary therapy to standardized Western medicine to promote greater muscle strength and to positively influence mental health. This review explores the use of dance to ease menopause-related stress. Previous research has revealed the benefits of physical activity in women undergoing menopause. However, in this review, the role of dance is explored, and whether it is superior to other forms of physical activity as well as whether it has additional benefits of improving self-image and self-esteem. Design: A literature review was conducted using PubMed. Keywords included “menopause,” “dance,” “emotional,” “movement,” “self-esteem.” Research was focused into two groups: impact of menopause on stress levels and the impact of dance on stress reduction. Results: Menopause has been shown to be a contributor to increasing stress levels and depressive symptoms in some aging women, likely due to societal stigmatization of menopause combined with sudden hormonal changes. Available data suggest that 12 weeks of DMT increases serotonin and decreases dopamine levels, stabilizing the sympathetic nervous system. This would likely be beneficial for menopausal patients, who may experience mood disturbances due to the depression of serotonin production and replacement with the function of estrogen and progesterone levels. Similarly, there are data that suggest DMT reduces depressive symptoms in individuals of all ages. This could also be advantageous to those with menopause-induced mood changes due to both biological and societal causes. In addition, the physical benefits experienced through dance may help women maintain their independence, which is, in turn, associated with increased feelings of wellness. This could counteract the depression and exhaustion experienced by some menopausal women. Furthermore, low self-esteem and loss of personal value have been associated with menopausal changes, DMT could also address this issue as it has been shown to increase self-esteem, again improving the mental wellness of menopausal women. Conclusion: Despite the historical association between dance and healing, dance is currently under- utilized as a management modality for many individuals, including those undergoing menopause. Additionally, dance is an inherently social activity, providing built-in social support to individuals and encouraging a form of camaraderie. Further research is needed to directly evaluate the relationship between dance and stress reduction in women experiencing menopause as well as the perceived benefit of increased social support through dance classes and events.

Sources of Funding: None

Cristina A. Ramirez Colunga, Gabriela Rodriguez Segovia, Resident, Carolina Valdez Alatorre, Selene M. Garcia Luna, Arturo Morales Martinez, Otto H. Valdes Martinez, Luis H. Sordia Hernandez, Marta O. Sordia Piñeyro. Biologia de la Reproduccion, Hospital Universitario, Monterrey, Mexico
Objective: To identify if demographic, and socio-cultural factors among menopausal women, are associated with an active and satisfactory sexual life. Design: Cross-sectional online surveys about sexual life, demographic and sociocultural factors, were conducted from March 9-26 2023, using Google forms platform. Obtained responses were analyzed using GraphPad Prism version 8.4.2 for Windows. Central tendency measures were used for the descriptive analysis and for comparison we used Fishers exact test. Results: A total of 100 Mexican eligible women, answered completely and consistently the survey. Table 1 depicts the demographic variables and the relationship with an active sexual life, in which no statistical significance was observed, except for marital status. More than half patients have an active sexual life, of which, 80% reported living a satisfactory sexual life (SSL). Regarding treatment, 76% were with hormone replacement therapy (HRT), but variation hormones neither represented a difference between have SSL or not. For 84% of women surveyed, it is difficult to talk about sexuality, we organized the reasons into cultural and social aspects, 70% was cultural embracing shame and taboo, 20% was social, which mainly included “education”, 17% included both aspects, and 3% did not answer. An attempt was made to relate it to the time of menopause without finding statistical significance OR 0.8685 (CI 0.2143 – 2.056). The patients who do not have an active sexual life, referred as main cause, decreased desire, vaginal dryness and sexual pain. Conclusion: Our results indicate that demographic factors are not directly related with an SSL. Be married or live with a partner seems to influence in having sexual activity. Contrary to the expected, been in menopause longer, or not being on HRT, does not affect in achieving a SSL. Among the main factors that influenced not achieving a SSL were symptoms related to lack of estrogen and sociocultural barriers.

Sources of Funding: None

Table 1. Comparison of demographic characteristics and an active sexual life.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Overall (N=100)</th>
<th>Active sexual life (N=59)</th>
<th>No Active sexual life (N=41)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD)</td>
<td>57 (5.2)</td>
<td>58 (54-60)</td>
<td>57 (55-61)</td>
<td>0.79</td>
</tr>
<tr>
<td>Marital Status, n(%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single</td>
<td>8%</td>
<td>2 (3%)</td>
<td>6 (15%)</td>
<td>0.001</td>
</tr>
<tr>
<td>Married/Living with partner</td>
<td>68%</td>
<td>49 (83%)</td>
<td>19 (46%)</td>
<td></td>
</tr>
<tr>
<td>Widowed</td>
<td>6%</td>
<td>7 (12%)</td>
<td>11 (27%)</td>
<td></td>
</tr>
<tr>
<td>Divorced/Separated</td>
<td>18%</td>
<td>3 (5%)</td>
<td>15 (37%)</td>
<td></td>
</tr>
<tr>
<td>Education, n(%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elementary</td>
<td>3%</td>
<td>0</td>
<td>3 (7%)</td>
<td>0.06</td>
</tr>
<tr>
<td>High School</td>
<td>5%</td>
<td>4 (7%)</td>
<td>1 (3%)</td>
<td></td>
</tr>
<tr>
<td>Professional degree</td>
<td>82%</td>
<td>47 (80%)</td>
<td>35 (85%)</td>
<td></td>
</tr>
<tr>
<td>Graduating</td>
<td>10%</td>
<td>8 (13%)</td>
<td>2 (5%)</td>
<td></td>
</tr>
<tr>
<td>Employment Status, n(%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unemployed</td>
<td>37%</td>
<td>22 (37%)</td>
<td>15 (39%)</td>
<td>0.66</td>
</tr>
<tr>
<td>Full/part-time employed</td>
<td>63%</td>
<td>37 (63%)</td>
<td>25 (61%)</td>
<td></td>
</tr>
<tr>
<td>Monthly Household Income, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;$500-599</td>
<td>30%</td>
<td>14 (24%)</td>
<td>16 (39%)</td>
<td>0.22</td>
</tr>
<tr>
<td>$600-1,599</td>
<td>28%</td>
<td>19 (32%)</td>
<td>9 (22%)</td>
<td></td>
</tr>
<tr>
<td>$1,600-4,000</td>
<td>42%</td>
<td>26 (44%)</td>
<td>16 (39%)</td>
<td></td>
</tr>
<tr>
<td>Religion, n(%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Catholic</td>
<td>84%</td>
<td>52 (88%)</td>
<td>32 (78%)</td>
<td>0.38</td>
</tr>
<tr>
<td>Christian</td>
<td>12%</td>
<td>5 (9%)</td>
<td>7 (17%)</td>
<td></td>
</tr>
<tr>
<td>Non-practicing</td>
<td>4%</td>
<td>2 (3%)</td>
<td>2 (5%)</td>
<td></td>
</tr>
<tr>
<td>Sexual Preference, n(%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterosexual</td>
<td>95%</td>
<td>56 (95%)</td>
<td>39 (95%)</td>
<td>&gt;0.99</td>
</tr>
<tr>
<td>Homosexual</td>
<td>5%</td>
<td>3 (5%)</td>
<td>2 (5%)</td>
<td></td>
</tr>
</tbody>
</table>
Objective: Let’s talk about sex: The role of communication in sexual satisfaction during menopause.

Let’s talk about sex: The role of communication in sexual satisfaction during menopause.

Most women experience vasomotor symptoms (VMS), including hot flashes and night sweats, at some point during the menopausal transition. This study aimed to estimate the prevalence of diagnosed VMS among US women aged 40–64 years and to assess diagnosis disparities based on sociodemographic characteristics. 

Design: Cross-sectional online surveys about sexual life in menopausal women were conducted from March 9 to March 25, 2023. Surveys were delivered to participants through Google forms platform. Responses were recorded on a Microsoft Excel spreadsheet and analyzed using GraphPad Prism version 8.4.2 for Windows. The source of healthcare disparities among women with VMS.

Conclusion: Among the women who don’t have communication with the partner, the main reasons given were lack of time, distrust, and fear of being judged. An interesting point about professional physicians was that of the patients who talk with them, 18% reported still having doubts, and 15% considered that their doctor was not qualified to provide information on sexual health. 

For our community, communication with the partner proved to be more significant than the information provided by a health professional in order to live a satisfied sexual life. There is an area of opportunity among professional physicians to acquire more knowledge about sexuality, and improve on how to transmit it to patients.

Sources of Funding: None.
P-82. Mobile application for screening metabolic syndrome in climacteric women.

Carolina Trovao2, Maria C. Rocha, 5 year1, João Pedro Rocha2, Andreia Teixeira3, Andreia Teixeira2, Isabel Machado4, Emelie Alves1, Carlos Moreira1, Catarina Abrantes1, Maria H. Moreira2, Maria C. Rocha, 5 year1, João Pedro Rocha2, Andrea Teixeira3, Isabel Machado4, Emelie Alves1, Carlos Moreira1, Catarina Abrantes1, Medicina, Faculdade de Ciências Médicas de Minas Gerais, Belo Horizonte, Brazil; 2Department of Sports Science, Desporto, Instituto Superior de Ciências Educativas do Douro, Penafiel, Portugal; 3Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; 4Universidade de Tras-os-Montes e Alto Douro, Vila Real, Portugal; 5CIDESD, Universidade de Tras-os-Montes e Alto Douro, Vila Real, Portugal; 6Departamento de Desporto, Instituto Superior de Ciências Educativas do Douro, Penafiel, Portugal

Objective: To describe the development process of an application aimed at primary care physicians, designed to facilitate the identification of climacteric women predisposed to develop metabolic syndrome (MS) from the calculation of an appropriate anthropometric index. Design: This is applied research initially composed of a planning stage, with the definition of the Body Roundness Index (BRI) and the Visceral Adiposity Index (VIA) as the most appropriate anthropometric measures to be used, according to a study that evaluated the ability of anthropometric indices to discriminate the MS in climacteric women. After defining the cutoff points of the BRI and the VIA, the application architecture was designed, containing the navigation and user interaction screens, with a brief explanation about the objectives, as well as the forms for selecting the variables and entering the anthropometric measurements needed to calculate the BRI and VIA. After defining the application’s design, we researched the best tool to build it. Based on emerging technologies, it was decided to use a mobile application development kit created by Google called Flutter, which eases the creation of applications and uses Dart programming language, also created by Google. Results: The mobile application developed was named ClimatMed. It is available for free on the Google Play Store Platform and can be installed on smartphones with the Android system. The initial screens of the application contain a brief introduction, with an explanation of the theme and the objective, and present the partner institutions of this project. When clicking on the “learn more” option, the person has access to the diagnostic criteria for MS according to the International Diabetes Federation - IDF (2006), in addition to the connection to the calculation of anthropometric measurements required. ClimatMed application development was performed through the “Start” button, the application displays a screen so the woman can define the climacteric period in which she is (pre- or postmenopause) and the variables that were adjusted (level of physical activity, alcohol consumption, and smoking). To assess the level of physical activity, we used the International Physical Activity Questionnaire (IPAQ), developed and validated by Craig et al. (2003). This questionnaire classifies women as very active/active, irregularly active, and sedentary through questions related to physical activity performed in the last week for at least 10 continuous minutes before answering the questionnaire. Then, the measurements required to calculate the BRI can be entered (abdominal circumference and height). As a result, the application provides the probability of developing MS. This probability is calculated by the logistic regression models obtained from the database created. After this, one can close the application or continue adding the anthropometric measurements required to calculate the BRI, triacylglycerides, and HDL. Then, it automatically calculates the index and the probability of the patient developing MS. The application also allows the storage of the history of the results, which eases the monitoring and improves the system. Conclusion: The insertion of computer technology into the medical consultation of climacteric women brings numerous contributions, especially to the public health system, because it allows cost savings, besides being simple and accessible to the professional. Additionally, the identification of this population predisposed to develop MS helps in the prevention of chronic cardiovascular diseases. As future work, ClimatMed will be made available for the IOS system and a version for Web browsers. Sources of Funding: None.
quality of life of postmenopausal women according to the groups considered for BMI, WC, MVPA, and steps/day. However, women with higher levels of adiposity seem to exhibit better scores in the physical domain, regardless of menopause characteristics.

Sources of Funding: None

P-85. Sedentary behavior and associated factors in climacteric women.

Camila Porto 4, Tahiana Freitas 2, Marcelo Rocha 5, Laércio Santos 6, Josiane Rocha 2, Marcos D’Angelo 6. 1Medicina, Faculdade de Ciencias Medicas de Minas Gerais, Belo Horizonte, Brazil; 2Programa de Pós-Graduação em Cuidado Primário em Saúde, Universidade Estadual de Montes Claros, Montes Claros, Brazil; 3Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; 4Medicina, Universidade Federal do Amazonas, Manaus, Brazil; 5Medicina, Universidade Estadual de Montes Claros Centro de Ciências Biológicas e da Saúde, Montes Claros, Brazil; 6Programa de Pós-Graduação em Ciências da Saúde, Universidade Estadual de Montes Claros, Montes Claros, Brazil.

Objective: To evaluate sedentary behavior in climacteric women and associated factors. Design: This is a population-based epidemiological study with a cross-sectional design, in the Municipality of Montes Claros, Minas Gerais, Brazil. Data were obtained through questionnaires, anthropometric evaluation, and collection of peripheral venous blood for biochemical parameters analysis. The data were typed and stored in the statistical software SPSS. Initially, an exploratory, descriptive analysis was performed, with the frequency distribution of the study variables according to sedentary behavior. The Random Forests (RF) classification technique was used, which listed the variables in order of predictive importance and selected the variables as input for the final classification model. To understand sedentary behavior related to the exposure variables, multivariate analysis was performed using the Decision Tree (DT) method. The DT method, with the Classification and Regression Tree (CART) algorithm, was used to investigate predictor variables of sedentary behavior as an alternative to the logistic regression method, given the limitations of these models available for analysis.

Results: A total of 873 climacteric women participated in the study, with a mean age of 51.0 ± 7.08 years. Regarding education, 65.7% of women had a 8 years of education, most had black color, with a steady partner, and family income averaged 1,362.91 ± 977.52 reais (Brazilian currency). Regarding reproductive variables, most women reported having had menarche at regular age, < 3 vaginal deliveries, 1 cesarean delivery, were classified in the pre/perimenopausal period, had natural menopause, did not use hormone replacement therapy (HRT), and had mild climacteric symptoms. Regarding behavioral characteristics, most interviewees reported not being smokers and alcohol drinkers. However, regarding sedentary behavior, 65.8% of the women were above the threshold (≥ 75 min/day). Regarding eating habits, a relevant group of women reported eating 1 fat, not adding salt and consuming 3 meals a day. As for the clinical variables, most women have compromised sleep quality, lack of daytime sleepiness, absence of metabolic syndrome, intermediate cardiovascular risk, no comorbidities, good psychological adjustment, low back pain, and cancer.

Concerning depressive and anxiety symptoms, a significant share of the population had mild symptoms and a positive perception of health status. The following variables were selected for input into the final classification model: skin color, menarche, diastolic blood pressure (DBP), low back pain, waist circumference, total cholesterol, HDL-cholesterol, and triglycerides. The decision tree indicated that the variables total cholesterol, diastolic blood pressure, body mass index (BMI), and triglycerides were associated with sedentary behavior. Those women with total cholesterol ≥ 236.5 mg/dL were more prone to sedentary behavior compared to women with total cholesterol < 236.5 mg/dL. Regarding diastolic blood pressure, women with DBP ≥ 75 mmHg formed a group more prone to sedentary behavior when compared to women who had DBP ≥ 75 mmHg. Women with BMI ≥ 30.02 were more inclined to sedentary behavior when compared to women with BMI < 30.02. Women with triglycerides ≥ 7.5 were also more likely to present sedentary behavior. The metrics used to evaluate the quality of the results of the Decision Tree model showed the following results: Accuracy = 0.6632; Recall = 0.8171; Precision = 0.7128; and F-score = 0.7614. Conclusion: The present study showed an elevated prevalence of sedentary behavior, which was associated with high total cholesterol levels, low diastolic blood pressure, obesity, and high triglyceride levels.

Sources of Funding: None

P-86. Investigating the effect of exposure to a novel digital menopause-focused education, care, and community platform on mid-life women.

Nikol Pugacheva1, Jacqueline Giansianni2, Anna M. Barbieri1, MD, Jannine Versi2, Pornjittra Rattanasirivilai, MBBCh2, Laura Stratte, RN2, Paula J. Doyle3. 1Icahn School of Medicine at Mount Sinai, New York, NY; 2Elektra Health, New York, NY; 3Departments of Obstetrics, Gynecology and Urology, University of Rochester School of Medicine and Dentistry, Rochester, NY.

Objective: The menopause experience is influenced by numerous factors, including physiological symptoms, cultural perceptions, available resources, and education on the menopause transition. Access to evidence-based, menopause-focused educational resources may help improve the menopause counseling experience and reduce the prevalence of a clinical condition. However, digital tools can help to mitigate issues of limited access. Prior research has demonstrated that exposure to a digital-based menopause-focused intervention has increased health-directed behaviors and decreased menopause-related symptom severity [1]. Thus, our hypothesis is that a digital health intervention will be effective in reducing menopause-related symptoms and improving the quality of life of postmenopausal women. Design: This single-center prospective intervention was conducted in Florida, USA. Pregnant participants were excluded. Age, race, use of hormone replacement therapy (HRT), and depression from the participant’s medical records. Baseline demographic and medical history data were abstracted from the medical record. Participants completed pre- and post-exposure clinically validated questionnaires, including Menopause Rating Scale (MRS) to assess menopause symptoms, and a depression (GAD-7), depression (PHQ-9) and non-validated menopause preparedness questionnaires, relating to mindset, work, and productivity. Once enrolled, subjects had 60 days of access to digital resources, including menopause-focused webinars, written articles, one-to-one coaching by menopause trained nurses or coaches. Engagement was assessed through completion of educational modules and counseling sessions. Results: Data collection is ongoing. The study is projected to be completed by September 2023. A total of 50 subjects aged 40 to 65 were consented and 95.6% completed the study and was complete by June 27th. The mean age was 54.6 years with twenty-seven (54%) participants identified as postmenopause. Seven (14%) participants are receiving HT. Thirty-two (64%) participants scheduled a virtual individual session with a menopause guide and 7 calls have been completed to date. Conclusion: Menopause preparedness is multifaceted and time-intensive from the provider perspective. Common barriers in receiving high quality menopause care and counseling include provider knowledge gap and visit time constraints. The results of this study will garner data that will meaningfully further the current understanding of how digital health interventions can help to mitigate constraints, and thereby improve quality of life for menopausal patients. Specifically, they will provide additional information on the effectiveness of utilizing an integrated menopause-focused digital health platform in women with menopause. Digital platforms with functionality being a powerful tool for women who have access to digital resources, high quality menopause care and management, and a supportive community.


Sources of Funding: None

P-87. Characterizing treatment patterns for endocrine therapy-related menopausal symptoms in the US.

Marian Saadecine1, Siir Su Saydamin2, Carina Dinkel-Keuthage1, Cecilia Catena1, Cecile Janssenwellen2, George Argyriou3, Martin Lavallee3, Nils Schoor2, Carsten Moeller2, Victoria Banks1. 1Mayo Clinic in Florida, Jacksonville, FL; 2Bayer AG, Leverkusen, Germany; 3Odysseus Data Services, Cambridge, MA.

Objective: Over 80% of women receiving endocrine therapy (ET) for breast cancer may experience menopause symptoms including vasomotor symptoms (VMS), which can impact quality of life and lead to ET discontinuation and reduced cancer survival. Effective treatment options for ET-related menopausal symptoms are limited as hormone therapy (HT) is contraindicated in women receiving ET. There is little evidence on utilization patterns of prescription medications for ET-related menopausal symptoms. This study aimed to describe treatment pathways for ET-related menopausal symptoms in the US.

Design: This large retrospective cohort study was conducted across administrative claims databases from the US, standardized to the Observational Medical Outcomes Partnership Common Data Model. Data from IBM® MarketScan® are reported (study period: January 2009 to June 2020). The study analyzed the sequence and combination of treatments prescribed to women aged 18–65 years following initiation of ET for breast cancer or for a condition considered high risk for breast cancer. Treatment classes of interest were HT, non-HT (as per the NAMS 2015 position statement) and benzodiazepines. A gap of less than 21 days between prescription and start date was considered as treatment discontinuation while a gap of 30 days or more indicated a change in line of treatment. Only treatment pathways with over 250 women were reported. Results: Overall, 23,486 women received a first prescription of ET with a diagnosis of breast cancer or at high risk for breast cancer; median follow-up duration was 1.1–4.0 years. The majority (71.0%) were aged over 50 years. The most common non-vasomotor comorbidities were hypertension (n=32,842, 13.7%), osteoarthritis (n=23,621, 9.9%), anxiety (n=23,369, 9.8%), and depression (n=19,387, 8.1%). Treatments of interest were recorded in 86,165 women (36.0%); 75,039 (31.3%) followed a treatment pathway with over 250 women. Pathways with only one line of treatment were reported in 65,079 women (86.7%); benzodiazepines, venlafaxine and gabapentin were most prescribed. Two lines of treatment were reported in 9,960 women (13.3%); benzodiazepines, venlafaxine and gabapentin were the most prescribed first-line and combinations of benzodiazepines with gabapentin or venlafaxine were the most common second-line treatments (Table 1). Pathways that featured HT were reported in 9,312 women (12.4%), of whom 8,413 (93.0%) had HT prescribed first-line. Estrogens were prescribed in 6,665 women (70.9%), progesterogens in 1,163 (12.5%), and raloxifene in 867 (9.3%) and combination estrogen and progesterogen in 677 (7.3%)

Conclusion: In this study, which included all women initiating ET for breast cancer or high breast cancer risk, without criteria for ET-related menopausal symptoms, only one-third of women received a treatment of interest. This suggests ET-related menopausal symptoms often go unrecognized and untreated. Almost 90% of women had only one reported line of treatment; benzodiazepines were most prescribed. Depression and anxiety were among the most common comorbidities; thus, usage may not be solely for menopausal symptom control. However, the most prescribed pathway included the combination of another medication with the first-line treatment, which may indicate that the initial medication was insufficient to control symptoms. Over 12% of reported pathways included HT, despite HT being contraindicated in this population, although there are no route of administration data so patients may have received vaginal...
P-88. Characterizing treatment pathways for natural menopausal symptoms in US women
Mariam Saaddeen1, Siri Su Saydam1, Carina Dinkel-Keuthage2, Cecilia Caetano2, Cecile Janssenswille2, George Argyrion1, Martin Lavalle1e, Nils Schoof1, Carsten Moeller1, Victoria Banks1, 1Mayo Clinic in Florida, Jacksonville, FL; 2Bayer AG, Leverkusen, Germany; 3Odysseus Data Services, Cambrige, MA

Objective: Menopausal women may experience a range of symptoms that can impact their quality of life, including vasomotor symptoms (VMS), sleep disturbances, and mood changes. Available effective treatments for menopausal symptoms include hormone therapy (HT) and nonhormonal treatments (non-HT). Despite paroxetine being the only non-HT approved for VMS in the US, antidepressants and anticonvulsants are often prescribed to menopausal women and are recommended by menopause experts. There is limited evidence on longitudinal HT and non-HT utilization patterns for symptoms of menopause. This study aimed to describe treatment pathways used to manage symptoms of natural menopause in the US. Design: This large retrospective cohort study was conducted across administrative claims databases from the US, standardized to the Observational Medical Outcomes Partnership Common Data Model (study period: January 2009 to June 2020). Data from IBM MarketScan© were analyzed. We analyzed the sequence and combination of treatments prescribed to women aged 40–65 years following a first recorded diagnosis of natural menopause. Treatment classes of interest were HT, non-HT (as per the NAMS 2015 position statement on nonhormonal management of VMS) and benzodiazepines. A gap of less than 30 days between prescriptions indicated a treatment combination while a gap of 30 days or more was considered a change of line of treatment. Only treatment pathways with over 500 women are reported. Results: Overall, 1,263,336 women diagnosed with natural menopause were included in the cohort with a median follow-up of 2.3 (interquartile range 1.2–4.1) years. The majority (57.3%) were aged 50–59 years, 21.6% were aged 40–49 years, and 21.1% were aged 60–65 years. The most common comorbidities were osteoarthritis (n=92,761, 7.3%), hypertension (n=90,692, 7.2%), and hypothyroidism (n=52,071, 4.1%). Treatments of interest were recorded in 454,726 (36.0%) women; 411,765 (32.6%) followed a treatment pathway with over 500 women. In total, 345,796 women (84.0%) had only one reported line of treatment; estrogens, benzodiazepines and gabapentin were most prescribed. Two lines of treatment were reported in 65,208 women (15.8%); estrogens and benzodiazepines were the most prevalent first-line treatments, with a median follow-up of 3.5 (IQR 1.2-6.0) years. The majority (61%) of pts never or almost never felt sexual desire/interests in the past month, particularly those whose sexual health was negatively impacted by prior ET (61%); 56% of pts felt bothered by low sexual desire. The vaginal/sexual side effects of BC treatment were a concern for most pts (80%), negatively impacting the frequency of sexual intercourse (61%) and their self-esteem (64%), and making 51% feel isolated. Most (78%) felt that BC negatively impacted their body image. About a third of pts felt poorly informed by their medical team (MT; 38%) and not comfortable talking with their MT (31%) about vaginal/sexual side effects; 33% also felt poorly equipped to improve these side effects. Pts were more likely to feel well informed by their MT (54% vs 27%) or more comfortable talking with their MT (59% vs 44%) about these side effects if they had a female vs male oncologist. Pts more frequently discussed vaginal/sexual side effects with their gynecologist (33%) than their oncologist (15%); similarly, they more frequently obtained information on these side effects from their gynecologist (33%) rather than oncologist (8%). The majority (93%) of pts showed interest in trying a treatment if it was effective in treating BC, FDA approved, and well tolerated, and could also improve vaginal/sexual health. Conclusion: In this survey of pts with ER+/HER2- mBC, >60% experienced vaginal symptoms and felt their sexual health was negatively impacted by prior ET. Pts were concerned about the vaginal side effects from their BC treatment, which negatively impacted their self-esteem and made them feel isolated. About a third of pts felt poorly informed or uncomfortable discussing these side effects with their MT. These data highlight unmet needs for improving vaginal/sexual health while treating BC, and better patient/oncologist communication about vaginal/sexual concerns.

Sources of Funding: Sermonix Pharmaceuticals
Patient experience and management of vasomotor symptoms due to menopause: voices from the PatientsLikeMe community

Deepshikha Singh, MPH 3, Shayna Mancuso, DO 2, 1Verywell Health, New York, NY; 2Anthropology, University of Hawai’i at Hilo, Hilo, HI; 3Anthropology, University of Massachusetts Amherst, Amherst, MA; 4Anthropology, University of Hawai’i at Hilo, Hilo, HI

Objective: Vasomotor symptoms (VMS) due to menopause cause significant burden and distress. Many women do not report symptoms to healthcare providers or seek treatment for various reasons including shame and discomfort. Some women join online communities to share with others their experiences with VMS, treatment outcomes, and ways to improve care through peer-to-peer interactions. About half of women who report symptoms have delayed seeking treatment for >6 months. This study aimed to describe women’s experiences with VMS and approaches to symptom management.

Design: Mixed-methods research was performed through database analysis of posts and in-depth interviews with members of the PatientsLikeMe (PLM) online community. PLM posts were searched using keywords such as hot flashes and sleep disturbance. Relevant text was extracted and screened to limit data to US females aged 40–65 years. Qualitative text analysis methods categorized and explored themes. Semi-structured interviews were then conducted with a convenience sample from PLM. Eligible participants were females aged 40–65 years who were experiencing VMS and were fluent in English. Interview moderators asked open-ended questions and prompted conversation about menopause. Interviews were recorded, transcribed, and themes identified. Results: Database analysis revealed the most common symptom was “experiencing hot flashes and night sweats.” Women described wide-ranging severity of symptoms that could last many years. Women’s posts reported that symptoms negatively affected mental health, quality of life, and ability to work. Interviews were conducted with 14 PLM members to confirm the presence of VMS due to menopause. Participants had a median age of 53.5 years; median age of symptom onset was 47 years, and median symptom duration was 8 years. Common concepts, themes, and patient quotes are presented in Table 1. Conclusion: Women reported diverse experiences with VMS due to menopause. For some women, symptoms impacted physical and mental well-being and negatively affected social activities, employment, and quality of life. Women also reported various approaches to managing VMS, including medication and lifestyle modification.

Sources of Funding: The study was sponsored by Astellas Pharma, Inc. (Northbrook, IL). Sources of Support: Nicole Boyer, PhD, MPH, and Lee Ann Braun, MPH, MEd, of Peloton Advantage, LLC, an OPEN Health company.

Table 1. Experiences of women with vasomotor symptoms: results from semi-structured interviews (n=14)

<table>
<thead>
<tr>
<th>Themes</th>
<th>Concepts</th>
<th>Quotes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptom type/frequency</td>
<td>Most common symptoms (number of mentions): night sweats (45), hot flashes (38), moca (37), and menopausal status (37)</td>
<td>“...you can do things the same I mean, not many people have to wake up and change...”</td>
</tr>
<tr>
<td>Impact on quality of life</td>
<td>Physical concerns were problematic: fatigue, anxiety, depression, emotional/mental state impacting social life and work productivity</td>
<td>“I felt miserable...I was so depressed...I couldn’t do anything...”</td>
</tr>
<tr>
<td>Symptom management</td>
<td>Over-the-counter medication (eg, clonidine)</td>
<td>“My doctor sent me on Clonidine...”</td>
</tr>
<tr>
<td></td>
<td>Prescription medication (eg, antidepressants, and corticosteroids)</td>
<td>“I tried many different antidepressants and corticosteroids...”</td>
</tr>
<tr>
<td></td>
<td>Hormone replacement therapy</td>
<td>“...I tried both bihormonal hormones and synthetic hormones...”</td>
</tr>
<tr>
<td></td>
<td>Other (eg, exercise, diet, and medications)</td>
<td>“...I try to eat only bihormonal hormones and synthetic hormones...”</td>
</tr>
</tbody>
</table>

P-91. Demographic and Behavioral Predictors of bothersome Hot Flashes and Night Sweats

Sofiya Shreyer, MA1, Daniel E. Brown, PhD2. 1Anthropology, University of Massachusetts Amherst, Amherst, MA; 2Anthropology, University of Hawai’i at Hilo, Hilo, HI

Objective: Hot flashes (HF) and night sweats (NS) are common and bothersome symptoms during the menopausal transition, occurring in approximately 85% of women. In the literature, HF and NS are often combined into one variable: vasomotor symptoms (VMS). However, some data show that predictors as well as the impacts of HF and NS are not the same. Additionally, while many studies focus on frequency of VMS, the botherfulness of VMS may be more important for health and well-being. In our study, we explore whether the bothersomeness of HF and NS are predicted by the same demographic and behavioral variables. Design: Our sample was drawn from a study of brown adipose tissue (BAT) activity among women aged 45–55 living in Western Massachusetts (n=274) were interviewed about their demographics, health, and menopausal experience. As part of the survey, women were asked about symptom severity, and HF and NS were coded as not bothersome (not at all or a little) or bothersome (somewhat or a lot). Binary logistic regressions were run separately for HF and NS in relation to financial comfort, marriage status, sex orientation, self-reported health, smoking status, alcohol consumption, employment status, total symptom experience (excluding VMS), and parity. Both models were adjusted for menopausal status. Results: Among all participants, 46% reported bothersome HF, and 43% reported bothersome NS. Postmenopausal status and older odds of both HF and NS were stronger in women who self-rated health scores were associated with an increase in risk for bothersome NS (Good Health: OR 2.64, 95% CI 1.08-6.48, Excellent Health: OR 2.97, 95% CI 1.11-7.98), but not for bothersome HFs (OR 1.87, 95% CI 0.95-3.80). Higher alcohol consumption reduced the odds of bothersome HF and NS (OR 0.50, 95% CI 0.29-0.86). Higher levels of financial comfort were associated with higher risk of HF and NS (OR: 1.07, 95% CI 1.03-1.11, NS: OR 1.08, 95% CI 1.04-1.12). Conclusion: We found that HF and NS were predicted by the same demographic and behavioral factors, with the exception of self-reported health. Alcohol consumption was associated with lower incidence of bothersome HF and NS, but total alcohol consumption in our sample was low (average 0.46 drinks per day). Higher total symptom experience may reflect a higher sensitivity to physical and emotional experiences, thus increasing the bothersomeness of both HF and NS. We suggest that future studies examine HF and NS separately to further elucidate the differences between the two symptoms.

Sources of Funding: NSF BCS-1848330

P-92. Brown adipose tissue activity increases the risk of bothersome hot flashes

Lynnette L. Sievert, PhD, Sofiya Shreyer, MA1, Daniel E. Brown, PhD2. 1Anthropology, University of Massachusetts Amherst, Amherst, MA; 2Anthropology, University of Hawai’i at Hilo, Hilo, HI

Objective: Hot flashes (HF) are experienced during the menopausal transition as sudden, uncomfortable, sensations of heat. Declining levels of estrogen result in a narrowing of the thermoneutral zone – between the temperatures that provoke shivering and sweating – and this narrowing contributes to an increased likelihood of HF. Even small changes in the core body temperature (Tc) can induce sweating responses, and small increases in Tc have been documented prior to HF occurrence. This study was prompted by perimenopausal women asking, “How can I be hot and cold at the same time?” We posited that brown adipose tissue (BAT) activation could increase Tc within a narrowed thermoneutral zone, and this could be a cause of HF. BAT is a specialized fat tissue that can induce non-shivering thermogenesis. The objective of this study was to test the hypothesis that women with more BAT activity would have more evidence of HF experience during the coldest months of the year (October through April) in western Massachusetts.

Design: To date, 269 women aged 45 to 55 years participated in semi-structured face-to-face interviews, anthropometric measures, and bio-vitality and impedance analysis (BIA). Hot flashes during the past two weeks were queried as “not at all,” “a little,” “somewhat,” or “a lot.” For this analysis, hot flashes were defined as not bothersome (“not at all” or “a little”) or bothersome (“somewhat” or “a lot”). BAT activity was estimated from the difference in skin temperature measured by infrared thermography before and after the participant placed her hand in cold (17°C) water for five minutes. Sternal temperature measures were used as a control. Body mass index (BMI) was computed as kg/m², and percent body fat (%BF) was computed from BIA. Menopausal status (pre-, peri-, post-) was based on changes in menstruation per STRAW+10 categories. Education (high school or less; some college or degree; some-postgraduate work or degree) and financial comfort (“struggling,” “OK,” “comfortable,” or “well-off”) were also included in analyses. Logistic regression analysis was applied to examine bothersome hot flashes in association with BAT activity while adjusting for menopausal status, adiposity (BMI or %BF), and socioeconomic status (education or financial comfort). BMI and %BF were highly correlated, as were education and financial comfort; one of each pair was included in separate models. Both models were adjusted for menopausal status.

Results: The study was sponsored by Astellas Pharma, Inc. (Northbrook, IL). Sources of Support: Nicole Boyer, PhD, MPH, and Lee Ann Braun, MPH, MEd, of Peloton Advantage, LLC, an OPEN Health company.

P-93. Screening for Ovarian Cancer among African American Women

Trisha Sinda, BA, MD; Gloria A. Bachmann, M.D., M.S.S., Riya Patel, Rutberg Roberts Wood Johnson Medical School, Piscatway, NJ

Objective: Ovarian cancer is one of the gynecologic cancers with the highest mortality that usually presents with nonspecific symptoms, often resulting in late diagnosis. Data from the Surveillance, Epidemiology and End Results (SEER) program showed that only ~20% of ovarian cancers are found at an early stage. However, when found early, 94% of women live longer than 5 years after diagnosis [1]. According to the American Cancer Society, half of all ovarian cancers are found in women 65 years or older, making this population especially vulnerable. Prior studies focus on screening...
recommendations for high-risk women, which includes those with BRCA1, BRCA2, MLH1, MSH2, MSH6, PM2, STR11, MUTYH and EPM2 mutations, and/or have family cancer history or any invasive testing, false negatives, and overt distress for a woman [2]. The UK Collaborative Trial of Ovarian Cancer Screening, one of the largest ovarian cancer screening trials to date found that neither multimodal nor transvaginal ultrasonography screening reduced ovarian cancer mortality vs. ovarian cancer in average risk postmenopausal women [5]. Given the difficulty of finding an appropriate screening test, other modalities have been explored. The ovarian cancer symptoms (GOSS) index was created that assesses specific symptoms in conjunction with their frequency and duration which was found useful in identifying women with ovarian cancer earlier. It included: pelvic/abdominal pain, urinary urgency/frequency, increased abdominal size/bloating, and difficulty eating/feeling full when they were present for <1 year and occurred >12 days per month [3]. Conclusion: These data suggest that there are no current screening procedures suitable for the early detection of ovarian cancer. Furthermore, most current literature focus on high-risk populations, which includes women with genetic predispositions or family history. These results highlight the importance of studying early detection methods of ovarian cancer in average-risk postmenopausal women, who make up a large percentage of ovarian cancer cases. Additional research should investigate the efficacy of educational interventions by clinicians. That is, patients should be made aware of the most common earliest presenting signs and symptoms of ovarian cancer as found by the ovarian cancer symptom (GOSS) index. Future direction includes studying if interventions exist when a woman becomes postmenopausal followed by annual symptom monitoring questionnaires improves detection, mortality, and stage of diagnosis among this specific population.

Sources of Funding: None

P.94. Association of primary ovarian insufficiency with depression in US women: a national population-based study
In Hye Song, MD1, Bo Ram Kim, MD2, Ji Yeon Han1, Sung Woo Kim1,2, Seung-Yup Ku1,2, Chang Suk Suh, MD, PhD2, Hoon Kim, MD, PhD2. 1Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea (the Republic of); 2Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul, Korea (the Republic of)

Objective: Higher frequency of depressive-like symptoms was reported in women with primary ovarian insufficiency (POI). However, few studies have investigated depression in women with POI in a nationwide study. We aimed to investigate the association of depression with POI. Design: This cross-sectional study is based on the National Health and Nutrition Examination Survey (NHANES) in the United States. We analyzed the national representative data on women with natural menopause in the United States aged 19-79 years from the NHANES from 2007 to 2018. POI was defined when the study participant had experienced the last menstrual period before age 40. Depression was defined by the patient health questionnaire-9 (PHQ-9). The weighted prevalence of infertility and access to infertility care and 93% confidence intervals (CIs) were calculated. The proportion of women with depression was determined with multivariable logistic regression and zero-inflated negative binomial regression with complex survey analysis. Results: A total of 1,592 women reported natural menopause, representing an estimated population of 10,575,335 postmenopausal women accounting for the complex sampling and weighting method. Women who were POI more likely to be younger, lean, Hispanic, less educated, and have a lower ratio of family income to poverty compared to women without POI. Women with POI had similar odds for having depression determined by PHQ-9 (odds ratio 0.88, 95% CI 0.37-2.11) after controlling for all potential confounders. Additionally, women who reported POI had a similar PHQ-9 score compared to those who reported natural menopause after the age of 40 years. Conclusion: There was no significant difference in the prevalence of depression determined by PHQ-9 between women with and without POI in this nationally representative study of postmenopausal women. The association was not different after adjustment for potential confounders.

Sources of Funding: This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (No. 2023R1A2C1005003).

P.95. Supplement Use Among a Diverse Sample of Peri-Menopausal and Menopausal Women in Rural Hawaii
Paris Stowers, MD, MSCR1,2; Emile Stickley, MD MPH1,2; 1Obstetrics, Gynecology, & Women’s Health, University of Hawai‘i at Manoa, Hilo, HI; 2Obstetrics & Gynecology, Hawaii Pacific Health, Hilo, HI

Objective: In the United States, 80% of women over the age of 60 use one or more dietary supplements. This widespread use may reflect an unmet medical need among this population and suggests people in this age group may be at increased risk for adverse drug interactions. Ethnically diverse populations may have different motivations for and meanings of supplement use. This study was designed to explore supplement use among peri-menopausal and post-menopausal individuals living on rural Hawaii Island. Design: This study is a cross-sectional survey of peri-menopausal and menopausal women presenting to an outpatient women’s health clinic on rural Hawaii Island. A validated survey was modified to include common supplements from East-Asian and the Pacific Islands. Non-pregnant women over the age of 40 were eligible to participate. Recruitment consisted of flyers posted in an academic women’s health clinic. Paper and web-based surveys were used to collect data concerning the prevalence of supplement use, types of supplements used, the motivations for taking each supplement, and the cost of supplement use. Descriptive statistics and a one sample t-test were used to analyze the resulting data. Results: From May to June 2023, 75 people participated in this study. The majority of this sample identified as Asian (47%), White/Caucasian (33%), or Native Hawaiian (15%). Mean age of participants was 62 (range: 41 to 91; standard deviation: 13). Nine percent of women reported using at least one supplement in the previous 6 months, which is higher than previously reported rates for the rest of the United States (p<0.01). Participants used an average of 5 different supplements (range: 0 to 22; standard deviation: 4.5). The most commonly used supplements include vitamin D (59%), calcium (49%), multivitamins (41%), vitamin C (31%), caffeine (29%), green tea (28%) and fish oil (27%). Mean monthly cost of supplements was $55 (standard deviation: $88). Thirty-three percent of participants report experiencing one or more side effects from supplement use. The most commonly reported sources for supplement recommendations were health professionals (71%), family members (33%), and friends (28%). Conclusion: Supplement use is common among this sample of peri-menopausal and menopausal women in rural Hawaii. This population looks to health professionals for advice and guidance concerning supplements. Understanding the type of supplements used and the reasons for taking these medications could allow for more effective counseling by clinicians.

Sources of Funding: None

P.96. Leveraging the Experience of Patients with Cystic Fibrosis: A Model to Advance the Study of Menopause in Chronic Illness
Sandy M. Sufian, PhD, MPH1,2, Pauline Mak1, PhD2. 1Medical Education, University of Illinois Chicago College of Medicine, Chicago, IL; 2Disability and Human Development, University of Illinois Chicago College of Applied Health Sciences, Chicago, IL; 3Psychiatry, University of Illinois Chicago College of Medicine, Chicago, IL

Objective: Context: Women with cystic fibrosis (CF) who seek primary and specialty healthcare consider menopause concerns essential to their overall health and well-being. However, menopause research and knowledge are absent for this and other chronic disease populations. Here we report findings from a four-year patient engagement project to empower women with CF to generate research questions and articulate their priorities about menopause to remedy gaps in scientific knowledge and inadequacies in CF and menopause clinical care. More broadly, this effort identified a methodological approach to advance menopause research and clinical care for women with chronic illness. Objective: To leverage the expertise of adult women with a chronic disease, CF, to advance menopause research and care. Design: Design: With Four CF patient-partners, three two-hour sessions focused on patient-centered research generation on CF and menopause. Additional meetings covered other CF-sexual and reproductive health (SRH) topics. We held meetings online to uphold infection control guidelines. We recruited adult women with CF through community-based social media platforms, clinic teams, and via community newsletters. We compensated attendees and the patient planning team for their time, participation, and knowledge. On average, 14 women attended each meeting to contribute their voices to directions in CF-menopause research. At each meeting, an expert presented a one-hour overview of existing research for educational purposes. Confidential patient-only breakout sessions in the second hour allowed attendees to discuss facilitative logistic questions, gaps in research gaps, and formulate research questions. At the end of the meeting, attendees ranked their top 2-3 research questions for each session in a Google poll to share with researcher-partners for translation into research studies. Investigators then created an online, transdisciplinary platform to promote team interactions and SRH research, including menopause. We divided this cohort into research pods of 3-4 researchers, each tasked with designing a study, developing a patient engagement and dissemination plan, and creating a visual map of potential funders and next steps. We shared the menopause questions with a team of CF-menopause researchers who chose two questions, created a research study, and submitted a letter of intent for a foundation grant. The research team is now awaiting a response about their application. Results: Results: Women with CF generated eight patient-driven research questions on menopause and CF during the project, including: What does menopause look like for women with CF? Do CF patients enter menopause earlier than the general population? And Is hormone replacement therapy (HRT) safe for women with CF? Our model of harnessing women’s expertise to generate research ideas and establishing research teams to pursue those priorities proved highly effective in reaching its goals. Conclusion: Conclusion: Women with CF propose highly innovative and relevant research questions precisely because of their proximity to, and expertise about, their illness experience. These questions are relevant and meaningful to the female patient community, potentially making recruiting them into research studies easier. Our framework for generating and leveraging patient-engaged research questions can be applied to other chronic disease populations to forward menopause research agenda responsive to those groups’ priorities and needs.

Sources of Funding: Funders for this project include the Cystic Fibrosis Foundation and the Connecticut Office of Research and Innovation (OCR).
P-97. Trends in the incidence, prevalence and sales volume of menopausal hormone therapy in Sweden from 2000 to 2021

Michela Sundell, PhD-student1, Jan Brynhildsen2, Anna-Clara Spetz Holm1, Mats Fredrikson1, Mikael Hoffmann1. 1Department of Biomedical and Clinical Sciences, Linköpings universitet, Linköping, Sweden; 2Department of Obstetrics and Gynaecology, Region Kalmar lan, Kalmar, Sweden; 3Department of Obstetrics and Gynaecology, Örebro universitet, Örebro, Sweden; 4Department of Obstetrics and Gynaecology, Universitetssjukhuset i Linköping, Linköping, Sweden; 5Linköpings universitet Institutionen för medicin och halsa, Linköping, Sweden

Objective: To describe the trends in use of menopausal hormone therapy (MHT) in Sweden, 2000–2021 and to analyse the impact of different lengths of run-in periods on the incidence. Design: Dispensation data were retrieved from the national mandatory Swedish Prescribed Drug Register. Aggregated sales volumes of MHT in Defined Daily Dose (DDD) were available from 2000 to 2021, and described as DDD per 1,000 women per day. Individual-level data on MHT dispensions for 2.5 million women 45–69 years of age were analyzed from 2006 to 2021 to describe the one-year prevalence and incidence proportion. The predictive values for incidence representing first-use of MHT were calculated for different run-in periods, which is a defined period without dispensations. A run-in period of 18 months was used to describe the incidence of MHT use. Results: Both the DDD, from 2000, and the prevalence, from 2006, decreased by over 80% in women aged 50–54 years, until 2010 when the use of MHT stabilized. The predictive value for incident users to be first-ever users was 88% in women aged 50–54 years, with a run-in of 18 months, in 2021. The incidence was stable between 2007 and 2016. From 2016 to 2017 an increase in the incidence by 10% was first identified among women aged 50–54 years, but not in other age-groups. Between 2017 and 2018 a further increase with 33% was seen in women 50–54 years and also an increase for 45–49 and 55–64 years In 2020, the first year of the covid-19 pandemic, the incidence decreased for all studied age intervals. At the same time, the amount in DDD and the prevalence continued to increase, although at a somewhat slower rate than in the preceding two years. Conclusion: MHT use decreased significantly after the turn of the century, but has increased since 2017, mainly in the ages close to menopause. A run-in period of 18 months was found suitable and reliable for defining incident users of MHT in the age intervals closest to menopause. Incidence seems to be a more sensitive measure than prevalence of MHT use. Sources of Funding: None

P-98. Nutrition Counseling in Postmenopausal Women: A Standard of Practice

Priyanka Suvan1, Natalie A. Gonzalez, MD, Gloria A. Bachmann, MD, MMS. 1University of Missouri Kansas City, Kansas City, MO; 2Women’s Health Institute, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ

Objective: The postmenopausal time period can bring many unwanted physical changes, including weight gain, as well as an increased risk for various diseases such as diabetes, osteoporosis, arthritis, cardiovascular disease, metabolic syndrome and cancer. Postmenopausal women as compared to men are much more likely to be affected by weight-related health complications. Providing universal preventive measures, such as nutrition counseling, could potentially positively affect the health of postmenopausal women and may lower their risk for mortality and morbidity. Design: The PubMed database was utilized, with inclusion criteria including English language articles that were published within the last five years. Key terms used were “post-menopause”, “nutrition”, “weight gain”, “nutrition counseling”, “weight”, “obesity”, “metabolism”, “postmenopausal women” and “nutrition education.” Results: Four relevant publications were found: two randomized controlled trials, one controlled clinical trial, and one qualitative study. Two of these publications assessed the effect of nutrition education in reducing the risk of osteoporosis. The study found that participants who received counseling reported increased intake of milk, calcium and vitamin D along with reduced total fat intake to support bone health. Similarly in the other study, participants receiving counseling reported increased intake of calcium, phosphorus and magnesium to support bone health. But additionally, participants benefited from reduced body mass index compared to the control group. Participants gained additional benefit from the community based approach which included weekly group discussions. This program also included educational sessions, allowing participants to understand and perform daily activities in their kitchen. Conclusion: People using nutrition education in their kitchens to provide nutrition education. The use of a virtual format allowed participants to engage with the material from their own kitchens and follow along in real time. Study participants reported lower BMIs and improved dietary habits. The results suggest that virtual kitchens may be an effective intervention to promote health in the menopausal transition. These data suggest that nutrition education may be an effective intervention to mitigate postmenopausal health consequences and may prevent the development of chronic conditions. Sources of funding: None

P-99. Higher Habitual Physical Activity Reduces Vascular Endothelial Dysfunction in Healthy Peri-Menopausal People

Tobin J. Wilkens1,2, Ra Luna Murphy1,2, Lynnette L. Sievert, PhD,3, Sarah Wiktorowski1. 1Exercise & Sport Studies, Smith College, Northampton, MA; 2Anthropology, University of Massachusetts Amherst, Amherst, MA

Objective: The risk for cardiovascular disease (CVD) in women increases as they transition through menopause. Vascular endothelial dysfunction is an early indicator of CVD and is measured via brachial artery flow-mediated dilation (FMD). FMD is mediated by the bioavailability of nitric oxide, a vasodilator released by endothelial cells in response to changes in shear stress. FMD decreases in healthy women as they progress from pre- to post-menopause with the greatest change during the peri-menopause. Habitual physical activity (PA) is known to be an influential factor in endothelial health in a variety of populations. However, the role of habitual PA in relation to endothelial health during the peri-menopause remains unclear. Therefore, the aim of this analysis was to test the hypothesis that endothelial function is better in higher- vs. lower-habitually active healthy peri-menopausal people. Design: Thirty-three peri-menopausal people aged 43-54 were included to date. Peri-menopause was defined via STRAW+10 guidelines. Exclusion criteria included a history of chronic renal injuries, surgical menopause, menopausal symptom treatment, pregnancy or lactating, oral contraceptives in the past six months, and menopausal hormone therapy. Other exclusions were high blood pressure, BMI, cholesterol (TC, LDL-C), triglycerides, fasting plasma glucose, and low HDL-C. Self-reported habitual PA was determined by the International Physical Activity Questionnaire. The higher-PA group (High) criteria were >3days/wk of vigorous PA of at least 1500MET-min/wk or 7days/wk of any activity of at least 3000MET-min/wk, and the lower-PA group (Low) criteria were <15min/wk of moderate PA or <75 min/wk of vigorous PA. Endothelial function was assessed via ultrasoundography of the brachial artery with an occlusion cuff placed on the arm to induce a reactive hyperemia in the brachial artery. The FMD protocol consisted of 2 minutes of baseline measurement, 5 minutes of cuff inflation (200 mmHg), and 4 minutes of hyperemic response. Blood flow and diameter were continuously tracked throughout the 11-minute study (Cardiovascular Suite, version 4.0) and used to measure the baseline diameter, peak diameter, absolute FMD response, relative FMD response, shear rate stimulus, and time to peak dilation. Participant characteristics and FMD outcome variables were compared between groups using a two-tailed, independent t-test (α=0.05, Rstudio, version 2023.03.0+386). The Mann-Whitney U test was used to test the difference between outcome variables that did not meet the Shapiro-Wilk normality assumption test. Results: There were no differences between activity groups for BMI, blood pressure, total cholesterol LDL-C, HDL-C, triglycerides, or fasting plasma glucose. As designed, groups differed by physical activity (High=5390±2183MET-min/wk, Low=934±477.2MET-min/wk, p<0.001). Absolute FMD was significantly higher in the High-PA compared with the Low-PA group (High=0.18±0.08mm, Low=0.12±0.07mm, p=0.043). Relative FMD was not significantly different between groups (High=5.00±2.29%, Low=5.37±3.16%, p=0.20). Baseline diameter trended toward significance with a greater diameter in the High-PA group (High=3.40±0.36mm, Low=3.18±0.34mm, p=0.088). Maximum diameter was significantly larger in the higher-PA group (High=3.57±0.35mm, Low=3.29±0.31mm, p=0.037). Shear rate maximum (SRmax) trended toward significance with a higher SRmax in the Low-PA group (High=869.3±246.3s-1, Low=1020.0±281.1s-1, p=0.085). Time to peak was not significantly different between groups (High=41.0±14.5s, Low=54.4±28.0s, p=0.25). Conclusion: Our preliminary results support our hypothesis and suggest that levels of habitual PA can maintain a more sensitive and responsive vasculature in healthy peri-menopausal people. Limitations include sample size and the cross-sectional design. Future work will include continued data.
P-100. Trabecular Bone Scoring and effects on Diagnosis Change in Menopausal Women in a Specialty Women's Health Center.

Holly Thacker, MD, FACP, NCMP, CCD^2. Center for Specialized Women’s Health, Cleveland Clinic, Cleveland, OH; Center for Specialized Women’s Health, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH.

Objective: Osteoporosis is a common problem in postmenopausal women. Menopausal risk assessment needs to include risk for Osteoporotic fracture. The FRAX risk assessment tool discriminates against women under age 60, and those with lower spine T-scores as well as younger persons under age 60 and spine bone loss as opposed to hip T-scores are used to calculate the 10 year risk for any Osteoporotic fracture and the 10 year risk for hip fracture. Better assessment of bone risk is needed in menopausal women undergoing Central Dual-Energy X-absorptiometry (DXA). The newer technology of Trabecular Bone Scoring (TBS) assesses Bone Architecture which adds information to the Bone Mineral Density testing via DXA and gives additional information about fracture risk.

Design: Data on all DXA scans performed in the calendar year 2022 for women scanned in the Center for Specialized Women’s Health (a referral tertiary care center,) were reviewed and categorized into “Diagnosis not changed” or “Diagnosis changed” by TBS. The percent of patients who had a changed Diagnosis on TBS were further scrutinized to see if the diagnosis worsened or improved. Only one ISCD certified densitometrist (author) interpreted all scans as per ISCD protocol. TBS software is only currently validated on female data with certain age and weight ranges and only for Caucasian and Asians. Thus age, weight and race affect whether a patient can have TBS assessment based on the software company validation studies. All eligible newly scanned patients who underwent ordered DXA in the Center had TBS performed at the same time and surveillance of the author’s existing patients who presented for serial report done. Results: Of the 1277 DXA scans performed in 2022; 432 included TBS ~34 % of scanned patients received TBS analysis 13/432 went from a Diagnosis of Normal to Osteopenia 3% 55/432 went from Osteopenia to Osteoporosis 8% So 11% of the TBS scanned patients received a WORSE diagnosis 160/432 improved Osteoporosis to Osteopenia Normal 4% 74/432 improved Osteopenia to Osteoporosis 1.6% So over 5 % improved equaling a total 16% diagnosis were changed in women undergoing TBS in our Center for Specialized Women’s Health. 108/432 were Normal 25% with diagnosis unchanged 167/432 were Osteopenia 38.6% with diagnosis unchanged 83/432 were Osteoporosis 19% with diagnosis unchanged So 83% of scanned TBS patients at A10 Center for Specialized Women’s Health did NOT have a change diagnosis. A previous study showed that 120/432 were Osteopenia at baseline which is consistent with our finding. Conclusion: Osteoporosis is a major problem in postmenopausal women and is under recognized and under treated. Bone density assessment and fracture risk assessment is a key component in Menopausal risk assessment and 16% of TBS scanned women had the DXA diagnosis changed. Intensity of prevention and treatment strategies are affected by fracture risk assessment and shared decision making between the patient and her physician. We are the first and only site in our health system to offer TBS as this is an extra expense and not uniformly reimbursed by insurance. The TBS T-score was calculated by the bone mineral density and thus the TBS T-score give a more precise fracture risk assessment in untreated patients, and may also help reflect response to treatment in treated patients. Since the majority of women who present for menopausal risk assessment are under age 60, those women with a TBS diagnosis of Osteoporosis or their individual 10 year FRAX risk may still be under 20% and 3% respectively. Decisions to use menopausal hormone therapy are broader and more inclusive of several factors compared to the decision to only institute osteoporosis prevention or osteoporosis treatment. The conclusion is that TBS provides meaningful additional information in the menopausal risk assessment, changing 16 % of women’s diagnosis who were eligible for TBS and thus provides additional bone assessment which is key in this special group of patients.

Sources of Funding: NONE

Table 2 Baseline Adjusted Plasma Estradiol (pg/mL) Pharmacokinetic Parameters

<table>
<thead>
<tr>
<th>Progestrone</th>
<th>Cycle 1</th>
<th>Cycle 2</th>
<th>Cycle 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estradiol</td>
<td>IVR1</td>
<td>IVR2</td>
<td>IVR1</td>
</tr>
<tr>
<td>N (n=160)</td>
<td>11</td>
<td>11</td>
<td>11</td>
</tr>
<tr>
<td>E2 (ng/mL)</td>
<td>1.10</td>
<td>1.19</td>
<td>1.25</td>
</tr>
<tr>
<td>SD</td>
<td>0.38</td>
<td>0.45</td>
<td>0.47</td>
</tr>
</tbody>
</table>

Table 2 Baseline Adjusted Plasma Estradiol (pg/mL) Pharmacokinetic Parameters

Progestrone, Cycle 1-3

<table>
<thead>
<tr>
<th>Cycle 1</th>
<th>Cycle 2</th>
<th>Cycle 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estradiol</td>
<td>IVR1</td>
<td>IVR2</td>
</tr>
<tr>
<td>N (n=160)</td>
<td>11</td>
<td>11</td>
</tr>
<tr>
<td>E2 (ng/mL)</td>
<td>1.10</td>
<td>1.19</td>
</tr>
<tr>
<td>SD</td>
<td>0.38</td>
<td>0.45</td>
</tr>
</tbody>
</table>

Table 2 Baseline Adjusted Plasma Estradiol (pg/mL) Pharmacokinetic Parameters

<table>
<thead>
<tr>
<th>Cycle 1</th>
<th>Cycle 2</th>
<th>Cycle 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estradiol</td>
<td>IVR1</td>
<td>IVR2</td>
</tr>
<tr>
<td>N (n=160)</td>
<td>11</td>
<td>11</td>
</tr>
<tr>
<td>E2 (ng/mL)</td>
<td>1.10</td>
<td>1.19</td>
</tr>
<tr>
<td>SD</td>
<td>0.38</td>
<td>0.45</td>
</tr>
</tbody>
</table>

P-102. A Phase 1/2, Open-label,Parallel Group Study to Evaluate the Preliminary Efficacy and Usability DARE-HRT1 (80 µg Estradiol/4 mg Progesterone and 160 µg Estradiol/8 mg Progesterone Intravaginal Rings) Over 12 Weeks in Healthy Postmenopausal Women.

Andrea R. Thurman, MD^1, Louise Hull, MBChB, PhD, FRANZCOG^2, Bronwyn Stuecky, MBBS FRACP^3, Jessica Hatheway, MBA^1, Nadene Zack, MS^1, Christine Mauck, MD MPH^1, David R. Friend, PhD^2. 1Dare Bioscience, San Diego, CA; 2University of Adelaide, PARC Clinical Research and Robinson Research Institute, Adelaide, SA, Australia; 3Keogh Institute For Medical Research Inc, Nedlands, WA, Australia.

Objective: The exploratory objectives of this study were to evaluate the usability and preliminary efficacy of DARE- HRT1, an intravaginal ring (IVR) which releases 17β-estradiol (E2) with progesterone (P4) over 28 days, in postmenopausal women. Design: Randomized, open-label, 2-arm, parallel group study in 21 healthy non-hysterectomized postmenopausal women conducted at two sites in Australia. The study was approved by the ethics boards at each study site (Central Adelaide Local Health Network Human Research Ethics Committees - Central Adelaide Local Health Network Research Ethics Committee 2021HRE00421) and registered at ClinicalTrials.gov (NCT05367973). Volunteers provided written informed consent prior to the performance of study procedures. Once eligibility was determined, women were randomized (1:1) to either DARE-HRT1 IVR1 (E2 80 µg/day with P4 4 mg/day) or DARE-HRT1 IVR2 (E2 160 µg/day with P4 8 mg/day). Volunteers were assigned for three 28-day cycles. Safety was measured by treatment emergent adverse events (TEAEs) and changes in systemic laboratories and the endometrial bilayer width. Baseline adjusted plasma PK of E2, P4 and estrone (E1) was described. Results: Twenty-one volunteers (median age 59 years) were screened and randomized to either DARE-HRT1 IVR1 or DARE- HRT1 IVR2 (n=10) and 19 women completed all three cycles. Both DARE-HRT1 IVRs were safe. All TEAEs were mild or moderate. Two participants in the DARE-HRT1 IVR2 group discontinued the study due to TEAEs (breakthrough bleeding, nipple tenderness and depressed mood). At baseline, the mean (SD) endometrial thickness was 2.80 (1.26) and 2.11 (0.71) mm for IVR1 and IVR2, respectively. At end of treatment, the mean (SD) endometrial thickness was 3.03 (1.86) and 2.50 (0.98) mm for IVR1 and IVR2 respectively. All endometrial thickness measurements were ≤ 4.8 mm. The baseline adjusted, month 3 mean (SD) steady state plasma E2 concentrations (Css) achieved with the 160 µg/day E2 dose (IVR2) (38.97 ± 10.79 µg/mL, range of 20.68 – 53.45 µg/mL) (Table 1), put all participants in the normal, pre-menopausal early follicular phase range. On the contrary, the mean (SD) baseline adjusted, month 3 Css plasma E2 achieved with the 80 µg/day E2 dose (IVR1) (22.17 ± 4.47 µg/mL, range of 17.67 – 29.52 µg/mL) kept some IVR1 users in the menopausal range for plasma E2. Baseline adjusted plasma P4 Css for both IVRs were in the normal, post ovulatory, late phase range, > 1 ng/mL, (Table 2), which supports the in vivo release of P4 would protect the endometrium from the proliferative effects of exogenous E2. Conclusion: Safety and PK data support further development of DARE-HRT1 for the treatment of menopausal symptoms. This would be the first combination E2/P4 IVR to treat vasomotor symptoms in healthy postmenopausal women with an intact uterus.

Sources of Funding: None

Results: Twenty-one participants were randomized and 19 women completed all study visits. P-102. A Phase 1/2, Open-label, Parallel Group Study to Evaluate the Preliminary Efficacy and Usability DARE-HRT1 (80 µg Estradiol/4 mg Progesterone and 160 µg Estradiol/8 mg Progesterone Intravaginal Rings) Over 12 Weeks in Healthy Postmenopausal Women.

Table 1: Preliminary Efficacy and Usability DARE-HRT1 (80 µg Estradiol/4 mg Progesterone and 160 µg Estradiol/8 mg Progesterone Intravaginal Rings) Over 12 Weeks in Healthy Postmenopausal Women.

| Sources of Funding: None |

Table 2: Preliminary Efficacy and Usability DARE-HRT1 (80 µg Estradiol/4 mg Progesterone and 160 µg Estradiol/8 mg Progesterone Intravaginal Rings) Over 12 Weeks in Healthy Postmenopausal Women.
Table 1 demonstrates significant improvement in vaginal pH, VMI, and vaginal cytology with use of either DARE-HRT IVR. At baseline, 14 of 21 participants indicated that vaginal dryness was their most bothersome gynecological and/or genitourinary symptom (MBS). Among this subset (8 from IVR1 cohort, 6 from IVR2 cohort), their median (interquartile range, IQR) reported vaginal dryness severity score was 2.0 (IQR 3) at baseline and decreased to median (IQR) of 0 (0, 0) by end of treatment (EOT) with their respective IVRs (p < 0.01). These 14 women also had a significant change in dyspareunia severity score from a median (IQR) of 1 (0, 2) at baseline to a median (IQR) of 0 (0, 0) at EOT (p < 0.01). There were significant decreases from baseline, indicating improvement in all MENQOL domains, for both DARE-HRT1 IVRs (all p values < 0.01), with the largest improvement in the HOT and MENQOL sexual domain. Based on MENQOL responses, the commonly reported and most severe VMS at baseline was night sweats. With use of DARE-HRT1 IVR1, there was significant improvement in the severity of hot flashes and night sweats (p values 0.02 and 0.02, respectively) while there were no significant changes in uterine (p = 0.28) as 6/11 IVR1 users did not complain of this symptom at baseline. Among DARE-HRT1 IVR2 users, there was significant improvement in the severity of hot flashes, night sweats and sweating (all p values < 0.03). Most women agreed or strongly agreed that the study product was comfortable to wear, convenient to use and worked to their expectation. Most women reported that they were likely or very likely to use an IVR for treatment of women’s health and other health conditions. Conclusion: This combination E2 and P4 IVR was acceptable and demonstrated preliminary efficacy for VMS and VTA treatment.

Sources of Funding: None

Table 1: Preliminary Markers of Local Estradiol Impact on Vaginal Epithelium

| Table 1: Plasma PK Parameters for Tamoxifen |
|----------------|----------------|----------------|----------------|
|               | DARE-VVA1 1 mg | DARE-VVA1 3 mg | DARE-VVA1 10 mg |
| Day 1 Cmax (ng/mL) | 0.04 ± 0.17 | 0.20 ± 0.24 | 5.69 ± 2.90 |
| Day 1 Tmax (hours) | 24.0 ± 2.0 | 24.0 ± 2.0 | 24.0 ± 2.0 |
| Mean T1/2 (hours) | 3.8 ± 0.3 | 3.8 ± 0.3 | 3.8 ± 0.3 |

Andrea R. Thurman, MD,1 LouiseHall, MBChB, PhD, FRANZCOG,2 Bronwyn Stuckey, MBBS FRACP,3 Jessica Hatheway, MBA,1 Christine Manck, MD MPH,1 Nadene Zack, MS,1 David R. Friend, PhD,1 Dare Bioscience, San Diego, CA,1 University of Adelaide, PARC Clinical Research and Robinson Research Institute, Adelaide, SA, Australia;1 Keogh Institute For Medical Research Inc, Neldans, WA, Australia
Objective: Safety, systemic pharmacokinetics (PK) and preliminary assessment of tamoxifen PK, were measured at healthy postsymptomatic women with moderate-to-severe vulvovaginal atrophy (VVA) in this first-in-woman study of DARE-VVA1, a soft gel vaginal tamoxifen capsule. Design: This was a randomized, placebo-controlled, double-blind, study of DARE-VVA1, vaginal tamoxifen, in 4 doses (1 mg, 5 mg, 10 mg and 20 mg). Women used study product daily for 14 days and then twice weekly for 6 weeks. Results: We screened 45 women and enrolled 17 (mean age 61 years); 14 women completed the study at two Australian clinical sites. Three participants (1 placebo, 2 in 5 mg group) were discontinued due to protocol violations. All treatment emergent adverse events (TEAEs) were mild or moderate in severity and were similarly distributed between active and placebo dosing groups. Endometrial thickness measurements were normal at baseline and end of treatment, with all <4.0 mm. Systemic tamoxifen and metabolite concentrations were highest among 20 mg users, but maximum mean (SD) plasma tamoxifen concentrations (Cmax on day 1) (2.66 ± 0.85 ng/mL) and day 56 (5.69 ± 1.87 ng/mL) were <14% of Cmax measured after a single oral 20 mg dose (40 mg/L) (Table 1). Similarly, the first metabolite of tamoxifen, N-desmethyl tamoxifen (NDT) had mean (SD) Cmax plasma concentrations on day 1 (0.20 ± 0.17 ng/mL) and day 56 (8.13 ± 2.90 ng/mL), which were <2% of that steady-state NDT concentrations (353 ng/mL) oral tamoxifen use. Plasma tamoxifen concentrations were negatively correlated with vaginal pH (R = -0.51, p < 0.01) and % vaginal parabasal cells (R = -0.53, p < 0.01), and were positively correlated with % vaginal superficial cells (R = 0.45, p < 0.01), % vaginal intermediate cells (R = 0.45, p < 0.01) and total VMI (R = 0.62, p < 0.01). Women reported vaginal dryness or dyspareunia as their most bothersome genitourinary symptom at baseline. The severity of these symptoms decreased significantly with active study product use (p = 0.02 for both), while placebo users’ dryness and dyspareunia decreased more than changes in the severity of these symptoms (p = 0.17, 0.33 vaginal dryness and dyspareunia respectively). Conclusion: These data support that DARE-VVA1 is safe and results in minimal systemic exposure to tamoxifen or its metabolites compared to orally administered tamoxifen. Preliminary efficacy data support the clinical development of DARE-VVA1 as an effectively lower vaginal pH and improve VMI and treat bothersome genitourinary symptoms.

Sources of Funding: None

Table 1. Preliminary Markers of Local Estradiol Impact on Vaginal Epithelium

P-104. The New, Undescribed, and Lethal Symptoms in the GSM and Advanced Menopause
Albeloro Dominguez-Bali MD,1 Fernando Resendez, B.S., Medical Student1, John Mark Unsworth, B.Sc., M.S., Medical Student1, Florida International University Herbert Wertheim College of Medicine, Miami, FL;2 Miami Center for Obstetrics Gynecology and Human Sexuality, Hialeah, FL;3 American University of Antigua, Coolidge, Antigua and Barbuda
Objective: This study endeavors to highlight new symptoms observed in patients with GSM and advanced menopause—not heretofore associated with the condition—including mortality risk: Total Vulvovaginal Obliteration (TVO), with possible secondary renal damage as well as, in those without Hormone Replacement Therapy (HRT), undiagnosed recurrent Urogenital Infections (UIIs), which may be accompanied by secondary sepsis, pneumonia, and mortality. Abnormal false pap smears are an additional albeit non-lethal consequence of GSM. The study will also outline a newfound association between decubitus ulcers and the lack of HRT. Design: This multi-method longitudinal study took place within a multidisciplinary healthcare facility and nursing homes over the course of 10 years. The sample population included menopausal and postmenopausal women with and without HRT. A comprehensive review of current medical literature was conducted to identify new findings associated with GSM not traditionally reported. Patients with GSM symptoms were diagnosed and treated according to established protocols. Current outlined identifications were used along with new findings such as: false abnormal pap smears, TVO, and undiagnosed rUTIs. Demographic and clinical data were collected for each patient including age, HRT and menopause status, n number of exacerbations, and mortality data. Participants were followed up regularly to monitor their progression and ensure the effectiveness of respective treatments. Results: Through the treatment of newly associated symptoms of menopause and GSM, this study resolved abnormal pap smears with local estrogen in more than 1500 cases, and successfully managed 8 cases of TVO with surgery, dilators, increased penetrative sex, and local estrogen. Descriptions of a dozen rUTI patients whose conditions progressed to sepsis, pneumonia, and even death were also seen and evaluated in home care facilities by the primary care provider. Women over 55 have a higher incidence of rUTI. UTI risk factors differ between pre- and postmenopausal women. Younger women are more likely to experience UTIs linked to sexual intercourse and vaginal infections; older women are more likely to experience them from hypoestrinism and secondary to vaginal decrease of their immunological response. For this reason, there may be multiple unnecessary antibiotic treatments, antibiotic prophylaxis, and altered patterns of resistance due to a lack of awareness of the association between the rUTI and GSM. Generally, menopausal and vaginal symptoms are satisfactorily resolved with systemic and local HRT and the appropriate antibiotic therapy. Though not associated with GSM, we have found that abnormal dryness and dyspareunia in nursing homes, women who have not been in HRT more frequently develop decubitus ulcers. Frequently this—combined with the comorbidities of diabetes mellitus, severe immobility, and geriatric age (centenarians)—increases mortality risk. Conclusion: This study finds GSM symptoms may include several beyond the usually considered scope.
of the disease—some of which are accompanied by mortality risk. These symptoms—
false abnormal plop smell results, TVO, and undiagnosed rUTIs—ought to be considered
and checked for in GSM patients. Physicians should note that risk factors for rUTIs differ
for pre- and postmenopausal women, to reduce the risk of multiple unnecessary
antibiotic treatments, antibiotic prophylaxis, and antibiotic resistance—that may arise
from an incomplete understanding of the association linking rUTIs and the GSM.
The implications of these findings are particularly salient for urologists, primary care,
internal medicine, OB/GYN physicians, geriatricians, and infectious disease specialists,
who should consider the expanding list of GSM symptoms in the treatment of their
menopausal and postmenopausal patients, ensuring regular screening, monitoring,
and the timely identification of new symptoms. Further research, and monitoring of
current GSM patients, is needed to ensure up-to-date understandings of GSM and its
constellation of associated symptoms—and more urgently—the best possible standard
of care for patients.

Sources of Funding: 1Mami Center for Obstetrics Gynecology and Human Sexuality
2American University of Antigua

P-105.

The Effect of Estetrol (E4) on Patient-Reported Outcome Measures in
Postmenopausal Women – Results From a Phase 3 Trial

Wulf Utian1, Melanie Taziaux2, Amanda Black3, Ulysse Gaspard4, Rogerio Lobo5, Jean
Michel Foidart4,2, 1Case Western Reserve University School of Medicine, Cleveland,
OH; 2Estera SRL, an Affiliate Company of Mitra Pharmaceuticals, Liege, Belgium;
3University of Ottawa, Ottawa, ON, Canada; 4Université de Liege, Liege, Belgium;
5University of North Carolina, Chapel Hill, NC, NY; Columbia University, New York, NY

Objective: Estetrol (E4) is a native estrogen in development for menopausal vasomotor
symptoms (VMS) in postmenopausal (PM) women. A previous phase 2 trial found that
E4 was effective for the treatment of VMS, genitourinary syndrome of menopause
(GSM), dyspareunia, and quality of life (QoL), with a favorable safety profile. Moreover,
E4 had minimal impact on hemostasis and had potentially beneficial effects on lipids,
carbohydrate metabolism, and bone turnover. Data from two Phase 3 trials demonstrated
a significant reduction in the frequency and severity of moderate to severe VMS. Here,
we present the patient-reported outcome results from a Phase 3 trial (E4Comfort1),
which was conducted at 151 enrolling sites in 14 countries in Europe, Latin America,
Asia, and North America. Design: In this randomized, placebo-controlled, double-
blind phase 3 trial, 640 PM women 40–65 years of age were randomized to receive E4
15 mg (n=213), E4 20 mg (n=213), or placebo (n=214) daily for 12 weeks. To ensure
endometrial protection all non-hysterectomized (NH) women received progesterone
200 mg once daily for 14 days after completion of E4 treatment. Secondary efficacy
endpoints including QoL, clinical meaningfulness, and GSM symptoms were measured
by validated patient-reported outcome questionnaires. For QoL, the Menopause-Specific
Quality of Life (MENQOL) questionnaire was completed at baseline and at week 12 and
consisted of 29 items: vasomotor (3 items), psychosocial (7 items), physical (16 items),
and sexual (3 items). Items pertaining to a specific symptom were rated as present or not
present, and if present, how bothersome on a zero (not bothersome) to six (extremely
bothersome) scale. The Clinical Global Impression questionnaire was completed at
baseline and at weeks 4 and 12 to evaluate clinical meaningfulness of VMS reduction.
Participants answered the following question: “Rate the total improvement, whether or
not in your judgment it is due entirely to drug treatment. Compared to your condition
at admission to the study, how much has it changed?” Potential responses included: “very
much improved,” “much improved,” “minimally improved,” “no change,” “minimally
worse,” “much worse,” or “very much worse.” “Very much improved” and “much
improved” were rated in the rating of clinical meaningfulness (meaningful improvement).GSM
symptoms were self-assessed at baseline and at week 12 and involved vaginal dryness,
vaginal and/or vulvar irritation/itching, dysuria, vaginal pain associated with
sexual activity (dyspareunia) (scored as 0 [none], 1 [mild], 2 [moderate], or 3 [severe]),
and incontinence associated with sexual activity (scored as 0 [absent], 1 [infrequent],
or 2 [frequent]). Statistical analyses on changes from baseline were performed using analysis
of covariance. Results: Significant improvements at week 12 versus placebo were found
in the total MENQOL score and in the vasomotor, psychosocial, and sexual functioning
domain scores after E4 15 mg and E4 20 mg treatment, and in the physical domain score
after E4 20 mg treatment (p<0.05). A significantly higher percentage of participants rated
their condition as “much improved” or “very much improved” compared with baseline
regarding the weekly frequency of moderate to severe VMS in the E4 15 mg (52.9% and
73.3%) and E4 20 mg (59.8% and 77.8%) groups versus placebo (27.0% and 47.0%) at
weeks 4 and 12, respectively (p<0.001). GSM symptoms numerically decreased in all
treatment groups after 12 weeks of treatment. A significant treatment effect was observed
with E4 15 mg compared to placebo at week 12 with a reduction in least square mean
difference versus baseline in vaginal pain associated with sexual activity (β=0.23 [95% confidence interval [CI]: -0.41, -0.04]; p=0.0142) and vaginal dryness (β=0.31 [95% CI:
-0.5, -0.09]; p=0.0030). Conclusion: E4 demonstrated beneficial effects on QoL and
GSM symptoms and provided clinically meaningful improvements in postmenopausal
women with moderate to severe VMS.

Sources of Funding: Funded by Estera SRL, an affiliate company of Mitra Pharmaceuticals,
Liege, Belgium

P-106.

Female sexual desire in couples aged 50–70 years: Importance of male
easessment

Ana Lucia R. Valadarelos, MD, PHD1, Janaina F. Pio, MD2, Maria Paula Perin3,
Lucia Costa Paiva, Md, PhD3, OBSTETRICS AND GYNECOLOGY, Universidade
Estadual de Campinas, Campinas, Brazil; 2MENOPAUSE CLINIC, Santa Casa BH, Belo
Horizonte, Brazil

Design: To assess the prevalence of low female sexual desire among couples aged
50 to 70 years and the male and female factors associated with female sexual desire.

The São Paulo Research Foundation, FAPESP- Process number:
MS1. 1Bonafide Health, LLC, Harrison, NY; 2Department of Obstetrics and Gynecology,
New York University Grossman School of Medicine, New York, NY; 3Department of
Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine, New
Haven, CT

Objective: The primary objective was to evaluate the effects of a nonhormonal, botanical
blend (VMS-BH02; Thermella™), on hot flashes and night sweats in women who
experience menopausal vasomotor symptoms (VMS). Preclinical studies showed that
the combination of these ingredients synergistically inhibited the neurotrans Bpathway
and did not raise estrogen levels nor induce cell proliferation in MCF-7 cells. This
was a single arm clinical study conducted to evaluate the clinical benefit of a
“thermella” (VMS-BH02) open-label study in women 45-65 years of age. Thirty peri- and
post-menopausal women were recruited if they reported a daily average of 5 or more VMS,
regardless of severity. Participants were instructed to consume 2 capsules of the supplement
daily. To date, participants have completed 8 weeks. The primary endpoint was the percent
change in total VMS, collected using daily diaries. Secondary endpoints were assessed using
various validated monthly questionnaires including the Menopause Specific Quality of Life
(MENQOL), the Hot Flash Related Daily Interference Scale (HFRDIS), the Greene
Climacteric Scale (GCS), and the Patient-Reported Outcomes Measurement Information
System Sleep Disturbance Short Form 8b (PROMIS). Participants completed all
questionnaires at Baseline, and weeks 2, 4, and 8, with the exception of the MENQOL,
which was not administered at week 2. Results: Thirty women completed weeks 8 (55.5 ±
3.7 yrs) of supplementation. There was a significant decrease in self-reported total
VMS occurrences (all severities) noted across the time points (Baseline: 10.7 ± 6.0;
Week 4: 6.2 ± 4.2; Week 8: 5.1 ± 4.4; p<0.01). Combined, moderate and severe hot
flashes were significantly decreased at all weeks when compared to baseline: Week 1:
5.1 ± 2.6; Week 2: 4.2 ± 2.6; Week 8: 2.5 ± 2.9; p<0.01). Night sweats significantly
decreased from baseline at weeks 4 and 8 (Baseline: 2.9 ± 2.1; Week 1: 1.5 ± 1.2, p:
0.002; Week 8: 1.4 ± 1.3, p<0.01). Significant improvements were also noted in the
mean total score at weeks 4 and 8 (Baseline: 3.8 ± 1.2; Week 4: 3.0 ± 1.1; Week 8: 2.7 ± 1.4;
p<0.01, the HFRDIS total score at all timepoints compared to baseline (Baseline: 42.7 ± 18.2;
Week 2: 31.0 ± 18.3; Week 4: 26.1 ± 20.4; Week 8: 18.4 ± 18.4; p<0.001), and the
GCS total sum at weeks 4, 8 and 12 compared to baseline (Baseline: 8.0 ± 8.3; p<0.001;
Week 4: 2.1 ± 8.5; p<0.001; Week 8: 2.5 ± 8.3; p<0.001). There were also significant improvements in PROMIS
total score at weeks 2, 4 and 8 compared to baseline (Baseline: 30.3 ± 7.8; Week 2: 26.4 ±
8.3; Week 4: 25.5 ± 8.1; Week 8: 23.4 ± 8.3; p<0.01). Conclusion: The eight-week
daily supplementation with Thermella™, which had a high affinity for inhibition of the
NK3 receptor oftoutin in significant and transparent reductions in vasomotor symptoms,
including hot flashes and night sweats. These improvements were observed as early as two weeks into the study and continued throughout the investigation period. Notably, the frequency and severity of these symptoms decreased over time. Supplemental therapy also showed positive effects on menopause-specific quality of life related outcomes and sleep disturbances. Overall, these findings underscore the promising clinical efficacy of this novel botanical blend in effectively managing vasomotor symptoms experienced by women throughout their menopausal transition.

Sources of Funding: Bonafide Health, LLC

P-108. Assessing Knowledge Gaps in Primary Care: Patients at High Risk for Breast Cancer

Jessica Fraiker, MD1, Sara Khan, MD2, Rachel Perez, MD1, Bhivaka Patel, MD1, Sandhya Pruhi, MD1, Lauren Correll, MD1, Lanyu Mi, MS1, Elisabeth Lim, MS1, Sunela Vegunta, MS1. 1Mayo Clinic Arizona, Scottsdale, AZ; 2Banner Desert Medical Center, Mesa, AZ; 3Mayo Clinic in Florida, Jacksonville, FL; 4Mayo Clinic Minnesota, Rochester, MN

Objective: The primary objective of this study is to 1) survey knowledge around breast cancer risk and 2) to identify potential knowledge gaps amongst PCPs. This information will subsequently be utilized to help develop an educational program tailored to PCPs to improve standardized knowledge base regarding breast cancer risk to identify and offer enhanced surveillance and/or risk reducing medications to women who are at high risk for breast cancer. Design: A short questionnaire was distributed to PCPs within the Mayo Clinic enterprise that assessed knowledge and awareness about breast cancer risk factors, risk assessment, and management of patients at high risk for breast cancer. Targeted respondents included physicians at or above the level of residency, and advanced practice providers (nurse practitioners (NPs) or physician assistants (PAs)). Knowledge assessment questions focused on clinical scenarios to assess various domains of practice, evidence-based management, and guidelines. Data analysis included patient demographics including age, gender, medical specialty, time in practice, and practitioner experience in caring for high-risk patients was collected. Results were modeled as univariate and multivariable linear regression with percent score as the outcome, as well as descriptive analysis. Results: 145 survey responses were received, the majority practicing family medicine (65.4%) or internal medicine (31.4%). 61.5% of respondents had been practicing at least 5 years. The average final score was 55.9% correct, with 55.2% (80/145) respondents receiving a final score of 60% correct or above and 44.8% (65/145) respondents receiving a final score of <60% correct. 46.2% of respondents correctly answered both breast cancer screening questions and 42.1% of respondents correctly answered the single question on utilization of risk reducing medications. 46.9% of respondents correctly identified the overall risk associated with menopausal breast cancer risk. Conclusion: PCPs demonstrated a knowledge gap in appropriate use of breast cancer screening modalities as well as risk-reducing medications for patients at high risk of developing breast cancer. As a one of the first points of contact in the health care system, further education-based programs should be developed to improve PCP knowledge of early breast cancer risk factors, detection, screening, and prevention options, in order to improve shared patient discussions surrounding breast cancer screening and ultimately improve overall patient outcomes.

Sources of Funding: Mayo department of medicine, AZCfR

P-109. Assessing Point of Care Diagnostic Methods for Vulvovaginal Candidiasis in Pre- and Postmenopausal Patients

Krystal Vera1, Gabrielle Mendes, BS1, Maria Rocktaschel, APN1, Nancy Phillips, MD1. 1Obstetrics and Gynecology, Rutgers Robert Wood Johnson Medical School New Brunswick, New Brunswick, NJ; 2Rutgers Robert Wood Johnson Medical School, Piscataway, NJ

Objective: The primary objective of this review is to assess the accuracy of point of care methods of diagnosing vulvovaginal candidiasis in comparison to standardized methods of diagnosis (culture and NuSwab/SureSwab) in pre- and postmenopausal patients. Design: This is a retrospective chart review of patients who were seen in the Rutgers Robert Wood Johnson Center for Vulvovaginal Health and diagnosed with vulvovaginal candidiasis between 1/1/2021 to 6/30/2021. Wet preparation findings, culture or NuSwab/ SureSwab results, presenting symptoms, and patient characteristics including age, race, menopausal status and use of hormone therapy (HT) at time of visit were abstracted from medical records. Patients ages 18 to 89 years old were included. Exclusion criteria was absence of yeast culture and/or NuSwab/SureSwab result despite wet preparation coming back negative. Statistical analysis was performed using a P-value calculator to determine statistical difference in accuracy of wet prep diagnosis versus laboratory diagnosis between groups. Results: A total of 157 premenopausal and 112 postmenopausal patients (64 on HT and 48 not on HT) were included in the final analyses. We found that the concurrence of wet prep and laboratory was significantly different between pre- and post-menopausal women (74.9% vs 54.5% p=0.005). However, this difference was present only in postmenopausal women not on HT (74.9% vs 25% p=0.0003) and not present in those on HT. (74.9% vs 76.6% p=0.81). Of the women on HT, 55 were on vaginal estradiol alone, 4 on systemic and 5 on both. Conclusion: The diagnosis of vulvovaginal candidiasis is postmenopausal women not on HT is significantly less accurate on wet prep point of care testing than in women who are either pre-menopausal or of post-menopausal on HT. Although VVC is less prevalent in the postmenopausal population not on HT, this diagnosis is suspected to be present, laboratory testing should be collected in addition to wet prep diagnosis for most accurate results.

Sources of Funding: none

P-110. Sleep Disturbances Among Menopausal Hispanic Subgroups

Eesha Vijayakumar, Gloria A. Bachmann, MD. Rutgers Women’s Health Institute, Morganville, NJ

Objective: Throughout modern Western history, stringent beauty standards have typically excluded aging women. Such beauty standards, which promote an eternal youthful appearance, have a significant negative impact on the self-image and mental health of aging women, who may be helpful for researchers to understand aspects of aging healthy. Fortunately, in recent years, the anti-ageism movement has challenged this concept and introduced the idea of aging as a positive experience. This review examined the popular media discourse on aging and beauty in women to assess whether the Western media is becoming more accepting of aging changes in women. Design: A Google search was conducted to determine the first five most followed online beauty magazines. The top 50 results from a search using the term “aging,” “beauty,” and “women” were obtained from each online magazine. Articles discussing aging women and self-care or beauty therapy were eliminated. Remaining articles were analyzed based on content that included views of beauty and aging. Results: The analyzed articles did support greater acceptance of beauty with aging. Anti-ageism articles critiquing anti-aging beauty standards and discussing celebrities, health experts, and older women embracing the aging process encompassed two out of five (40%) articles obtained from Elle, 20 out of 41 (48.78%) articles obtained from Allure, 18 out of 43 (44.26%) articles from Vogue, and three out of four (75%) articles from InStyle. Relatively neutral, informational articles on skin care during aging or the aging process accounted for one (20%) article from Elle, 18 (43.9%) articles from Allure, 21 (51.22%) articles from Vogue, 4 (100%) articles from Beauty News NYC, and one (25%) article from InStyle. However, articles perpetuating anti-aging beauty standards were also present. Two (40%) articles from Elle, one (2.44%) article from Allure, and two (4.88%) articles from Vogue expressed anti-aging products as “treatments” for aging, likening aging to a disease that must be fixed. Two (4.88%) articles from Allure also included celebrities behind anti-aging beauty standards. Over one hundred articles were analyzed, seven (7.37%) perpetuated anti-aging beauty standards. Conclusion: Recent years have shown great progress in accepting life-long beauty in women. However, anti-aging beauty standards still persist. To further assess prevalent beauty standards for aging women, research in other forms of media other range of magazines should be done. Surveying aging women’s perceptions of their experiences may be useful to determine whether improving acceptance of beauty with aging has a positive impact on women’s mental health. Research comparing the beauty standards of Hispanic women to other women should also be done to distinguish whether more stringent beauty standards apply to aging women.

Sources of Funding: None

Ht = hormone therapy

P-111. Growing Acceptance of the Life-long Beauty of Women in the Media

Eesha Vijayakumar, Gloria A. Bachmann, MD. Rutgers Women’s Health Institute, Morganville, NJ

Objective: The objective of this study is to 1) survey knowledge around breast cancer prevention options, in order to improve shared patient discussions surrounding breast cancer risk for breast cancer. A short questionnaire was distributed to PCPs within the Mayo Clinic enterprise that assessed knowledge and awareness about breast cancer risk factors, risk assessment, and management of patients at high risk for breast cancer. Targeted respondents included physicians at or above the level of residency, and advanced practice providers (nurse practitioners (NPs) or physician assistants (PAs)). Knowledge assessment questions focused on clinical scenarios to assess various domains of practice, evidence-based management, and guidelines. Data analysis included patient demographics including age, gender, medical specialty, time in practice, and practitioner experience in caring for high-risk patients was collected. Results were modeled as univariate and multivariable linear regression with percent score as the outcome, as well as descriptive analysis. Results: 145 survey responses were received, the majority practicing family medicine (66.4%) or internal medicine (31.4%). 61.5% of respondents had been practicing at least 5 years. The average final score was 55.9% correct, with 55.2% (80/145) respondents receiving a final score of 60% correct or above and 44.8% (65/145) respondents receiving a final score of <60% correct. 46.2% of respondents correctly answered both breast cancer screening questions and 42.1% of respondents correctly answered the single question on utilization of risk reducing medications. 46.9% of respondents correctly identified the overall risk associated with menopausal breast cancer risk. Conclusion: PCPs demonstrated a knowledge gap in appropriate use of breast cancer screening modalities as well as risk-reducing medications for patients at high risk of developing breast cancer. As a one of the first points of contact in the health care system, further education-based programs should be developed to improve PCP knowledge of early breast cancer risk factors, detection, screening, and prevention options, in order to improve shared patient discussions surrounding breast cancer screening and ultimately improve overall patient outcomes.

Sources of Funding: None
P-112. The Menopause-related Gut Microbiome: Associations with Metabolomics, Inflammatory Protein Markers, and Cardiometabolic Health in Women With and Without HIV

Yi Wang1, Anjali Sharma1, Kathleen M. Weber2, Elizabeth Topper2, Allison A. Appleton3, Deborah Gustafson4, Clay B. Clish5, Robert C. Kaplan5, Robert D. Burak6, Qinbin Qi7, PhD, Brandon A Peters, PhD8. 1Cook County Health, Chicago, IL; 2Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; 3Department of Epidemiology and Biostatistics, University at Albany School of Public Health, Rensselaer, NY; 4Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA; 5Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY; 6Department of Obstetrics & Gynecology and Women’s Health, Albert Einstein College of Medicine, Bronx, NY; 7Department of Neurology, State University of New York Downstate Health Sciences University, Brooklyn, NY; 8Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY. 9Broad Institute, Cambridge, MA; 10Department of Medicine, Albert Einstein College of Medicine, Bronx, NY

Objective: Menopause may alter the gut microbiome, but little is known regarding mechanisms linking menopause-related gut microbiome alterations and cardiometabolic risk. We sought to identify menopause-related gut microbial species, as well as their related metabolites and inflammatory protein markers, and link with cardiometabolic risk factors in women with and without HIV (WWH and WWOH).

Methods: In a nationwide, cross-sectional study, we performed shotgun metagenomic sequencing on 696 stool samples from 446 participants (67% WWH), and quantified plasma metabolomics and serum proteomics in a subset (~86%). We examined associations of menopause (post- vs. pre-menopause) with gut microbial features in a repeated-measure design, and further evaluated those features in relation to metabolites, protein markers, and cardiometabolic risk factors. Mean age was 53.0 ± 8.7 years and 69% were post-menopause at the time of their first stool sample. Menopause was associated with altered overall gut microbial composition in WWH only. We identified a range of gut microbial features that differed between post- vs. pre-menopause WWH (but none in WWOH), including 32 species and lower β-glucuronidase bacterial gene abundance. Specifically, highly abundant species Faecalibacterium prausnitzii, Bacteroides sp. CAG-98 and Bifidobacterium adolescentis were depleted in post-menopause WWH. Menopause-depleted species (mainly class Clostridia) in WWH were positively associated with several glycerophospholipids, while negatively associated with imidazolepropionic acid and FGF-21. Furthermore, cardiometabolic traits, especially waist-to-hip ratio, were associated with menopause-related microbes, metabolites and FGF-21 in WWH (Figure 1).

Conclusion: Menopause may shift the gut microbiome in WWH, leading to altered metabolite and protein profiles that potentially contribute to elevated cardiometabolic risk.

Sources of Funding: B.A.P., Q.Q., and R.C.K. were supported by the National Heart, Lung, and Blood Institute (B.A.P. K01HL160146; R.C.K. R01HL148094 and U01HL146204-04G1; Q.Q. and R.C.K. R01HL146976).

Figure 1. Network plot visualizing relationships of the menopause-related microbiome score with metabolites, inflammatory protein markers, and cardiometabolic traits in women with HIV.

P-113. Bridging Menopausal History and Alzheimer Disease: A Pilot Study Targeting Sex-Based Disparities in Alzheimer’s Risk

Amber Watts, PhD1, Pilar Thangwaromi, MA2, Valerie Medina, MA3, Pallavi Khanna4. 1Psychology, University of Kansas College of Liberal Arts and Sciences, Lawrence, KS; 2Health Science Center, University of Tennessee, Memphis, TN

Objective: Two-thirds of Alzheimer’s disease (AD) patients are women. Compelling evidence suggests females have a protective capacity against AD. Women also report worse sleep, worse emotional well-being, and higher pain compared to men. In women, menopause may increase AD risk. We aimed to target women’s AD risk through lifestyle factors. Results will support funding applications for longitudinal follow up and inform the design of AD risk reduction interventions in peri- and post-menopausal women.

Methods: We recruited adults ages 40-60, from the Kansas City and Wichita, KS metropolitan areas. Via online surveys, we collected 1) sociodemographic characteristics (age, education, race/ethnicity, disability, SES), 2) reproductive history (menarcheal status & history, gynecological surgery history, menopausal symptom presence & severity, pregnancy history, medication history), 3) cardiometabolic risk (ACSM checklist, personal & family history of health & dementia history, BMI, waist circumference), 4) psychological factors (PROMS depression & anxiety scales, Adverse Childhood Experiences (ACE) questionnaire), and 5) lifestyle (International Physical Activity Questionnaire, Rapid Eating Assessment for Patients, Soy Foods Screener, Pittsburgh Sleep Quality Index, smoking, alcohol, & tobacco).

Results: To date, 114 participants have completed (60.6% WWH, 39.4% WWOH). The sample mean age was 53.0 ± 8.7 years and 69% were post-menopause (spontaneous), 22.4% had surgical menopause, and 16.5% did not have periods for other reasons. On average, women had lower income (t(df)=2.40(101), p<.009). Women reported more family history of dementia (X2(df)=11.19(1), p<.001), hypertension (X2(df)=8.42(1), p<.005), and hypercholesterolemia (X2(df)=6.18, p<.022). Women were more likely to report heart palpitations (t=6.81, p<.009). Psychologically, women had higher ACE scores (t(df)=2.76(100.5), p<.003), more depression (t(df)=2.81(104), p<.003) and anxiety (t(df)=1.70(101), p<.046). Women spent less time in vigorous physical activity (t(df)=4.87(1), p<.004). Women who underwent ovariectomy had survival lengths that were shorter compared to women without this surgery, including lower educational attainment (t(df)=2.92(67), p<.005) and greater rates of disability (X2(df)=5.96(1), p<.044). They reported higher ACE scores (t(df)=2.30(66), p<.025), and more anxiety (t(df)=2.61, p<.011). They ate more fried foods and sweets (t(df)=2.84(67), p<.006), and reported poorer sleep (t(df)=2.39(67), p<.020). Post-menopause women reported more dizziness (X2(df)=4.87(1), p<.034) and eating more sweets (t(df)=2.18(65), p<.029).

Conclusion: We have successfully begun building a midlife cohort with diverse participants to support the development of interventions targeting sex-based disparities in AD risk that may originate in or be exacerbated by the menopausal transition. Preliminary results support the existence of differences in AD risk based on sex and menopausal history that warrant further investigation. Although the present study was conducted by online self-report, participants indicated willingness to participate in future research including health interventions, neuroimaging, and biomarker collection.

Sources of Funding: P30AG053982

P-114. Obstructive Sleep apnea and type 2 diabetes mellitus in middle-aged and older women

Yunmi Kim, Ph.D., You Lee Yang, Ph.D., RN. College of Nursing, Eulji University, Seongnam, Korea (the Republic of)

Objective: Sleep problems are known to affect insulin sensitivity and glucose metabolism. However, limited evidence is available on the association between obstructive sleep apnea (OSA) and type 2 diabetes mellitus (T2DM) in middle-aged and older women in menopausal transition. Hormone changes may alter the risk of OSA and T2DM. The aim of this study was to explore the association between OSA and T2DM among middle-aged and older women living in South Korea. Design: This was a cross-sectional study using nationwide data extracted from the Korean National Health and Nutrition Examination Survey. Of the 6,003 participants, 14.0% had T2DM and 0.8% had a high risk of OSA. Data analysis, the Rao-Scott χ2 test for categorical variable, t-test or F-test for continuous variable, and multiple logistic regression were conducted using the SAS software program. Results: Of the 6,003 participants, 14.0% had T2DM and 0.8% had a high risk of OSA. The prevalence of T2DM significantly differed among women in low- (11.8%), moderate- (22.8%), and high-risk (32.7%) groups for OSA (X2=106.70, p<.001). Women with a high risk of OSA (mean=6.0) had a higher HbA1c concentration than those with a low risk of OSA (mean=5.8) in age-adjusted F-test (p<.001). There was significant difference between pre- and post- menopause group on the risk of OSA (p<.001). Upon multiple logistic regression, women with a moderate- (Odds Ratio [OR]: 1.48, 95% Confidence Interval [CI]: 1.18-1.84) or high- (OR: 3.65, 95% CI: 1.55-8.58) risk of OSA had a higher risk of T2DM than low risk of OSA. Thus, post-menopause women had higher risk of T2DM than pre-menopause women (OR: 1.51, 95% CI: 1.02-2.03) after adjusting covariates. Conclusion: The study results supports the need for screening and managing middle-aged and older women for OSA and T2DM, and for women to enhance their glucose control. Because of the methodological limitation in the cross-sectional study, we suggest that further studies should be conducted to fully understand the interrelationships between OSA and T2DM.

Sources of Funding: This study was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (Ministry of Science and ICT) (No. NRF-2020R1C1C1006343).
P-115. Relationship Between Menopausal Hormone Therapy and Breast Cancer: A Cohort Study Utilizing the Health Insurance Database in South Korea (HISK)-II

Tae-ran Kim, MD, Jin-Sung Yuk, M.D., Ph.D., Department of Obstetrics and Gynecology, Inje University Sanguye Paik Hospital, Nowon-gu, Korea (the Republic of)

Objective: The purpose of this retrospective cohort study was to evaluate the breast cancer risk of women with menopausal hormone therapy (MHT). Design: Postmenopausal patients over the age of 40 who were selected using the National Health Insurance Database in South Korea (2011-2014) were included in this study. Women who had used MHT for more than six months during this period were selected as the MHT group while women who had never used MHT were selected as the non-MHT group. The two groups were matched 1:1 based on several variables using propensity score matching. Both groups were followed until 2020. Results: The non-MHT and MHT groups comprised 153,736 women each. In an extended Cox proportional hazard analysis with time-dependent covariates, MHT was associated with an increased risk of breast cancer (hazard ratio [HR] 1.224, 95% confidence interval [CI] 1.152–1.302). Tibolone (HR 0.973, 95% CI 0.896–1.057), estradiol valerate (EV)/medroxyprogesterone acetate (MPA) (HR 1.525, 95% CI 0.946–2.459), EV/norethisterone acetate (NETA) (HR 1.772, 95% CI 0.571–5.498), conjugated equine estrogen (CEE) (HR 0.834, 95% CI 0.517–1.344), EV (HR 1.049, 95% CI 0.892–1.234), estradiol hemihydrate (EH) (HR 1.137, 95% CI 0.366–3.529), CEE/micronized progesterone (MP) (HR 0.223, 95% CI 0.031–1.583), CEE/MPA (HR 2.005, 95% CI 0.501–8.024), EV/MP (HR 0.791, 95% CI 0.297–2.110), EV/MPA (HR 2.066, 95% CI 0.984–4.340), and EH/MP (HR 0.763, 95% CI 0.191–3.052) did not increase the risk of breast cancer compared to the non-MHT group. However, EHDrospirenone (DRSP) (HR 1.511, 95% CI 1.38–1.655), EHEdrogestosterone (DYD) (HR 1.367, 95% CI 1.155–1.676), and EVDydrogesterone (DYD) (HR 1.741, 95% CI 1.544–1.964) increased the risk of breast cancer compared to the non-MHT group. Subgroup analyses by duration of MHT use showed that MHT was associated with an increased risk of breast cancer at all durations of use. Conclusion: MHT is associated with an increased risk of breast cancer. Most combined estrogen plus progestin, including EHDrospirenone, EHDydrogestosterone, and EV/MPA, were also associated with a higher risk of breast cancer.

Sources of Funding: None

P-116. Prevalence and impact of vasomotor symptoms due to menopause: Canadian subgroup of the Women with Vasomotor Symptoms Associated Prevalence and impact of vasomotor symptoms due to menopause: Canadian subgroup of the Women with Vasomotor Symptoms Associated

Eunice Yuki, BS, PharmD, of Echelon Brand Communications, LLC. Writing support provided by Hannah L. Mayberry, PhD, and Jessica D. Herr, PharmD, of Echelon Brand Communications, LLC, an OPEN Health company, was funded by Astellas.

In the WARM study, 14.7% of Canadian women in postmenopause reported moderate/severe VMS. VMS had a considerable effect on QoL, work, daily activities, and sleep, highlighting an unmet need for access to menopause management and effective therapies to relieve symptoms and help alleviate the impact of moderate/severe VMS due to menopause.

Sources of Funding: The study was sponsored by Astellas Pharma, Inc. (Northbrook, IL). Writing support provided by Hannah L. Mayberry, PhD, and Jessica D. Herr, PharmD, of Echelon Brand Communications, LLC, an OPEN Health company, was funded by Astellas.